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Commentary on the Contributions of the Author to the Four Papers 
Included in this PhD Thesis by Publication 
Publication 1. This is a review article that was written by Professor Martin 
Banwell. Mr Taher has made significant contributions to the preparation of 
this review article. It incorporates descriptions of research conducted by 
the co-authors including Mr Taher. Mr Taher also carried out relevant 
literature surveys as part of his additional contributions to the preparation of this 
article.  
Publication 2. This is a full paper detailing extensive experimental work 
directed towards the synthesis of various analogues of the phytotoxic natural 
product phomentrioloxin A. Mr Taher carried out more than 80% of the 
experimental work reported in this article. In addition he collated/formatted all 
of the spectral data presented in the Supporting Information (SI) part of the 
document. Mr Taher also wrote ca. 85% of the Experimental Section and 
conducted relevant literature surveys. Dr Anthony Wills, the RSC’s then 
resident crystallographer, conducted the X-ray crystallographic studies 
reported in this paper. Professor Martin Banwell wrote the body of the 
paper (viz. the Introduction, the Results and Discussion section as well as the 
Conclusion).   
Publication 3. Professor Martin Banwell proposed the research work reported 
in this article. Mr Taher assigned various of the structures to the products 
described therein while completion of some aspects of the experimental work 
was carried out by Dr Ping Lan with assistance from Ms Lauren White (a 
Summer Research Scholar in the RSC). Mr Taher also wrote ca. 40% of the 
Experimental Section and conducted relevant literature surveys. Dr Anthony 
Wills, the RSC’s then resident crystallographer, conducted the X-ray 
crystallographic studies reported in this paper. Professor Martin Banwell 
wrote the body of the paper (viz. the 
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Introduction, the Results and Discussion section as well as the Conclusion). In 
overall terms, Mr Taher’s contributions to this paper were of the order of 50%. 
Publication 4. This is a full paper. It details extensive work directed towards the 
design and synthesis of derivatives and analogues of (–)- and (+)-galanthamine, 
the former being an alkaloid that inhibits the enzyme acetylcholinesterase. Mr 
Taher carried out just over 50% of the entirety of the laboratory work reported in 
this article. In addition he collated/formatted half of the spectral data presented in 
the Supporting Information (SI) part of the document. Mr Taher also wrote ca. 
50% of the Experimental Section and conducted relevant literature surveys. Drs 
Anthony Wills and Paul Carr, the RSC’s then resident crystallographer and his 
successor, respectively, conducted the X-ray crystallographic studies reported in 
this paper. Professor Martin Banwell wrote the body of the paper (viz. the 
Introduction, the Results and Discussion section as well as the Conclusion).   
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Abstract 
 
Various genetically modified microorganisms that over-express dioxygenase-
type enzymes can be used for the large scale production of compounds such as A 
(and known as cis-1,2-dihydrocatechols) from the corresponding aromatic 
precursor. These metabolites, which are almost invariably obtained in near 
enantiomerically pure form, have served, over many decades, as valuable starting 
materials in chemical synthesis. The papers presented in this thesis by publication 
reinforce this proposition. 
 
 
 
In order to appropriately contextualize the work undertaken by the author, an 
extended survey of the use of compounds such as A in total syntheses undertaken 
by the Banwell Group (and within which the author worked) is provided. Copies 
of the author’s four publications (and, where relevant, the associated Supporting 
Information documents) are then presented.  
 
The first publication (Publication 1) associated with this body of work represents 
an invited review article and also serves to contextualise, albeit from a somewhat 
broader perspective than given in the above-mentioned survey,  the work reported 
in the next parts of the thesis by describing various of the contemporary ways in 
which homochiral and microbially-derived cis-1,2-dihydrocatechols such as A 
have been exploited as starting materials in the stereochemically-controlled 
synthesis of a range of natural products and their analogues. 
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Publication 2 details syntheses of a series of twenty-eight analogues of the 
phytotoxic geranylcyclohexentriol (–)-phomentrioloxin A (B). These have been 
prepared through cross-couplings of various enantiomerically pure 
iodoconduritols or certain deoxygenated derivatives with either terminal alkynes 
or borylated alkenes. Some of these analogues display modest herbicidal 
activities and physiological profiling studies suggest that one, C, inhibits 
photosystem II in isolated thylakoids.  
 
 
 
Publication 3 is concerned with the development of so-called chemoenzymatic 
total syntheses of the natural product (+)-asperpentyn and the enantiomer of the 
structure assigned to aspergillusol A. These syntheses start from the 
enantiomerically pure cis-dihydrocatechol D, itself obtained through the whole-
cell biotransformation of iodobenzene. 
 
 
 
Specifically, then, Publication 3 details the establishment of a concise (five step) 
synthesis of (+)-asperpentyn (E) and an eight-step reaction sequence leading to 
compound F, the enantiomer of the structure, G, assigned to the natural product 
6
aspergillusol A. Both routes employ the enantiomerically pure cis-1,2-
dihdrocatechol D as starting material and use Sonogashira cross-coupling 
chemistry to install the required enyne side-chain. 
On the other hand, Publication 4 describes syntheses of certain di- and mono-
oxygenated derivatives (e.g. H and I, respectively) as well as analogues such as 
K-M of both the (–)- and (+)-enantiomeric forms of the alkaloid galanthamine
(J). All have been assessed for their capacities to inhibit acetylcholinesterase but,
in contrast to the predictions from docking studies, none binds strongly to this
enzyme.
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The Exploitation of Enzymatically-Derived cis-1,2-Dihydrocatechols and 
Related Compounds in the Chemoenzymatic Synthesis of Biologically 
Active Natural Products 
An Extended Survey of the Research Contributions 
from the Banwell Group 
Summary: cis-1,2-Dihydrocatechols of the general form 1 can be produced at 
large scale and in essentially enantiomerically pure form (when X ≠ H) through 
the whole cell biotransformation of the corresponding aromatic. The “dense” and 
varied functionality associated with these metabolites mean that they have 
become increasingly useful chirons for the total synthesis of a range of natural 
product types. This overview details the outcomes of a nearly three-decade long 
campaign within the Banwell Group to exploit these compounds in the synthesis 
of a diverse range of small molecule natural product targets. The work done by 
the Group over this period is subdivided according to the key manipulation(s) 
applied to the relevant cis-1,2-dihydrocatechol in each synthesis. The exploitation 
of other chirons that “complement” the utility of the title metabolites is also 
described. This extended survey serves to contextualise the published work of 
the author that is presented within the body of the thesis.     
1. Introduction
Small molecule natural products (SMNPs) have played crucial roles in societal 
development over millennia by providing, for example, a multitude of therapeutic 
agents as well as agrochemicals and cosmetics.1 The award of the 2015 Nobel 
Prize in Physiology and Medicine to Tu, Campbell and Ōmura for their 
discoveries of artemisinin and avermectin underpins the continued importance of 
SMNPs in the modern era.2 Synthetic chemistry has also been pivotal because of 
the ever-evolving capacities it offers for providing useful quantities of otherwise 
difficult-to-access SMNPs and/or, through structural modification of them, more 
efficacious variants. Indeed, the development of synthetic chemistry has been 
driven over many decades by the remarkable structures that are encountered in 
8
SMNPs and by their exquisite biological profiles.3 As a consequence the synthetic 
chemist’s “toolbox” is replete with a stunning array of methods for molecular 
assembly.  
A less-studied topic is the high-value-adding production of building blocks for 
SMNP synthesis through the action of enzymes on abundant chemical feedstocks. 
One particular aspect of this topic that has been investigated within the Banwell 
Group’s laboratories over a number of decades is the subject of the present 
survey. Specifically, it details the utility of the enzymatically-derived, readily 
accessible and often enantiomerically pure cis-1,2-dihydrocatechols of the 
general form 1 (Figure 1) as starting points in chemical synthesis.4 It should be 
noted that while the present survey is confined to a small set of such compounds, 
many hundreds of related ones have been reported4c but they have yet to receive 
the same level of attention in synthesis as those shown and discussed below. 
Figure 1: The cis-1,2-Dihydrocatechols (1) – Abundant and Versatile Starting 
Materials in Chemical Synthesis. 
2. The Discovery and Production of the cis-1,2-Dihydrocatechols
In 1968 David Gibson and his co-workers at the University of Iowa reported5 that 
a chemically mutated form of P. putida lacking a key dehydrogenase enzyme 
could effect the oxidation of benzene and so allowing for the accumulation of cis-
1,2-dihydrocatechol 1 (X = H) that could then be isolated and characterised. By 
employing genetic engineering techniques, organisms such as E. coli JM109 
X
OH
OH
1
(X = H, Cl, Br, I, Me, CH=CH2, CN...)
9
(pDTG601)6 have been now produced that overexpress the toluene dioxygenase 
(TDO) enzyme responsible for this fascinating biotransformation. As a result 
kilogram if not tonne quantities of these types of compounds can be generated. 
The opportunities for synthesis on offer as a result were highlighted by the 
compelling early work of Stephen Taylor at ICI PLC, Steve Ley, then at 
Imperial College, and Tomas Hudlicky, then at Virginia Polytechnic. Thus, 
Taylor demonstrated7 that the parent compound [1 (X = H)] could be 
converted into high-grade polyphenylene while Ley used the same 
material in making the racemic modification of the cyclitol pinitol.8 
Hudlicky, on the other hand, and in the first of his many profound 
contributions to the area, was able to use the enantiomerically pure 
toluene-derived diol, viz. compound 1 (X = Me), in the synthesis of terpene 
and prostanoid synthons and thus establishing, inter alia, a formal total 
synthesis of PGE2α.9  Another potent illustration of the power of such 
biotransformations is seen in the conversion of styrene into compound 1 (X = 
CH=CH2)10 – there is no parallel for the observed chemoselectivity associated 
with this conversion in the strictly chemical world (and the enzyme effects this 
with exquisite regio-, stereo- and enantio-selectivity as well!).  
3. The Reactivity Profile of the cis-1,2-Dihydrocatechols
The Banwell Group’s work in the area started in 198911 when the then ICI PLC 
in the UK very kindly provided a sample of compound 1 (X = H). Initial studies 
focussed on adding dichlorocarbene to the acetonide derivative of this 
material as a prelude the constructing, through ring-expansion processes, 
various specifically substituted troponoid compounds.  In doing this it was 
discovered that cis-1,2-dihydrocatechols can undergo almost explosive 
acid-catalysed dehydration and re-aromatisation!12 As a result of such early 
studies and those 
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conducted by others4 a reactivity profile for these compounds was established and 
this is summarised in Figure 2.  
Figure 2: The Reactivity Profile of the cis-1,2-Dihydrocatechols 
In particular, under carefully controlled conditions the acetonide derivatives of 
such systems can be formed and then manipulated in various useful ways. 
Furthermore, when X ≠ H then the two hydroxyl groups reside in sterically 
distinct environments and can, therefore, be functionalised separately. 
Furthermore, when X = Cl, Br or I then the two double bonds are electronically 
quite distinct and such that the non-halogenated one reacts preferentially with 
electrophiles. The facial selectivity of such processes can be dictated by the steric 
demands of the diol unit (or the acetonide moiety if that has been installed first). 
The simple reaction sequence shown in Scheme 1 not only serves to emphasise 
these possibilities but also to highlight the regioselectivity of the ring opening the 
epoxide, 3,13 derived from acetonide 2. So, for example, on treating compound 3 
with acetic acid in the presence of a mineral acid such as HCl then attack by the 
nucleophile takes place at the allylic rather than the homoallylic carbon of the six-
membered ring with the result that differentially protected conduritols (cyclohex-
X
OH
OH
mono- or di-protection
selective manipulation
(when X  ≠ H)
more hindered hydroxyl
(when X ≠ H)
site for cross-coupling
(when X = halogen)
s-cis-diene
for Diels-Alder
cycloadditions
more nuclephilic
double-bond
(when X = halogen)
Hazards:
(i) Diels-Alder
dimerisation
(ii) dehydration/
aromatisation
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5-en-1,2,3,4-tetraols) such as 4 of defined configuration can be generated in an
entirely predictable manner.14
Scheme 1 
When an halogenated carbon is present within compound 1 (i.e. X = Cl, Br or I) 
then it, or its derivatives, can be engaged in various metal-catalysed cross 
coupling reactions while the conjugated s-cissoid diene moiety participates in a 
range of inter- and intra-molecular Diels-Alder reactions, most especially if the 
diol moiety is “tied up” as the corresponding acetonide. Through esterification of 
the hydroxyl groups with unsaturated esters then substrates that engage in exo-
selective intra-molecular Diels-Alder (IMDA) reactions are also produced.  
Another notable feature of both the cis-1,2-dihydrocatechols themselves and 
various of their readily accessible derivatives is that they embody allylic alcohol 
residues that can thus be engaged in Claisen-type rearrangement reactions. By 
such means a range of useful additional derivatives have been obtained and 
exploited in chemical synthesis.  
X
OH
OH
1
(X =  Br)
Br
2
O
O
Br
3
O
O
O
Br
4
O
O
OH
m-CPBA
water/THF
HClHO
2,2-DMP
p-TsOH
93%
93%
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The following sections illustrate, through examples chosen from the Banwell 
group’s ongoing research program, the value of various of these types of 
transformations in the total synthesis of a range of natural products and their 
analogues.    
4. Synthetic Studies Involving Early-stage Electrophilic Addition
Reactions (including oxidative cleavage processes)
As implied above, some of the Group’s earliest work employing the cis-1,2-
dihydrocatechols involved (Scheme 2) the addition of dihalocarbenes to the 
acetonide derivative, 5,15 of the parent compound 1 (X = H) and so affording 
cyclopropane 6.15 Upon hydrolysis of the associated acetonide unit and bis-O-
methylation of the resulting diol then the corresponding bis-ether16 was obtained. 
A lithium-for-bromine exchange using n-BuLi at –100 °C followed by 
protonation of the resulting anion with methanol then gave the mono-bromide 7. 
Dihydroxylation of the olefinic residue within the last compound followed by 
two-fold oxidation of the resulting diol then gave the α-hydroxyenone 8 that 
was readily converted into the enone acetate 9 on exposure to acetic 
anhydride in pyridine. Finally, successive treatment of compound 9 with the 
non-nucleophilic base DBU (to induce ring-expansion) then aqueous sodium 
hydroxide (to cleave the resulting tropolone acetate) afforded 3,4-
dimethoxy-α-tropolone (10), a natural product isolated from 
Streptoverticillium hadanonense and found to be active against both Gram-
negative and Gram-positive bacteria.   
13
Scheme 2 
By related means the troponoid natural products stipitatic acid (11) and puberulic 
acid (12) as well as certain simpler systems were also obtained. 
Another useful electrophilic addition reaction is shown in Scheme 3 and involves 
a regio- and stereo-selective bromohydrin forming step through treatment of 
6
O
O
5
O
O
CHBr3, C6H6
aq. NaOH
BnEt3NCl
50%
Br
Br
7
H
Br
OMe
OMe
8
H
Br
OMe
OMeO
OH
9
H
Br
OMe
O
OAc
OMe
O
HO OMe
OMe
10
(i) THF/aq. HCl;
(ii) NaH, MeI
(iii) n-BuLi then MeOH
51%
(i) OsO4
t-BuOOH
(ii) Swern
oxidation
40%
Ac2O
pyridine
87%
DBU then
aq. NaOH
94%
O
HO OH
OH
12
O
HO
OH
11
HO2C HO2C
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compound 1 (X = Br) with N-bromosuccinimide (NBS) in aqueous THF.18 The 
bromotriol 13 so formed reacts with sodium methoxide to afford the diol epoxide 
14 that can be engaged in a regioselective Mitsunobu reaction, using α-
chloroacetic acid as the nucleophile, to give ester 15. Oxidation of the remaining 
free hydroxyl group within the last compound using pyridinium dichromate 
(PDC) then gave the keto-ester 16 that upon saponification afforded (–)-
bromoxone (17), the enantiomer of an epoxyquinol-based natural product.  
Scheme 3 
The oxidative cleavage of the double bond remaining after manipulations of the 
non-halogenated one in the ways detailed above has provided a powerful means 
X
OH
OH
1
(X =  Br)
Br
13
Br
14
Br
15
(t-BuOCON)2
Ph3P
ClCH2CO2H
56%
59%
OH
OH
Br
HO
O
OH
HO
O
O
Br
17
Br
16
MeOH
Zn(OAc)2
77%
88%
OO
O
O
O
Cl
OH
O
Cl
HO
O
NBS, water
THF
89%
NaOMe
PDC
15
for producing a range of intriguing natural products or analogues thereof. So, for 
example, selective dibromocarbene addition to the bis-TBDMS-ether 18 
(Scheme 4)19 derived from diol 1 (X = Br) affords tribromide 19 that can be 
engaged in an exhaustive methyl-for-bromine exchange reaction on exposure to 
the higher order cuprate Me2Cu(CN)Li2 to afford alkene 20 that upon ozonolytic 
cleavage followed by reductive work-up with dimethyl sulfide affords the keto-
aldehyde 21. Subsequent and straightforward manipulations, including a 
Pb(OAc)4-mediated oxidative cleavage of the unmasked vic-diol moiety then 
gave the chiral non-racemic cyclopropane 22, a key synthon for the preparation 
of the highly active and commercially significant (1R)-cis-class of pyrethroid 
insecticides.      
Scheme 4 
Using related chemistries, enantiopure analogues of (+)-presqualene diphosphate 
have been produced20 from the toluene-derived diol 1 (X = Me). The Group’s 
Br
OTBDMS
OTBDMS
18
Br
19
2021
(R = TBDMS)
68%
78%
OTBDMS
OTBDMS
Me2Cu(CN)Li2
Br
Br
OTBDMS
OTBDMS
CHBr3, C6H6
aq. NaOH
PhCH2NEt3Cl
70%
(@ 70% conversion)
O3
then Me2S
OHC
O
OR
OR
22
MeO2C
CHO
four steps
37%
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synthesis of vitamin C from the chlorobenzene-derived metabolite 1 (X = Cl), as 
shown in Scheme 5,21 is indicative of the utility of products arising from the 
cleavage of the halogenated double bonds themselves. Thus, the chloro-analogue, 
23,13 of acetonide 2 is readily converted into the epoxide 24 that undergoes the 
anticipated mode of ring cleavage on exposure to benzyl alcohol in the presence 
of triflic acid. The resulting tri-protected cyclohex-5-en-1,2,3,4-tetraol 25 was 
then treated with ozone followed by sodium cyanoborohydride and thereby 
affording, through cyclisation of a intermediate equivalent to a J-hydroxylated 
acid chloride, the L-gulonolactone 26. Relatively conventional manipulations of 
this last compound then gave vitamin C (L-ascorbic acid, 27).  
Scheme 5 
X
OH
OH
1
(X =  Cl)
Cl
23
O
O
Cl
24
O
O
O
Cl
25
O
O
OH
m-CPBA
BnOH
TfOHBnO
2,2-DMP
p-TsOH
87%
O3
then 
NaBH3CN
37%
(from 24)
26
O
O
O
O
OBn
H
H
27
O
O
OH
H
H
OH
OH
HOHO
five steps
12%
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This work constitutes the only synthesis of compound 26 from a non-
carbohydrate source and may provide a useful means for make specifically 17O-, 
13C- and/or 2H-labelled variants required for biological studies. By related means 
a range of other carbohydrate-type systems have been prepared including the D-
aldopentoses,14b (+)-3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN),22 
(–)-N-acetylneuraminic acid (Neu5Ac),23 side-chain truncated analogues there-
of,24 the epimeric 6C-methyl-D-mannoses,25 certain differentially protected D-
talose derivatives,26 and (–)-1-deoxymannojirimycin (DMJ).27 
The carbohydrate-like motifs available by the means just described can be “re-
integrated” into larger ring systems as seen, for example, in the Banwell Group’s 
synthesis of the macrolide (+)-aspicillin (Scheme 6).28  Thus, epoxide 24 was 
subject to reductive ring-cleavage and the ensuing alcohol protected as the 
corresponding TBDMS ether 28. Ozonolysis of the chloroalkene residue within 
the last compound in the presence of methanol followed by reduction with 
sodium borohydride gave an ester-aldehyde that upon Wittig methylenation 
afforded the alkene 29. A further seven steps, the crucial ones involving 
Wadsworth-Horner-Emmons (WHE) and ring closing metathesis (RCM) 
reactions, then completed the synthesis of the target macrolide 30. Those atoms 
associated with the starting metabolite 1 (X = Cl) and intermediate 28 are 
highlighted in red. 
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Scheme 6 
A pathway leading to the 12-membered macrolide (–)-cladospolide C involving 
distinct, early stage manipulations of metabolite 1 (X = Cl) is shown in Scheme 
7. Thus, selective reduction of the non-chlorinated double bond within the latter
compound, inversion of configuration of the allylic alcohol using Mitsunobu
chemistry and p-nitrobenzoic acid as the nucleophile, cleavage of the product
ester and protection of the ensuing trans-diol as the Ley ketal using 2,2,3,3-
tetramethoxybutane (2,2,3,3-TMB) gave compound 31.29,30
Cl
24
Cl
28
O
O
O
29
O
O
71%
O
O
OH
OH
OH
O
O
O
OTBDMS
OTBDMS
MeO
30
WHE
RCM then
hydrogenation
(i) DIBAl-H
(ii) TBDMSCl
imidazole
79%
(i) O3, MeOH
then NaBH4
(ii) Ph3P=CH2
seven steps
34%
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Scheme 7 
Ozonolytic cleavage of the chloro-olefinic residue within the last compound 
followed by reductive work-up and Wittig olefination of the product ester-
aldehyde then gave the terminal olefin 32. A further nine steps, including those 
involving RCM and WHE olefination reactions, then gave (–)-cladospolide C 
(33),31 the non-natural enantiomeric form of a compound that inhibits shoot 
elongation in rice seedlings without causing signs of necrosis.  
The Banwell Group have exploited the sorts of chemical “cutting” (through 
ozonolysis) and “stitching” (often using RCM) processes described in Schemes 
6 and 7 in developing syntheses of a range of other macrolides including (–)-
cladospolides A (34)32 and B (35),30 the resorcylic acid lactone L-783,290 (36),33 
its cis-isomer L-784,277 (37),34 ent-bengamide E (38)35 and goniodiol (39).36  
Cl
1
(X = Cl)
31
O
32
71%
OH
OH
MeO
O
O
OH
OH
(i) H2, Rh on Al2O3
(ii) p-O2NC6H4CO2H, Ph3P
DEAD
(iii) K2CO3, MeOH
(iv) 2,2,3,3-TMB, H+
54%
(i) O3, MeOH
then Me2S
(ii) Ph3P=CH2
nine steps
26%
O
O
OMe
OMe
33
O
O
OMe
OMe
Cl
20
They have also employed analogous processes in constructing polyoxygenated 
cyclo-octenones such as 40 related to the Eastern hemisphere of the novel 
macrolactam tripartilactam 41.37
An electrophilic epoxidation/nucleophilic ring-opening sequence that provided 
access to analogues of the C-riboside showdomycin is shown in Scheme 8.38  
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Scheme 8 
This involved treating the epoxide 3 derived from cis-1,2-dihydrocatechol 1 (X = 
Br) with pyrrole 42 in the presence of indium chloride and thus affording adduct 
43. Acetylation of the hydroxyl group within the last compound followed by
exposure of the resulting ester 44 to hydrogen in the presence of palladium on
carbon resulted in deletion of the bromo-alkene residue and formation of the tetra-
substituted cyclohexane 45. Treatment of compound 45 with TBAF afforded the
mono-substituted pyrrole 46 and exposure of this to pyridinium chlorochromate
(PCC) then gave the maleimide 47 that was converted into the target analogue
48. Evaluation of compound 48 as a cytotoxic agent revealed that it was a potent
and selective inhibitor of the HEK293 cell line (IC50 = 4.76 µM) and thus only
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slightly less active than showdomycin (49) (IC50 = 3.27 µM). In related work 
epoxide 3 was reacted with a series of diamines and thus producing a range of 
linked cyclitols that, after sulfation, were employed as heparin sulfate mimetics 
to probe to the heparin/heparan sulfate binding specificity of certain proteins.39   
5. Synthetic Studies Involving Cross-coupling and Related C-C Bond
Forming Reactions
The synthetic utility of the two halogenated cis-1,2-dihydrocatechols 1 (X = Br 
or I) is greatly enhanced by the capacity to engage them or (more commonly) 
their derivatives in cross-coupling and related processes. Prompted by the early 
studies of Ley,40 one of the Banwell Group’s first studies of such processes 
involved the synthesis of the (–)-gabosine A, a carba-sugar enone from 
Streptomycetes, congeners of which display cytotoxic and plant-growth 
regulating properties.41 The reaction sequence used is shown in Scheme 9 and 
involved the initial mono-silylation of the less hindered hydroxyl group within 
substrate 1 (X = I) and stereoselective hydroxylation of the olefinic residue 
within product 50 so as to form triol 51 the acetonide derivative, 52, of 
which was oxidised to the α-iodoenone 53. Attempts to replace the iodine 
within the last compound with a methyl group using Stille, Kumada or 
Negishi-type cross coupling protocols all failed. In stark contrast, this 
substrate reacted with methylmagnesium chloride in the presence of 
ferric chloride to produce compound 54 that upon treatment with acidic 
methanol afforded (–)-gabosine A (55). Compound 1 (X = I) rather than its 
methylated congener was used as the starting material in this reaction 
sequence because of the greater degree of regioselectivity observed in the 
first two steps when the former cis-1,2-dihydrocatechol was employed.41   
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Scheme 9 
Suzuki-Miyaura cross-coupling reactions have been successfully employed with 
various compounds derived from the cis-1,2-dihydrocatechols (1, X= Br or I). 
For example, brominated cyclohexenes such as 43 (see Scheme 8) can be reacted 
with a wide range of arylboronates as a key step in generating a series of 
disulfated cyclitols, some of which are regarded as promising candidates for 
development of agents that act against the herpes simplex virus.42   
A synthesis of the non-natural enantiomeric form of the Amaryllidaceae alkaloid 
lycoricidine from compound 1 (X= Br) is shown in Scheme 10 and also employs 
a Suzuki-Miyaura cross-coupling reaction as a key step.43 This synthesis involves 
an initial six-step sequence, including reactions of the types detailed in the 
preceding sections, leading to the trichloroacetimidate 56. Subjection of this to a 
thermally induced Overman rearrangement reaction afforded, after reduction of 
the initially produced acetamide, the amine 57. This last compound was then 
engaged in a Suzuki-Miyaura cross-coupling reaction with the aryl boronate 58, 
with the primary product of this reaction engaging in a spontaneous lactamisation 
reaction to establish the target framework. The MOM-ether residues associated 
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with the lactam so-formed were cleaved with trimethylsilyl bromide and so 
forming ent-lycoricidine (59). Interestingly, the above-mentioned Overman 
rearrangement reaction is the first example of such a process involving an 
halogenated alkene, a process that has since been extended to some related 
systems albeit while also involving competing formation of allylic chlorides.44
Scheme 10 
The Banwell Group have also employed related Suzuki-Miyaura cross-couplings 
in the synthesis of the enantiomers of other Amaryllidaceae alkaloids including 
ent-narciclasine (60),45 ent-clividine (61),46 the enantiomer, 62,47 of the structure 
originally assigned to nobilisitine A, the enantiomer, 63,48 of the true structure of 
the same alkaloid as well the enantiomerically related compounds 6449 and 6550 
either of which could represent the structure of narseronine, a recently isolated 
alkaloid for which no optical rotation data has been reported. The fact that both 
enantiomers 64 and 65 were prepared from the same starting material, viz. 1 (X = 
Br) highlights the capacity to deploy certain cis-1,2-dihydrocatechols in 
enantiodivergent syntheses. The cytotoxic properties of certain of the above-
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mentioned compounds were assessed but none proved to be as active as their 
naturally occurring enantiomers.51  
Tandem Suzuki-Miyaura cross-coupling/intramolecular Mitsunobu displacement 
(cyclisation) reactions provided the means to prepare the neurologically active 
ribisin class of natural products and, in some instances, correct the structures 
originally assigned to them.52 So, for example, compound 1 (X = Br) was readily 
converted (Scheme 11) over six conventional steps into the bromoconduritol 66 
and this engaged in a Suzuki-Miyaura cross coupling reaction with the 
commercially available phenylboronic acid ester 67 and so affording the 
anticipated product 68 (80%). This last compound participated in an 
intramolecular Mitsunobu reaction to give the benzofuran isomer 69 (88%) that 
upon sequential treatment with 2-methoxyethoxymethyl chloride (MEM-
Cl)/NaH then m-chloroperbenzoic acid (m-CPBA) gave benzofuran 70 and upon 
Swern oxidation this was converted into the ketone 71 (49% from 69). 2,3-
Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)-mediated cleavage of the PMB 
ether residue associated with compound 71 gave the corresponding alcohol that 
was immediately subjected to a Mitsunobu reaction using α-chloroacetic acid as 
the nucleophile and thus affording ester 72 in 69% yield. Successive cleavage of 
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the MEM-ether and then the ester moieties associated with compound 72 finally 
gave, via intermediate 73, ribisin A (74) in 50% yield.  
Scheme 11 
Related cross-coupling reactions have been employed in the assembly of various 
natural products embodying alkynyl-substituted cyclohexene moieties. The 
synthesis (–)-tricholomenyn A by such means is illustrative of the protocols that 
were developed.53 Thus, treatment of compound 1 (X = I) with NBS in the 
presence of water afforded the bromohydrin 75 (66%) (Scheme 12) that upon 
reaction with sodium methoxide gave epoxide 76 (79%). The sterically less 
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hindered hydroxyl group associated with this last compound could then be 
engaged in a Mitsunobu reaction using acetic acid as nucleophile and the 
hydroxyl-ester 77 (62%) so-formed oxidised with PDC to give the enone 78 in 
76% yield. Finally, a Stille-type cross coupling between compounds 78 and 79 
then completed the synthesis by providing (–)-tricholomenyn A (80) in 72% 
yield.   
Scheme 12 
In a related vein, a Sonogashira cross-coupling reaction between compound 77 
and the terminal alkyne 81 provided compound 82 (85%) that was readily 
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elaborated to the carboxylic acid 83, the putative biosynthetic precursor to 
trichlomenyn B (84) (and the first example of a natural cyclohexenoid containing 
an acetylenic ansa bridge). However, all attempts to effect the conversion 83 o 
84 failed.54  
Closely related studies undertaken by the author and detailed in Publication 2 
have allowed for the preparation of the naturally occurring and phytotoxic 
geranylcyclohexentriol (–)-phomentrioloxin (85)55 as well as a series of 
analogues including the deoxy-compound 86 that has been shown, through 
various test conducted by colleagues at BASF in Germany, to display modest 
herbicidal activities.56 Physiological profiling studies suggest that this analogue 
inhibits photosystem II in isolated thylakoids in vitro.  
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As another part of the work carried out by the author (see Publication 3 for 
details), compounds 87 and 88, representing the structures assigned to (+)-
asperpentyn and ent-aspergillusol A respectively, have also been prepared using 
Sonogashira cross-coupling protocols and by such means the structures assigned 
to the natural products confirmed.57
Other effective methods for replacing the halogen derived from the relevant cis-
1,2-dihydrocatechols with carbon based groups are possible. Thus, during the 
course of establishing the synthesis of a highly functionalised cyclohexenone 
related to the A-ring of the furanosteroid viridian from compound 1 (X = Br), it 
was shown that two derived β-bromocyclohexenones readily engaged in 
conjugate addition/elimination reaction with methyl lithium in the presence of 
PhSCu to give the corresponding β-methylcyclohexenones.58 Furthermore, 
Negishi cross-coupling reactions have provided an effective means for replacing 
the halogen within, for example, the acetonide derived from compound 1 (X = I) 
by various unsaturated hydrocarbon chains and thus allowing for, inter alia, intra-
molecular Diels-Alder reactions to be carried out. Details of some such processes 
are provided in the following section.
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6. Inter- and Intra-molecular Diels-Alder Reactions of the cis-1,2-
Dihydrocatechols as Key Steps
As highlighted in Figure 2, the presence of a cyclohexa-1,3-diene unit within cis-
1,2-dihydrocatechols of the general form 1 suggests they could participate, as 4π-
addends, in Diels-Alder reactions. The reality is that while the parent systems are 
themselves rather unreactive in this respect,59 various derivatives readily 
participate in such cycloaddition reactions. In particular, the corresponding 
acetonides, including compounds 2, 5 and 23, engage in a range of Diels-Alder 
processes including (often frustratingly!) dimerisations in which one molecule 
acts as the diene and another as the dienophile.  
The Banwell group’s earliest attempt to exploit the Diels-Alder adducts derived 
from cis-1,2-dihydrocatechols is shown in Scheme 13.60 This started with the 
conversion of the toluene-derived cis-1,2-dihydrocatechol 1 (X = Me) into the 
corresponding acetonide 89 (95%) and reacting this in a facially selective and 
thermally induced Diels-Alder reaction with maleic anhydride to produce adduct 
90 (68%) that was readily converted over conventional three steps into diol 91 
(87%). Selective oxidation of the hydroxyl group remote from the bridgehead 
methyl group within the last compound using the sterically demanding 
oxammonium salt derived from the disproportionation of 4-acetamido-TEMPO 
then gave acyloin 92 (97%), the acetate derivative of which could be 
deoxygenated using samarium diiodide to give ketone 93 (81%). The 
stereoselective addition of vinyl magnesium bromide to this last compound then 
gave the allylic alcohol 94 (61%) that could be engaged in an anionic oxy-Cope 
rearrangement reaction using potassium hydride in the presence of 18-crown-6 
(18-C-6) to give, after acid work up, the cis-decalin 95 (80%).  
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Scheme 13 
By related means involving selective protection of the hydroxyl group remote 
from the bridgehead methyl group within diol 91 the allylic alcohol 96 could be 
obtained (ca. 23% over six steps) and on engaging this in an anionic oxy-Cope 
rearrangement reaction the pseudo-enantiomeric cis-decalin 97 (55%) was 
produced.60  
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Extensions of this chemistry wherein the acetonide 2 is engaged in a Diels-Alder 
reaction with p-benzoquinone (rather than maleic anhydride) and a cyclopentene-
derived organo-cerium reagent is used in place of vinyl magnesium bromide has 
allowed for the formation of the steroid-like tetracyclic system 98.61Variations on 
this Diels-Alder cycloaddition/anionic oxy-Cope rearrangement “theme” have 
also provided the means for constructing the AB-ring substructures of taxoids and 
ent-taxoids, as manifest in compounds 99 and 100, respectively.62 A product from 
the latter studies has also enabled the development of a total synthesis of the 
sesquiterpenoid (–)-patchoulenone (101)63 while the application of a Wolff ring-
contraction protocol to a taxoid-type AB-ring substructure has provided a route 
to the carbobicyclic core of the CP-225,917 (102), an inhibitor of Ras farnesyl 
transferase.64 
 
 
 
 
In 2006 the Banwell Group reported65 that the high-pressure promoted Diels-
Alder cycloaddition of 2-cyclopenten-1-one (103) to diene 89 proceeds (Scheme 
14) in both a regio- and a stereo-controlled manner to give adduct 104 (71%) that 
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has served as the precursor to various linear triquinane-type sesquiterpenoid 
natural products. 
Scheme 14 
So, for example, successive treatment of compound 104 with lithium 
hexamethyldisilazide (LiHMDS) then methyl iodide then LiHMDS and Mander’s 
reagent (MeO2CCN) gave the crystalline ester 105 (75%) that could be elaborated 
over four conventional steps, including a Barton-McCombie deoxygenation 
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reaction, into diol 106 (ca. 75%). Selective oxidation of the hydroxyl group 
within this last compound followed by benzoylation of the resulting acyloin then 
gave keto-ester 107 (74%) that was subjected to an oxa-di-π-methane 
rearrangement66 by photosensitized irradiation and thus affording the 
cyclopropannulated triquinane 108 in 81% yield. Successive reductive cleavages 
of the benzyloxy group (using samarium iodide) and three-membered ring 
(using n-Bu3SnH/AIBN) associated with compound 108 and Saegusa-type 
oxidation of the resulting cyclopentenone then gave enone 109 (74%), an 
established precursor to the natural products (+)-hirsutic acid (110) and (–)-
complicatic acid (111).
Extensions of these protocols have since been reported67 that provide total or 
formal total syntheses of phellodonic acid (112), (–)-connatusin A (113), (+)-
connatusin B (114), (–)-hypnophilin (115) and (–)-coriolin (116). A route to the 
octahydro-1,6-methano-1H-indene framework associated with the marine 
sesquiterpenoid 2-isocyanoallopupukeanane (117) has established by related 
means.68 
By subjecting annulated bicyclo[2.2.2]octenones related to compound 107 (see 
Scheme 14) to direct rather than sensitized irradiation these have been shown to 
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participate in 1,3-acyl or Givens rearrangement reactions66 and so providing the 
tricarbocyclic frameworks of the fascinating protoilludane class of 
sesquiterpenoid natural product. Specifically, then, and based upon earlier model 
studies,69 it has been possible to effect a total synthesis of the enantiomers of the 
structures assigned to 8-deoxydihydrotsugicoline and radudiol, compounds 
isolated from, inter alia, a saprotrophic, wood-decay fungus encountered in 
deciduous forests throughout East Asia, North America and Europe.70 Once 
again, the reaction sequence starts with the Diels-Alder adduct 104 (Scheme 15) 
that is gem-dimethylated under standard conditions to give compound 118 (56%) 
that over four steps and in 41% overall yield was converted into diol 119. A 
regisoselective oxidation reaction followed and after deletion of the remaining 
hydroxyl group in the usual way the cyclopentannulated bicyclo[2.2.2]octenone 
120 was obtained in 65% yield. On direct irradiation of a dichloromethane 
solution of this last compound the pivotal 1,3-acyl migration reaction ensued and 
so producing the pivotal 5/6/4 tricarbocyclic system 121 albeit in just 28% yield. 
Nevertheless sufficient quantities of this photoproduct could be accumulated so 
as to complete the syntheses of the target protoilludanes. Thus, a three-step 
procedure involving a (none-selective) epoxidation of compound 121 with 
dimethyl dioxirane (DMDO), a base-promoted E1cB reaction of the relevant 
epoxide and a conjugate addition reaction of the product J-hydroxyenone using 
the Gilman reagent then gave compound 122 (18%), the enantiomer of the natural 
product 8-deoxydihydrotsugicoline. Reduction of cyclobutanone 122 using Red-
Al proceeded non-stereoselectively to afford a chromatographically separable 
mixture of alcohols 123 (41%) and 124 (53%). The structure of the former 
product was established by single-crystal X-ray analysis and this proved to be 
enantiomerically related to the natural product radudiol. 
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Scheme 15 
In a related study,59d it was demonstrated that the Diels-Alder adduct derived from 
the direct α-face addition of cyclopentenone 103 to cis-1,2-dihydrocatechol 1 (X 
= Me) could be elaborated to the natural enantiomeric or (+)-form, 125, of the 
protoilludane aryl ester armillarivin. 
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The intramolecular Diels-Alder (IMDA) reactions of derivatives of the cis-1,2-
dihydrocatechols incorporating tethered dienophiles have proven to be 
particularly valuable processes in terms of providing access to novel molecular 
scaffolds.71 So, for example, as shown in Scheme 16 the readily prepared bis-
crotonate ester 126 (81%) of diol 1 (X = Me) engages, on heating, in the two 
possible IMDA processes to give the corresponding and chromatographically 
separable and lactone-containing adducts 127 (40%) and 128 (26%). Cleavage of 
the ester residues within the second of these then gave the corresponding alcohol 
129 (74%) that could be oxidised to the ketone 130 (86%). Similarly, lactone-
ester 127 is readily converted into the alcohol 131 (79%) and this, in turn, can be 
oxidized to the corresponding ketone 132 (94%). Significantly, the frameworks 
associated with each of the compound pairs 127/128, 129/131 and 130/132 are 
enantiomerically related (the bis-desmethyl analogues of keto-lactones 130 and 
132 are enantiomers).   
Scheme 16 
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Since each of compounds 130 and 132 incorporates a bicyclo[2.2.2]octenone 
residue these are each capable of engaging in either photochemically-promoted 
oxa-di-π-methane or 1,3-acyl migration reactions. The behaviour of compound 
130, as shown in Scheme 17, is indicative of the possibilities. Thus, 
photosensitized irradiation of this substrate produces the lactone-annulated 
diquinane 133 (40%) while direct photolysis afforded mixtures of the 1,3-acyl 
migration product 134 and its decarbonylated counterpart 135 with the precise 
ratio of these last two compounds being determined by the length of the 
irradiation period.71b  
 
 
Scheme 17 
 
The Negishi cross-coupling of acetonide 136 derived from cis-1,2-
dihydrocatechol 1 ( X = I) with the racemic organozinc species 137 (Scheme 18) 
provided triene 138 (65-85%) as a mixture diastereoisomers that upon heating in 
refluxing toluene engaged in an IMDA reaction to give a 1:1 mixture of the 
epimeric forms of adduct 139 (89% combined yield).72 It has been assumed this 
remarkably facile and efficient intramolecular cycloaddition reaction involving 
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an unactivated dienophile is facilitated through activation of the diene by 
annulation with the acetonide ring. Various standard manipulations allowed for 
the conversion of this mixture of adducts, over six steps, into the corresponding 
mixture of bis-benzoates 140 (68%) and over a further two steps this was 
transformed into the exocyclic olefin 141 (84%). Cleavage of the benzoate 
residue within this last compound using potassium carbonate in methanol gave 
the anticipated alcohol that was oxidised to corresponding ketone and under 
Saegusa dehydrogenation conditions this could be transformed into enone 142 
(61%), an established precursor to platencin (143) which is a structurally novel 
and potent anti-bacterial agent that exerts its beneficial effects via a novel mode 
of action.  
Scheme 18 
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In subsequent and somewhat more convergent approach to platencin, the Banwell 
Group reported73 that acetonide 136 could be cross-coupled with the Z-configured 
alkenylstannane 144 (Scheme 19) and so affording product 145 (80%) that was 
oxidized to the corresponding ketone 146 (53%) using the Dess-Martin 
periodinane (DMP). On heating the last compound in refluxing toluene it 
underwent an IMDA reaction to form adduct 147 (70%) that embodies many of 
the structural features of the natural product. Using many of the features 
associated with the earlier study72b compound 147 could be carried forward to 
complete a total synthesis of platencin.  
Scheme 19 
Recently the Banwell Group has been able to combine their knowledge of the 
IMDA reaction of trienes derived from acetonides such as 136 with that of the 
photochemical behaviours of annulated bicyclo[2.2.2]octenones in establishing a 
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route to the sterpurene framework.74 Thus, as shown in Scheme 20, the cis-1,2-
dihydrocatechol 148 derived from the whole-cell biotransformation of p-
iodotoluene was converted, under standard conditions, into the corresponding 
acetonide 149 (80%) and this was itself engaged in a Negishi cross-coupling 
reaction with organozinc species 150 so as to form the triene 151 (97%). When a 
toluene solution of compound 151 was heated under reflux a smooth IMDA 
reaction took place to give the tricarbocyclic compound 152 (88%) and this could 
be elaborated over four conventional steps and in 33% yield to the photosubstrate 
153. On direct irradiation of this last compound a smooth 1,3-acyl migration 
reaction took place and thus affording compound 154 (85%) that embodies the 
targeted 5/6/4 tricarbocyclic system. Over a further nine steps and in 11% overall 
yield photoproduct 154 was converted into diol 155 that represents the 
enantiomer of the structure, ent-155, assigned to a metabolite isolated from the 
culture broth of the fungus Stereum purpureum that causes silver-leaf disease. 
However, a comparison of the NMR data recorded on the synthetic material 155 
with that reported for the natural product revealed they are different compounds 
and so it was concluded that the structure of the metabolite has been assigned 
incorrectly.  
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Scheme 20 
Acetonide 149 also served as the starting material in a synthesis of the 
sesquiterpene khusiol (Scheme 21).75 Thus, metallation of this compound so as 
to form the cuprate and selective addition of the latter to the less hindered β-
terminus of the penta-1,4-diene-3-one 156 provided the conjugate addition 
product 157 (60%). Comformational restrictions prevented compound 157 from 
engaging in an IMDA reaction but one of the epimeric alcohols, 158, (83%) 
derived from Luche reduction did cyclise on heating to give adduct 159 (44%) 
that embodies the framework of the target sesquiterpenoid. Over a further thirteen 
steps this last compound could be elaborated to khusiol (160) that upon treatment 
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with POCl3 underwent dehydrative rearrangement to give prezizaene (161)76 in 
53% yield. 
 
 
 
Scheme 21 
 
Extensions of the chemistry defined in immediately above have enabled the 
synthesis of bis-ester 162 that embodies the tetracyclic core of the biologically 
active tashironin class of sesquiterpenoid, the parent member of which is 
compound 163.77 The tricarbocyclic framework associated with the marine-
derived sesquiterpenoid viridianol (164) has also been obtained by similar 
means.78 
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7. Other Manipulations of the Functionalities Present in Derivatives of 
the cis-1,2-Dihydrocatechols 
 
The abovementioned successes exploiting the cis-1,2-dihydrocatechols or their 
derivatives as 4π-addends in the Diels-Alder reactions prompted the Banwell 
Group to begin exploring their capacity to participate in other cycloaddition 
processes. They rapidly established79 that acetonide 2 engaged (Scheme 22) in a 
regio-and stereo-selective [2 +2] cycloaddition reaction with in situ generated 
dichloroketene and thus generating adduct 165 (65%) that on treatment with 
diazomethane afforded the ring-expansion product 166 (57%). This 
tetrahydroindanone was then elaborated to the cycloalkenylstannane 167 that was 
itself cross-coupled with enol triflate 168 to give diene 169 (34%). This last 
compound then participated in a thermally promoted Diels-Alder reaction with 
N-phenylmaleimide (170) to afford a mixture of adducts 171 and 172 (53% 
combined yield) that embody steroidal frameworks.  
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Scheme 22 
 
Intramolecular [2+1], [2+2] and [3+2] cycloaddition reactions have also been 
developed with the substrates required for such processes normally being 
prepared using Negishi cross-coupling chemistry.80 So, for example, acetonide 
136 could be coupled (Scheme 23) with the organozinc compound 173 and so 
forming ester 174 (83%) that was readily converted, via the corresponding acid, 
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into the diazoketone 175 (80%). Exposure of this last compound to Cu(acac)2 in 
refluxing dichloromethane then gave, presumably through addition of the derived 
carbenoid to the proximate double bond of the cis-1,2-dihydrocatechol residue, 
the cyclopropane 176 (85%). An exploration of the reactivity of this 
intramolecular cycloaddition product revealed that on being heated at 140 °C it 
rearranged to give the spirocyclic system 177 in 70% yield. 
 
 
 
Scheme 23 
 
Annulated aziridines and related compounds can also be generated by analogous 
means and Banwell and Matveenko have thereby been able to establish a 
synthesis of the anti-influenza agent Tamiflu™ (178) from cis-1,2-
dihydrocatechol 1 (X = Br).81  
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While the cis-1,2-dihydrocatechols embody two allylic alcohol residues and 
could, in principle, be substrates for Claisen-type rearrangement reactions the 
conditions normally required to effect such processes would be expected to result 
in the dehydrative aromatisation of the title compounds. That said, such 
rearrangements do take place when one or other of the double bonds is removed. 
So, for example, Banwell and White were able to convert, by standard methods, 
cis-1,2-dihydrocatechol 1 (X = Br) into the conduritol 179 (Scheme 24) and then 
engage the latter in an Eschenmoser-Claisen rearrangement reaction by heating it 
with the dimethyl acetal of N,N-dimethylacetamide.82 By such means amide 180 
(94%) was obtained and this was carried forward in a conventional manner and 
over six steps into the α-iodocyclohexenone 181 (51%). The palladium-catalysed 
Ullmann cross coupling of this halogenated material with 2-iodo-5-
methoxynitrobenzene (182) then gave compound 183 (92%) that upon exposure 
to hydrogen in the presence of Raney cobalt underwent a tandem reductive 
cyclisation reaction to give the indole annulated perhydroquinoline 184 (85%), a 
compound that was readily elaborated to congener 185. The last compound 
embodies most of the key structural elements associated with alkaloid vindoline 
(186), a biogenetic and synthetic precursor to the therapeutically important 
natural products vinblastine and vincristine. 
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Scheme 24 
 
Given the capacity it provides to construct quaternary carbon centers in a 
predictable manner, the Eschenmoser-Claisen rearrangement reaction has also 
played a pivotal role in the development of total syntheses of the clinically-
deployed anti-Alzheimer’s drug galanthamine (187) and, as shown in the author’s 
4th Publication, various analogues.83-85 When used in conjunction with the Suzuki-
Miyaura cross-coupling, intramolecular SNc and Pictet-Spengler reactions, the 
Eschenmoser-Claisen rearrangement has also allowed the establishment of a total 
synthesis of (+)-amabiline (188), the enantiomer of a crinine alkaloid.86,87 
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Another very useful feature associated with derivatives of the chlorinated and 
brominated cis-1,2-dihydrocatechols 1 (X = Cl and Br, respectively) is the 
capacity to engage them in intramolecular, radical addition/elimination reactions. 
So, for example, when the D-thiophenylated amide 189 (Scheme 25) derived 
from compound 1 (X = Cl) is treated with under radical generating conditions it 
is converted into the lactam 190 (94%) that can be elaborated, using Pictet-
Spengler chemistry, to compound 191, the enantiomer of the montanine alkaloid 
(–)-brunsvigine.88 Interestingly, the equivalent radical cyclisation of the bromo-
analogue of compound 189 is a much less efficient process (29% of compound 
190 was obtained). Extensions of this chemistry have provided routes to (+)-
nangustine (192)89 and the structure, 193,90 erroneously assigned to (+)-
montabuphine. Efforts to establish the true structure of this last natural product 
continue, as do those directed towards further exploiting the above-mentioned 
radical addition/elimination process.91  
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Scheme 25 
8. New Chirons
Another facet of the Banwell Group’s studies in the general area detailed above 
has been the identification of chirons that might complement the utility of 
cis-1,2-dihydrocatechols 1. In doing so, they have developed syntheses of 
the homochiral γ-hydroxycyclohexenone 194 and its enantiomer from D-(–)- 
and L-(+)-tartaric acid, respectively, and used the former chiron to prepare the 
cyclic carbonate-containing natural product aspergillusol B (195).92,93 The 
now abundant metabolite (–)-3-dehydroshikimic acid (196) was also used by 
Group members in the development of a synthesis of the sialic acid (–)-KDN 
(197)94 who also developed simple protocols for converting it into its enantiomer 
198.95 With the assistance of microbiologists in the biotech industry the Banwell 
Group have also produced new cis-1,2-dihydrocatechols such as 19996 as  
well as beginning to explore the chemistry levoglucosenone (200), a material 
that is now available in tonne quantities through pyrolysis of acid-impregnated 
waste paper and other
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cellulosic materials. As part of that study the Banwell group has been able to 
devise ways in which compound 200 is converted into its so-called quasi-
enantiomer isolevoglucosenone (201).97 They have also established a method for 
the four-step conversion of cis-1,2-dihydrocatechol 1 (X = Br) into the 5,6-trans-
dihydroxylated α-bromocyclohexenone 202.13
9. Conclusions
The cis-1,2-dihydrocatechols (1) obtained through the whole-cell 
biotransformation of the corresponding aromatic have proven to be 
extraordinarily effective chirons in a diverse range of synthetic endeavours. When 
one considers this and that only a very small fraction of the known metabolites of 
this type have been deployed in chemical synthesis then the possibilities for the 
further development of the field (of chemoenzymatic synthesis) seem almost 
endless. In order for such developments to be most effective strong collaborations 
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between chemists and microbiologists are required in order that “customised” 
metabolites are produced for the particular synthetic pathway being followed. 
Otherwise it is all too tempting for the molecule makers to use strictly chemical 
means (rather than microbiological ones) to offset the suboptimal nature of 
a given (and more readily available) metabolite and so introducing possibly 
unnecessary steps into the synthesis. So, the more profitable future will be the 
one where the chemist and the microbiologist work to identify (and then 
produce) the optimal metabolite for a given task. Current best practice in this 
regard can be found in the very elegant work being undertaken by Tomas 
Hudlicky and his colleagues at Brock University in Canada. The capacity of 
microbiologists to engineer metabolic pathways such that orchestrated 
sequences of metabolic events can take place within the one biotransformative 
“event” also holds great promise. As a modest example of such possibilities 
the whole-cell (“one-pot”) biotransformation of m-ethyltoluene into 
metabolite 199 (and the result of the operation of both mono- and di-
oxygenases) stands out. The bottom line (as far as the author is concerned) is 
that synthetic chemists need to spend more time talking with microbiologists. 
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Abstract 
The whole-cell biotransformation of mono-nuclear aromatic compounds using certain genetically-
engineered micro-organisms that over-express the enzyme toluene dioxygenase (TDO) allows for the 
large scale production of compounds known as cis-1,2-dihydrocatechols.  These metabolites, which are 
normally obtained in enantiomerically pure form, can be manipulated, by chemical means, in a range of 
distinct (and predictable) ways with the result that they have proven to be especially versatile starting 
materials for the assembly of a range of structurally diverse and biologically active systems.  Herein we 
describe, on a case-by-case basis, the recent applications of various combinations of TDO-mediated and 
chemical steps in so-called chemoenzymatic total syntheses of a range of organic compounds with 
therapeutic potential. 
 
 
Introduction 
Chemical space (viz. the space spanned by all 
possible small molecules and chemical 
compounds) is essentially infinite.1  The 
challenge, then, has been to access the most 
meaningful or useful parts of it.  Nature has 
provided critical inspirations.  So, 3.8 billion 
years of evolution has produced a global 
molecular library of unsurpassed size, 
structural diversity and functional value – our 
planet’s chemome.2,3,4  Humankind has 
sought to “mine” this bioactive molecule 
resource for its benefit and such endeavors 
have been spectacularly successful as 
evidenced by the existence of the remarkable 
array of medicines, materials and 
agrochemicals that underpin society as we 
know it today.  As a result the world we live 
in has been transformed.  This is evidenced 
by our exploitation of drugs with household 
names such as penicillin, morphine and 
Taxol®.  There are many additional but 
perhaps less well-known examples.  For 
instance, organ transplant surgery would fail 
completely without the post-operative 
application of the chemome-derived anti-
rejection drugs such FK506 and cyclosporin 
A.5  Similarly, a significant number of agents 
that control agricultural pests, and so helping 
to ensure both the security and efficiency of 
world food production, have also come from 
Nature/the global chemome.6 
Despite such successes, enormous 
challenges remain.  So-called unmet scientific 
and societal needs include those arising from 
the development of resistance to current 
therapies (perhaps seen most prominently in 
the area of antibiotics7) and, in the 
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agrochemical sector, pest-control agents.8 In 
addition, there is a desperate need for small 
molecule entities that provide, inter alia, 
effective control of neurodegenerative 
diseases and diabetes in a globally aging 
population, for ones that treat certain types of 
refractory cancers and for others that 
effectively modulate mammalian and other 
immune systems. 
After forays into areas such as 
combinatorial chemistry,9 major players in the 
pharmaceutical industry, sometimes in 
partnerships with Government-funded 
agencies, are returning to interrogation of the 
chemome (or at least portions thereof) as a 
means for productively probing chemical and 
thence biological space.10  There are a number 
of reasons for such moves10 including the 
recognition that, for example, the current 
pharmaceutical industry is built on <10% of 
the biosynthetic capacity of the microbial 
world, one that continues to show a 
remarkable ability to deliver biologically 
relevant small molecules.11 
Occurring in tandem with these trends is 
the emergence of a plethora of new 
techniques and concepts concerned with the 
generation of biologically relevant molecular 
diversity involving the use of, inter alia, 
techniques of de novo biosynthesis for 
producing functionally annotated chemome 
components,12 the creation of new metabolic 
pathways,12 synthetic fermentation,13 and 
activity-directed synthesis.14  Simultaneously, 
new synergies are being recognized between 
in vitro, in vivo and in silico studies of drug 
metabolism 15 and thus allowing for much 
more efficient/rapid assessments of the utility 
of certain compounds as molecular probes, 
drugs and/or agrochemicals. 
The development of new methods and 
protocols for effecting the chemical synthesis 
of biologically active natural products and 
various analogues remain important parts of 
the range of activities concerned with 
exploiting components of the global 
chemome for therapeutic and other purposes.  
At least two motivations drive such efforts, 
the first being the need to address issues of 
supply.  Thus, it is often the case that 
secondary metabolites2 are only available in 
miniscule amounts from their natural source 
with the result that insufficient material is 
available for development purposes. 
Chemical synthesis is often the best method 
for addressing such issues.  Secondly, truly 
useful chemical syntheses offer the capacity to 
generate analogues of the natural product that 
would not normally be available through 
manipulation of the natural product itself.  
This article, which is based on a lecture 
presented by the senior author at the 
University of Sydney as part of the RSNSW’s 
2014 Liversidge Award, details work being 
undertaken at the Australian National 
University on the exploitation of certain 
chemoenzymatic methods for the synthesis of 
biologically active natural products and their 
analogues.  The work is presented according 
to the class of natural product being targeted 
as well as the structural and chemical 
relationships between them. 
 
Results and discussion 
The term chemoenzymatic synthesis used in 
this article, and elsewhere,16 refers to the 
assembly of target compounds using a 
combination of chemical and enzymatic 
techniques.  While there are many variations 
on this theme that reflect the extraordinarily 
diverse range of chemical and enzymatic 
transformations available these days, the 
specific form of the latter that applies here 
involves the whole-cell biotransformation of 
a range of simple and readily available 
aromatic compounds of the general form 1 
(Scheme 1) into the corresponding cis-1,2-
dihydrocatechols (2).16  When genetically 
engineered micro-organisms such as E. coli 
JM109 (pDTG601)17 are used for such 
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purposes, these metabolites can be readily 
produced at kilogram scales and are often 
obtained in >99.95 enantiomeric excess (ee).  
In the illustrated cases the enzyme 
responsible for these conversions is toluene 
dioxygenase (TDO) but a number of related 
ones are known including biphenyl 
dioxygenase, naphthalene dioxygenase and 
toluate dioxygenase.  The end result is that a 
remarkable suite of cis-1,2-dihydrocatechols 
and related metabolites is known - these 
number in the many hundreds at the present 
time.16c  Given the capacities to produce 
numerous mutants, and thus expand the 
range of substrates that can be 
biotransformed, the possible extensions of 
such processes would appear to be vast.  A 
further fascinating aspect of them is the 
“chemoselectivities” they can display.  So, for 
example, styrene (1, X = CH=CH2) is 
converted into the triene 2 (X = CH=CH2), a 
process wherein the aromatic ring is oxidised 
in preference to the exocyclic olefin, a 
functional group selectivity that cannot be 
achieved by any of the strictly chemical 
methods known at the present time.18 
 
 
 
Scheme 1 
 
The utility of the cis-1,2-dihydrocatechols (2) 
as starting materials in chemical synthesis has 
taken some time to be recognised in a 
broader sense.  Various groups, especially 
those led by Ley in the UK19 and Hudlicky in 
North America,16a,d have carried out the 
pioneering work in the area.  Such studies 
established the reactivity “patterns” shown in 
Figure 1 as well as attendant hazards arising 
from the dehydrative re-aromatisation of 
these substrates20 and the propensity of 
certain derivatives, most notably the 
corresponding acetonides, to engage in 
normally unproductive Diels-Alder (DA) 
dimerization reactions.21 
 
 
 
Figure 1 
 
Our own contributions in the area began in 
the late 1980s22 and in the intervening period 
we have been able to establish a series of total 
syntheses (Figure 2) that emphasise the 
extraordinary range of natural product targets 
available through manipulation of these 
metabolites.  Some specific examples arising 
from our recent research are discussed on a 
case-by-case basis in the following sections. 
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Figure 2 
 
The Ribisins 
Ribisins A-D were isolated by Fukuyama and 
co-workers from Phellinus ribis (Schmach.) 
Quél (Hymenochaetaceae),23 a fungus used in 
traditional medicine for various purposes.  
Using a range of spectroscopic methods they 
were assigned structures 3-6 (Figure 3), 
respectively, and shown to enhance neurite 
outgrowth in PC12 cells at ca. 1 µM 
concentrations.  As such they have potential 
for development as agents for the treatment 
of certain neurological disorders. 
 
 
 
 
 
Figure 3 
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Given the structural resemblance of the 
polyoxygenated cyclohexane ring of these 
natural products to the cis-1,2-
dihydrocatechols 2 (X = Br) we sought a 
means for effecting the relevant chemical 
conversions.  The route used for establishing 
a synthesis of compound 5, the structure 
assigned to ribisin C and the most active 
compound in the series, is shown in Scheme 
2.24  
 
 
 
 
 
Scheme 2 
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The opening stages of this reaction sequence 
are typical of the manner in which the cis-1,2-
dihydrocatechols can be manipulated and 
involve the initial conversion of compound 2 
(X = Br) into the corresponding acetonide 
and the regio- and stereo-selective 
epoxidation of the latter to give the oxirane 7.  
Treatment of compound 7 with aqueous 
mineral acid resulted in a regioselective ring-
opening reaction to afford the trans-diol 8 that 
could be bis-O-methylated under conven-
tional conditions and the resulting acetonide 
was then cleaved, again under conventional 
conditions, to give the cis-diol 9 that embodies 
most of the key elements of the Eastern 
hemisphere of target 3.  Compound 9 could 
be engaged in a Suzuki-Miyaura cross-
coupling reaction with the commercially 
available boronate ester 10 and two products 
thereby formed, namely the bis-phenol 11 and 
the dihydrobenzofuran 12.  Product 12 is 
presumably formed through cyclisation of the 
initially produced cross-coupling product 
while congener 11 arises from successive loss 
of the elements of water and methanol (no 
particular order implied) from the same 
intermediate.  The lone hydroxyl group within 
compound 11 could be protected as the 
corresponding α-chloro-acetate 13, a 
necessary step because of the looming 
introduction of a second hydroxyl group as 
the precursor to the ketone moiety.  The use 
of the α-chloroacetate as a protecting group 
proved essential as in the final step of the 
reaction sequence attempts to remove the less 
labile parent acetate resulted in 
decomposition of the substrate. Epoxidation 
of compound 13 using m-chloroperbenzoic 
acid (m-CPBA) led, presumably via 
spontaneous rearrangement of the initially 
formed oxirane, to the benzofuran alcohol 14 
that could be oxidised to the corresponding 
ketone 15 under Swern conditions.  Cleavage 
of the α-chloroacetate residue within this last 
compound was accomplished using zinc 
acetate in methanol and thus forming the 
target compound 5.  While all the usual 
spectroscopic data acquired on compound 5 
matched those reported for ribisin C, the 
specific rotation derived from the synthetic 
material was of the same magnitude but the 
opposite sign to that reported for the natural 
product.  The implications are clear – the 
structure of ribisin C is represented by 
structure ent-5 rather than 5. Since we 
required an authentic sample of ribisin C (ent-
5) for biological testing, a synthesis of it was 
pursued.  This could be achieved (Scheme 3) 
using the same starting material and many of 
the same transformations as employed in 
generating its enantiomer (5).  A key step of 
the fourteen-stage reaction sequence involved 
the inversion of configuration at C3 within a 
derivative of compound 2 (X = Br) using 
Mitsunobu chemistry.  As a result ribisin C 
was obtained and all of the derived data, 
including the specific rotation, matched those 
reported for the natural product. 
 
 
 
Scheme 3 
 
Extensions of this sort of chemistry enabled 
the synthesis of all of the structures originally 
assigned to the ribisins and thus revealed that 
while ribisins A and D are constituted as 
originally described23 that attributed to 
congener B is, like C, incorrect.25 The true 
structures of all the ribisins are shown in 
Figure 4 with the corrected stereocentres 
within compounds B (16) and C (ent-5) 
highlighted in red. Extensive biological 
evaluations of the ribisins and the range of 
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congeners prepared during the course of our 
synthetic studies are now underway. 
 
 
 
Figure 4 
 
Analogues of Galanthamine 
Ribisin D (6) bears a “provocative” structural 
resemblance to the ABC ring-system of the 
alkaloid galanthamine (17) that is used in 
many countries for the symptomatic 
treatment of Alzheimer’s disease (Figure 5).26  
As such we were prompted to explore means 
by which the chemistry described above 
could be adapted so as to produce 
compounds bearing greater similarities to 
galanthamine (or, in the first instance at least, 
the enantiomer thereof). 
 
 
 
Figure 5 
 
An efficient reaction sequence leading to a 
dioxygenated derivative of ent-galanthamine is 
shown in Scheme 427 and involves an initial 
reaction of the abovementioned oxirane 7 
with p-methoxybenzyl alcohol (p-MBOH) in 
the presence of boron trifluoride diethyl 
etherate to generate the anticipated addition 
product that upon treatment, in a second 
step, with methanol containing pyridinium p-
toluenesulfonate (PPTS) affords triol 18.  This 
last compound could be converted into the 
corresponding Ley ketal 1928 through 
treatment with 2,2,3,3-tetramethoxybutane 
(2,2,3,3-TMB) in the presence of p-
toluenesulfonic acid (p-TsOH)/trimethyl 
orthoformate (TMOF) and Suzuki-Miyaura 
cross-coupling of this with the boronate ester 
20 (produced directly from o-methoxyphenol 
using a C-H functionalization protocol) 
afforded the arylated cyclohexene 21. This last 
compound that was itself engaged in an 
intramolecular Mitsunobu reaction using di-
iso-propyl azodicarboxylate (DIAD) to afford 
the dihydrobenzofuran 22. 
Despite the potential for aromatisation 
(through simple double-bond migration), 
compound 22 could be engaged in an 
Eschenmoser-variant of the Claisen 
rearrangement reaction using the dimethyl 
acetal of N,N-dimethylacetamide29 and thus 
affording the angularly substituted ABC-ring 
analogue 23 of ent-galanthamine. Over three 
conventional steps compound 23 could be 
converted into its mono-methylated 
counterpart 24.  The last compound 
participated in a Pictet-Spengler cyclisation 
reaction on exposure to a mixture of 
paraformaldehyde and trifluoroacetic acid 
(TFA) and the presumably first-formed 
product 25 underwent cleavage of the Ley 
acetal residue to give diol 26 as the only 
isolable product of reaction.  Compound 26, 
representing a dioxygenated derivative of ent-
galanthamine (ent-17), and various congeners 
that have been prepared using related reaction 
sequences are currently being subjected to 
evaluation as inhibitors of the neurologically 
significant enzyme acetylcholine esterase 
(AChE). 
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Scheme 4 
 
It is worth noting, at this point, that the 
enantiomer of certain of the cis-1,2-
dihydrocatechols described above are also 
available.30  So, for example, biotransform-
ation of p-iodotoluene or p-iodobromo- 
benzene [27a (X = Me) and 27b (X = Br), 
respectively] (Scheme 5) using E. coli JM109 
(pDTG601) affords metabolite 28 that upon 
exposure to dihydrogen in the presence of 
palladium on carbon undergoes 
hydrogenolytic cleavage of the associated C-I 
bond and thus delivering either cis-1,2-
dihydrocatechol ent-2 (X = Me) or ent-2 (X = 
Br). 
 
Scheme 5 
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The Opiates 
Morphine and its congener codeine are 
members of opiate family. They are used 
extensively for the management of pain and 
represent the most widely applied and highest 
grossing medicines in the world today.31 Their 
structural complexity means that for the 
moment, at least, opiates such as morphine 
are obtained from natural sources and then 
derivatized by simple chemical means so as to 
produce related drugs.  Nevertheless, much 
progress has been made in terms of 
developing commercially viable total 
syntheses of these systems. Hudlicky and co-
workers have defined the current “gold 
standard” in the area.32  Given the tantalising 
structural resemblance between the readily 
available compound 23 and ent-codeine (29) 
(Figure 6) we are now attempting to modify 
the synthesis of the former so as to access the 
latter.  This will likely involve introducing the 
necessary additional two-carbon unit by using 
a variant of boronate ester 20 and completing 
the synthesis of the less functionalised 
cyclohexane ring within target 29 using an 
intramolecular SN" reaction that 
simultaneously cleaves the Ley acetal subunit. 
 
 
Figure 6 
 
Vinblastine, Vincristine and Vindoline 
Vinblastine (30) and vincristine (31) (Figure 
7) are indole-indoline-based alkaloids derived 
from various plant sources, perhaps most 
notably the Madagascan rosy periwinkle.33 
They are used in the clinical treatment of 
non-Hodgkin’s lymphomas as well as 
testicular, breast and lung cancers.  These 
compounds are derived in vivo from the 
significantly more abundant and co-occurring 
alkaloid vindoline (32).  Given the 
development of direct, chemically based and 
“bio-inspired” methods for effecting the 
conversion of this simpler compound into 
alkaloids 30 and 31, vindoline has become the 
focus of considerable attention as a synthetic 
target.34 
Our own efforts in this area have been 
inspired by the observation (Figure 8)35 that 
the mutant organism P. putida BGXM1 can 
effect, in an enantioselective fashion, the 
whole-cell biotransformation of abundant m-
ethyltoluene (33) into the carboxylic acid diol 
34 that bears a striking resemblance to the 
highly functionalised C-ring of vindoline. 
Accordingly, a recent focus of some of our 
work in the area of chemoenzymatic synthesis 
has been on identifying methods for 
converting this metabolite into vindoline (32) 
and thence into vinblastine (30) and 
vincristine (31). 
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Figure 7 
 
Figure 8 
 
The model study outlined in Scheme 6 has 
provided encouragement.36 Thus, the cis-1,2-
dihydrocatechol 2 (X = Br), representing a 
model for congener 34, was converted, by the 
means described earlier, into the oxirane 7.  
Treatment of this last compound with acetic 
acid in the presence of mineral acid afforded a 
trans-diol mono-ester that was protected 
under standard conditions as the 
corresponding MOM-ether and thus 
affording compound 35 that could be cross-
coupled with ethyl boronic acid in the 
presence of a Pd[0] catalyst to give, after 
completing cleavage of the acetate residue 
using methanolic potassium carbonate, the 
allylic alcohol 36. This last compound was 
engaged in a sluggish Eschenmoser-Claisen 
rearrangement reaction to give amide 37, the 
side-chain of which could be elaborated, over 
three steps, into the nitrile 38. Over a further 
three conventional steps this was converted 
into the α-iodocyclohexenone 39 that itself 
served as a substrate for a palladium-catalysed 
Ullmann cross-coupling reaction37 with o-
iodonitroarene 40 and so delivering the α-
arylated cyclohexenone 41. On exposure to 
dihydrogen in the presence of Raney cobalt38 
and a proton source compound 41 engaged in 
a series of chemoselective reductions and two 
cyclisation reactions with the result that the 
tetracyclic compound 42 was formed.  The 
completion of the synthesis of the pentacyclic 
framework of vindoline proved straight-
forward and involved reaction of the last 
compound with 2-bromoethanol in the 
presence of base, mesylation of the resulting 
alcohol 43 and treatment of the sulfonate 
ester so formed with potassium tert-butoxide 
to generate the isoindole 44.   
In an effort to introduce the 
carbomethoxy group associated with alkaloid 
32, compound 44 was subjected to successive 
treatment with tert-butyllithium then Mander’s 
reagent (NCCO2Me).39 However, rather than 
obtaining the hoped-for C-carbomethoxy-
lated imine, carbamate 45 was produced, 
presumably by a pathway whereby the tert-
butyllithium acts as a hydride source40 with 
the resulting indoline anion then reacting (at 
nitrogen) with the added electrophile.  Efforts 
are now underway to adapt these chemistries 
so as to convert metabolite 34 into vindoline.  
The most challenging issue associated with 
doing so will be finding a means for 
introducing the C-C double bond 
incorporated within the D-ring of target 32. 
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Scheme 6 
The Protoilludanes 
The title sesquiterpenes embody a distinctive 
tricyclic framework wherein a central 
cyclohexane ring is annulated, in an angular 
arrangement, to both a four- and a five-
membered ring.41  The protoilludane aryl 
ester (+)-armillarivin (46) (Figure 9) has been 
found in the edible sugar mushroom 
Armillaria mellea42 while representative 
additional natural products in this family 
include 4743 and 4844 that are derived from 
the saprotrophic wood decomposing fungus 
Granulobasidium vellereum (Ellis & Cragin) 
Ju lich. 
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Figure 9 
 
 
In 2013 we described the first and thus far 
only total synthesis of (+)-armillarivin.45 A key 
element of our approach (Scheme 7) was an 
initial high-pressure promoted and completely 
regio- and stereo-selective Diels-Alder 
reaction between the cis-1,2-dihydrocatechol 2 
(X = Me) and cyclopentenone.46  Relatively 
conventional but rather extensive 
manipulations of the resulting adduct lead to 
the cyclopentannulated bicyclo[2.2.2]octen-
one 49 that engaged, as a second pivotal step 
of the synthesis, in a photochemically-
promoted 1,3-acyl migration reaction (Givens 
rearrangement)47 to afford the tricyclic isomer 
50.  This last compound, which embodies the 
tricyclic protoilludane framework, was readily 
manipulated over just three steps to deliver 
(+)-armillarivin.  The structure of this 
synthetically produced material was 
confirmed by single-crystal X-ray analysis and 
all the derived spectroscopic data, including 
specific rotation, matched those reported for 
the natural product.  
Subjection of the acetonide derivative of 
compound 2 (X = Me) to a Diels-Alder 
reaction with cyclopentenone affords, via 
addition of the dienophile to the face of the 
diene opposite to that “occupied” by the 
hydroxyl groups, cyclopentannulated bicyclo- 
[2.2.2]octenones that are enantiomerically 
related to those obtained by the pathway 
described immediately above.  In essence, 
then, by controlling the facial selectivity of 
such cycloaddition reactions either 
enantiomeric form of the relevant Diels-Alder 
adduct can be obtained. 
 
 
 
 
 
Scheme 7 
72
JOURNAL & PROCEEDINGS OF THE ROYAL SOCIETY OF NEW SOUTH WALES 
Banwell et al.– Chemoenzymatic Pathways 
46 
 
By such means we have recently been able to 
complete total syntheses of the enantiomeric 
forms of the protoilludanes 47 and 4848 and 
thus confirming, for the first time, the 
structures assigned to them. 
 
Platencin 
The Diels-Alder cycloaddition chemistry 
involving cis-1,2-dihydrocatechols as the 4π-
component can be effectively extended to 
intramolecular variants. This is perhaps best 
exemplified in our recently completed first- 
and second-generation chemoenzymatic 
syntheses of platencin (51),49,50 a compound 
isolated from Streptomyces platensis MA7327 
that acts as a potent and dual inhibitor of 
FabH and FabF, key enzymes associated with 
fatty acid biosynthesis in bacteria (Figure 
10).51  By virtue of its novel structure and 
modes of action, platencin is regarded as an 
important new lead in the development of 
urgently needed, next-generation anti-
bacterial agents.52  
In our first generation synthesis of 
compound 51 (Scheme 8),49 the acetonide 
derivative, 52, of the cis-1,2-dihydrocatechol 2 
(X = I) was engaged in a Stille cross-coupling 
reaction with the Z-configured 
alkenylstannane 53 to give the tetra-ene 54. 
Substrate 53 was prepared in a 
straightforward manner with the 
stereochemistry at the quaternary carbon 
centre being controlled through the agency of 
a chiral auxiliary. 
While compound 54 failed to engage in 
an intramolecular Diels-Alder (IMDA) 
reaction, the readily derived ketone 55 did so 
when heated in refluxing toluene and thus 
affording, in stereochemically pure form, 
adduct 56 embodying the tricarbocyclic core 
of platencin.  Over a further thirteen steps 
compound 56 could be converted into (–)-
platencin (51).  
Some of these steps were needed to deal 
with functional group incompatibilities, an 
issue that has been addressed, albeit in a 
modest way, through our recently disclosed 
second-generation synthesis.50 In a devel- 
oping collaboration with the Hudlicky group 
at Brock University (Canada), efforts are now 
focussed on a third-generation approach. 
 
 
 
 
 
Figure 10 
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Scheme 8 
 
Conclusions 
Enzymes have an almost unparalleled 
capacity to transform simple organic 
substrates into synthetically more valuable 
ones, especially enantiomerically pure 
compounds (EPCs).  Through the use of 
various genetic engineering, gene shuffling 
and directed evolution techniques the 
opportunities to expand upon the existing 
“library” of metabolites seem almost infinite.  
Furthermore, pathway-engineering techniques 
provide a capacity to produce (mutant) 
organisms that effect, through the 
orchestrated action of a series of enzymes, 
multistep transformations.  The conversion 
of m-ethyltoluene (33) into compound 3435 is 
a case in point and wherein both mono-
oxygenases and dioxygenases act in concert to 
produce a potentially high-value metabolite.  
When combined with the power of chemical 
synthesis (as manifest in the techniques of 
chemoenzymatic synthesis), such bio-
transformations provide a powerful tool kit 
for preparing a wide range of compounds of 
biological relevance.  Ironically, perhaps, 
while microbiologists have a remarkable 
capacity to generate a diversity of low 
molecular weight metabolites (and often at 
multi-kilogram or larger scale) and synthesis 
chemists have an almost insatiable appetite 
for new synthons, the often siloed nature of 
academic research activities results in less than 
desirable overlap of the relevant sets of 
expertise.  Changing this situation can only 
benefit both disciplines. 
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ABSTRACT: A series of 28 analogues of the phytotoxic geranylcyclohexentriol (−)-phomentrioloxin A (1) has been
synthesized through cross-couplings of various enantiomerically pure haloconduritols or certain deoxygenated derivatives with
either terminal alkynes or borylated alkenes. Some of these analogues display modest herbicidal activities, and physiological
proﬁling studies suggest that analogue 4 inhibits photosystem II in isolated thylakoids in vitro.
■ INTRODUCTION
Among agricultural pests, weeds have the most signiﬁcant
adverse eﬀects on crop productivity,1 and the absence of good
means for controlling them is a primary source of concern for
farmers.2 As a consequence, herbicidal applications outstrip the
combined use of fungicides and insecticides in the U.S.A. and
probably in many other countries as well.3 The ongoing
development of resistance to current herbicides has prompted
an intense search for new ones with novel modes of action, but
there has been little recent success in this regard.4
Natural products have attracted attention as potential sources
of new agrochemicals or at least inspirations for them.5 However,
in contrast to the impressive contributions natural products have
made to the development of new therapeutic agents,6 they have
not, thus far, been particularly useful sources of herbicides.4,5 In
an eﬀort to redress this situation, certain studies have focused on
phytotoxic metabolites produced by fungi associated with
economically signiﬁcant weeds. For example, while seeking
new agents to control the saﬀron thistle (Carthamus lantus L. ssp.
lanatus), a widespread winter-growing annual weed of both
pastures and crops that has been declared noxious throughout
Australia, Evidente and co-workers7 identiﬁed pathogenic strains
of Phomopsis sp. and the teleomorphDiaporthe gulyae associated,
respectively, with diseased strains of the saﬀron thistle and with
the sunﬂower (Helianthus annuus L.). Three of the various
phytotoxic metabolites produced by these fungi were identiﬁed
as phomentrioloxins A−C (structures 1−3, respectively, in
Figure 1) that embody a polyoxygenated cyclohexene “core” and
a geranyl-type “side-chain”. The illustrated structure of the ﬁrst of
these metabolites, viz. compound 1, was conﬁrmed by our
synthesis8 of it from a homochiral cis-1,2-dihydrocatechol of
deﬁned absolute stereochemistry that is readily produced
through the whole-cell biotransformation of iodobenzene. A
key feature of our synthesis was the linking of an iodinatedmono-
O-methylated conduritol with the relevant terminal alkyne using
a Sonogashira cross-coupling reaction.
Evidente and co-workers carried out a small structure−activity
relationship study on derivatives of phomentrioloxin A. This
Received: September 28, 2016
Published: December 5, 2016
Figure 1. Structures of phomentrioloxins A−C (1−3, respectively).
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revealed that various structural modiﬁcations of it led to changes
in phytotoxic properties7a,9 and, as a result, it was suggested that
such natural products could form the basis for developing
mycoherbicides for the biocontrol of noxious weeds including
saﬀron thistle. Given the potential ﬂexibility of our synthetic
route to natural product 1, we sought to prepare a collection of
Figure 2. Phomentrioloxin analogues 4−14 prepared for the present study that retain the geranyl-type side-chain.
Figure 3. Phomentrioloxin analogues 15−22 prepared for the present study and incorporating a phenylacetylene-type side-chain.
The Journal of Organic Chemistry Article
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J. Org. Chem. 2017, 82, 211−233
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otherwise diﬃcult-to-access analogues and subject these to
commercially relevant screening regimes, including ones that
could provide insights into their modes of action. The outcomes
of such studies are reported here.
■ RESULTS AND DISCUSSION
Chemical Synthesis Studies. The ﬁrst tranche of
phomentrioloxin analogues to be prepared were compounds
4−14 (Figure 2), wherein variations were made to the nature of
the oxygenation pattern in the cyclohexene core and, in parallel,
to the degree of unsaturation in the geranyl-type tail (see
structures 10−14).
The second tranche of analogues, namely compounds 15−22
(Figure 3), also involved variations in the nature of the
oxygenation pattern within the core and, more signiﬁcantly,
variations to the side-chain. Speciﬁcally, the geranyl-type tail
associated with the natural product 1 was replaced with a C10-
containing arylacetylene unit that it was thought would represent
a similarly lipophilic but potentially more stable motif. Several
3,5-dimethoxy-substituted arylacetylene side-chains were intro-
duced in an eﬀort to explore the impact of modiﬁcations to
electron density within this part of the molecular framework.
The ﬁnal tranche of analogues, namely compounds 23−31
(Figure 4), involved, inter alia, systems incorporating E- or Z-
conﬁgured styrenyl or β-arylethyl-type side-chains as well as
variations within the core. Throughout the collection of
analogues, certain acetonide-containing precursors were also
tested as another means of investigating the impact of increased
lipophilicity of the cyclohexene core on activity. The exhaustively
protected precursor, 31, to triol 29 was also subject to biological
evaluation for the same reasons.
The reaction sequence shown in Scheme 1 is indicative of the
protocols employed in the synthesis of the above-mentioned
phomentrioloxin A analogues. It follows that employed in our
synthesis of the “parent” system 1.8 Thus, the cis-1,2-
dihydrocatechol 32, which is readily obtained in enantiomerically
pure form through the whole-cell biotransformation of
iodobenzene,10,11 was converted into the corresponding
acetonide under previously deﬁned conditions and thus aﬀording
the known12 and rather unstable compound 33. Regio- and
diastereo-selective cis-dihydroxylation of the nonhalogenated
double bond within diene 33 proceeded readily under the
UpJohn conditions13 to give diol 3412 (62% from 32) that was
subject to 2-fold O-methylation using methyl iodide and thus
providing the bis-ether 35 in 47% yield. Sonogashira cross-
coupling of this last compound with the known14 and readily
accessible terminal alkyne 36 under standard conditions using
cuprous iodide and PdCl2(PPh3)2 in the presence of diethyl-
amine then gave the targeted phomentrioloxin analogue 9 in 48%
yield.
Hydrolytic cleavage of the acetonide residue within the last
compound could be achieved by heating it in an acetic acid/water
mixture at 70 °C for 5 h and thus aﬀording an O-methyl ether
derivative, 8, of phomentrioloxin in 81% yield. All the spectral
Figure 4. Phomentrioloxin analogues 23−31 prepared for the present study and incorporating a styrenyl or phenylethane-type side-chain.
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data acquired on compounds 8 and 9 were in complete accord
with the assigned structures.
The syntheses of remaining analogues used in this study are
detailed below. In broad terms, these involved straightforward
modiﬁcations of the protocols deﬁned above with the head and
tail “sections”/side-chains of these analogues being linked
through either Sonogashira or Suzuki−Miyaura cross-coupling
protocols. Post-coupling chemical modiﬁcations included
acetonide group cleavages, thermally induced Z- to E-oleﬁn
isomerizations, and/or exhaustive catalytic hydrogenation of the
oleﬁnic residues within compounds 23 and 24 (and thus
aﬀording, as single diastereoisomers, 25 and 26, respectively).
The formation of the 7-oxabicyclo[2.2.1]heptene-containing
analogue 30 from precursor 27 on thermolysis in reﬂuxing
chlorobenzene (Scheme 2) clearly involves a cyclodehydration
reaction. Interestingly, under the conditions used there was no
accompanying Z- to E-isomerization of the styrenyl double bond.
Single-crystal X-ray analyses were secured on compounds 15,
23, and 27 as well as certain precursors to congeners 7−9 and 17.
Details of these are provided in the Experimental Section and the
SI.
The reaction sequence used to prepare compound 4, one of
the more active of the phomentrioloxin analogues, is shown in
Scheme 3. Thus, the previously reported epoxide 38,15 which is
readily obtained over two steps from diol 34, was subjected to
reductive cleavage with DIBAl-H and thus providing the
homoallylic alcohol 39 (72%). O-Methylation of the last
compound under Irvine−Purdie conditions then gave ether 40
(47%), the acetonide residue of which was cleaved using acidiﬁed
AG-50W-X8 resin in THF/methanol to aﬀord cis-diol 41 (88%).
Finally, Sonogashira coupling of compound 41 with dienyne 36
under essentially the same conditions as described above for the
conversion 35 + 36→ 9 gave analogue 4 in 64% yield.
A related sequence of reactions, as shown in Scheme 4, was
used to obtain analogue 5. Thus, compound 3210 was treated
with N-bromosuccinimide (NBS) in wet THF, and the resulting
bromohydrin 4216 immediately treated with 2,2-dimethoxypro-
pane (2,2-DMP) and p-toluenesulfonic acid monohydrate (p-
TsOH·H2O) and so producing acetonide 43 (71% from 32).
Reaction of this last compound with sodium hydroxide in a
water/glyme mixture then gave epoxide 44 (44%) that was
reductively cleaved with DIBAl-H and produced alcohol 45
(66%) that was O-methylated under standard conditions and
thus providing ether 46 (71%). An acetonide hydrolysis/
Sonogashira coupling sequence then gave, via intermediate diol
47 (64%), the target analogue 5 in 60% yield over the last step.
Phomentrioloxin analogue 6 was readily produced from
epoxide 38 (Scheme 5) by reacting this with methanol in the
presence of (+)-camphorsulfonic acid [(+)-CSA]. The protected
conduritol 48 (45%) thus obtained was subjected to acetonide
hydrolysis under standard conditions, aﬀording triol 49 (75%).
Scheme 1. Synthetic Sequence Used To Prepare Phomentrioloxin Analogues 8 and 9
Scheme 2. Thermally Induced Cyclodehydration of Triol 27
Leading to Compound 30
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Sonogashira cross-coupling of this last compound with terminal
alkyne 36 then gave compound 6 (40%).
The preparation of analogue 7 followed the same sort of
synthetic pathway (Scheme 6). Thus, the acetonide unit within
the product, 50 (93%), of acid-catalyzed methanolysis of epoxide
44 was cleaved in the usual way to give triol 51 (36%) that was
itself cross-coupled with alkyne 36, aﬀording compound 7
(34%).
The reaction sequence used to prepare the enyne side-chain
synthon required for the preparation of analogues 10−14 is
shown in Scheme 7. This started with the commercially available
and unsaturated ketone 52 that was hydrogenated under
conventional conditions to aﬀord its saturated counterpart
5317 (81%). This was converted, via a kinetically controlled
deprotonation process, into the enol triﬂate 54 (68%) that was
itself subjected to a Sonogashira cross-coupling reaction with
trimethylsilylacetylene, aﬀording the silyl-capped alkyne 55
(85%). Treatment of this last compound with potassium
carbonate in methanol resulted in removal of the silyl group
and the formation of the required terminal alkyne 56 (73%).
The side-chain synthon 56 was ﬁrst exploited in the synthesis
of the phomentrioloxin analogue 10 by using the reaction
sequence shown in Scheme 8. Thus, alcohol 57,8 the previously
reported product of the regio-controlled O-silylation of diol 34,
was subject to reaction with methyl iodide in the presence
sodium hydride, and a chromatographically separable mixture of
the regio-isomeric O-methyl ethers 58 (8%) and 598 (90%)
thereby was obtained. Heating a solution of the latter product
with wet acetic acid resulted in hydrolysis of the acetonide group
and formation of triol 608 (68%) that was coupled with
compound 56 under the now standard Sonogashira conditions
and thus producing analogue 10 in 80% yield.
In a slightly diﬀerent timing of the side-chain installation
process, bis-ether 35 (Scheme 9) was cross-coupled with enyne
56 to give compound 61 (96%) that was itself subject to
acetonide hydrolysis using acetic acid/water. By such means,
analogue 11 was obtained in 60% yield.
As was the case with analogue 6, epoxide 38 served as the
starting material for the synthesis of the cyclohexene-containing
headgroup associated with target compounds 12 and 14
(Scheme 10). In the present case, however, the three-membered
ring within compound 38was cleaved with potassium hydroxide,
and the trans-diol 6215 (72%) so-formed was selectively silylated
at the oxygen of the allylic alcohol moiety (rather than the
homoallylic one) using triisopropylsilyl triﬂate (TIPSOTf) in the
presence of 2,6-lutidine and produced compound 63 (49%). O-
Methylation of this last compound proceeded uneventfully, and
product 64 (65%) was then treated with tetra-n-butylammonium
ﬂuoride (TBAF) to give the protected conduritol 65 (90%) that
could be cross-coupled with terminal alkyne 56 to give analogue
Scheme 3. Reaction Sequence Leading to Phomentrioloxin A Analogue 4
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14 (68%). Cleavage of the acetonide residue within this last
compound was a straightforward matter, and analogue 12 (72%)
was thereby obtained.
The synthesis of analogue 13 is shown in Scheme 11 and
exploited an intermediate associated with the preparation of
congener 10 (see Scheme 8). Thus, silyl ether 59 was treated
with TBAF, and the resulting alcohol 668 (88%) was then cross-
Scheme 4. Reaction Sequence Leading to Phomentrioloxin A Analogue 5
Scheme 5. Reaction Sequence Leading to Phomentrioloxin A Analogue 6
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coupled with enyne 56 in the usual manner, aﬀording target
compound 13 (70%).
The aromatic side-chain synthon required for the assembly of
the phomentrioloxin analogues 15−20 was prepared by the very
straightforward reaction sequences shown in Scheme 12. Thus,
the commercially available iodide 67 was cross-coupled with
trimethylsilylacetylene, and the product alkyne 68 (68%) was
treated with potassium carbonate in methanol and thus
delivering the required and previously reported synthon 6918
in 72% yield. The corresponding dimethoxylated synthon 70was
a commercially available material.
Synthon 69 was ﬁrst exploited in the synthesis of analogues 15
and 19 by cross-coupling the former compound with the
iodinated cyclohexene 66 (Scheme 13). This process delivered
compound 19 (76%), and the associated acetonide residue was
cleaved using aqueous acid and thus aﬀording the triol 15, albeit
in just trace amounts.
A closely related reaction sequence, as shown in Scheme 14,
lead from conduritol 35, via analogue 20 (72%), to diol 16,
although, once again, this last compound was only obtained in
trace amounts.
The synthesis of analogue 17 was a little more involved and
started (Scheme 15) by treating silyl ether 58 with TBAF. The
acetonide residue associated the product alcohol 71 (80%) was
hydrolyzed using aqueous acetic acid, and the resulting triol 72
(72%) cross-coupled with alkyne 69 to give the target compound
17 (73%).
Closely related reactions sequences were used to prepare
analogues 18 (Scheme 16), 21 (Scheme 17), and 22 (Scheme
18).
The synthesis of the ﬁnal side-chain synthon required for the
present study is shown in Scheme 19 and simply involved the
rhodium-catalyzed and selective addition of pinacol borane (75)
to terminal alkyne 69, aﬀording the Z-conﬁgured and β-
substituted styrene 76 in 52% yield.
Side-chain synthon 76 was ﬁrst exploited in the preparation of
the phomentrioloxin analogues 23, 25, and 27 as shown in
Scheme 20. Thus, Suzuki−Miyaura cross-coupling of compound
76 with the conduritol 60 gave analogue 27 (80%), which upon
hydrogenation using 5% rhodium on carbon as catalyst delivered
the cyclohexane 25 in 47% yield and as a single diastereoisomer.
The illustrated conﬁguration at the newly created stereogenic
Scheme 6. Reaction Sequence Leading to Phomentrioloxin A Analogue 7
Scheme 7. Reaction Sequence Leading to the Side-Chain Synthon 56 for the Preparation of Analogues 10−14
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center within compound 25 is assigned on the basis that the
hydroxyl groups within substrate 27 will direct the delivery of
hydrogen from the α-face and establish a β-oriented side-chain.
Extended thermolysis of the Z-conﬁgured alkene 27 in reﬂuxing
chlorobenzene aﬀorded the corresponding E-isomer 23 in 85%
yield based on recovered starting material (brsm).
An analogous series of reactions (Scheme 21) starting with
diol 74 led, via Z-alkene 28 (78%), to the E-alkene 24 (80%
brsm) and to cyclohexane 26 (40%).
A more involved reaction sequence was required to secure
analogues 29 and 31. Thus, as shown in Scheme 22, the
homochiral cis-1,2-dihydrocatechol 77 was ﬁrst converted into
the corresponding and well-known acetonide 78 (85%) under
relatively standard conditions, and the latter then was subject to a
regio- and diastereo-selective epoxidation reaction using m-
chloroperbenzoic acid (m-CPBA). The product oxirane 79
(85%) was then cleaved using potassium hydroxide in aqueous
THF, and the resulting trans-diol 8019 (70%) was selectively
mono-O-silylated using TIPSOTf in the presence of 2,6-lutidine.
The homoallylic alcohol 81 (51%) so-formed was O-methylated
using methyl iodide in the presence of sodium hydride, and the
methyl ether 82 (41%) thus obtained engaged in a Suzuki−
Miyaura cross-coupling reaction with the borylated alkene 76 to
aﬀord analogue 31 (78%). Interestingly, when the last compound
was heated in aqueous acetic acid, the associated acetonide and
silyl ether residues were cleaved, but the Z-conﬁgured alkene
moiety remained intact and such that analogue 29 was obtained
in 70% yield.
Biological Evaluation Studies. The biological evaluations
of compounds 1 and 4−31were carried out at BASF’s facilities at
Limburgerhof in Germany. Preliminary evaluations of herbicidal
activity were conducted in a green house. The plant species used
for this purpose were Setaria viridis (SETVI, green foxtail) and
Amaranthus retrof lexus (AMARE, pigweed). The outcomes of
conducting such tests are presented in Table 1 and represent the
average rating for each of the two plant species involved. In broad
terms, the active compounds caused a generalized necrosis of the
aerial moieties of the plant species against which they were
tested, suggesting they are eliciting their eﬀects via a nonspeciﬁc
pathway. In structure−activity terms, variations in the locations,
Scheme 8. Reaction Sequence Leading to Phomentrioloxin A Analogue 10
Scheme 9. Reaction Sequence Leading to Phomentrioloxin A Analogue 11
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conﬁgurations, degrees of O-methylation, and/or deletions of
oxygen-containing groups could have deleterious impacts on
activity (see entries 4 and 6) and certainly no obviously beneﬁcial
ones (relative to the parent system 1). Increasing the degree of
saturation in the geranyl-type side-chain also had generally
negative eﬀects, but replacement of such a moiety with an
arylacetylene equivalent led to series of analogues with more
pronounced herbicidal eﬀects (see entries 14, 16, 18, and 20). In
contrast, introduction of a styrenyl or β-arylethyl side-chain had a
generally negative eﬀect on activity; there were certainly no
beneﬁcial ones. A simple interpretation of these results is that
those compounds containing the more stable/durable arylace-
tylenic side-chains probably had the longest half-lives under the
extended testing conditions involved and were thus able to exert
more sustained herbicidal eﬀects.
Physiological proﬁling (PP) protocols were used for the
purposes of trying to draw conclusions regarding the mode of
action of the phomentrioloxin analogues as herbicides as well as
for ranking their selectivities and potencies. PP20 involves an
array of physiological and bioassays that allow for diﬀerentiation
between the distinct responses of diﬀerent structures (whole
plant, tissue, meristem cells, organelles), developmental stages
(seed germination, vegetative growth), types of metabolism
(phototrophic, heterotrophic), and physiological processes. The
assays are designed to be sensitive, allow facilitated uptake and
translocation of the applied compounds, and include all potential
herbicidal target sites. The bioassays included those involving
heterotrophic cleaver (Galium mollugo) and photoautotrophic
green alga (Scenedesmus obliquus) cell suspensions, isolated white
mustard (Sinapis alba) shoots, and germinating cress (Lepidum
Scheme 10. Reaction Sequence Leading to Phomentrioloxin A Analogues 12 and 14
Scheme 11. Reaction Sequence Leading to Phomentrioloxin A
Analogue 13
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sativum) seeds. The physiological assays included studies of the
Hill reaction of isolated wheat thylakoids, respiration measure-
ments in cleaver cell suspensions, the formation of reactive
oxygen species, chlorophyll ﬂuorescence and ATP measure-
ments in Lemna plants, carbon dioxide assimilation measure-
ments in cleaver (Galium aparine) plants, and toluidine blue
staining of cress hypocotyls for detecting any inhibition of very
long-chain fatty acid (VLCFA) biosynthesis.
In broad terms, phomentrioloxin A (1) as well as analogues 9
and 20 generated weak/inconclusive PPs. Analogues 5−7 and 11
had minor eﬀects on the growth of heterotrophic Galium
suspension cells, unicellular algae, and Lemna plants, indicating
uptake limitations or rapid metabolic detoxiﬁcation. In addition,
analogue 7 caused moderate inhibition of cress germination in a
light-dependent manner. Themost consistent eﬀect among these
compounds was a moderate inhibition of carbon dioxide
assimilation, indicating a not-further-characterized inhibitory
eﬀect on photosynthesis. Analogues 15, 16, 19, and 22 caused
moderate inhibition of cell division in heterotrophic suspension
cells together with intensiﬁed green leaf pigmentation in Lemna
plants. The origins of these eﬀects remain unknown. The PP of
compound 4 diﬀered somewhat from the others, as this analogue
caused moderate inhibition of the Hill reaction and must thus
have an eﬀect on photosynthetic electron-ﬂow. In addition, light-
dependent inhibition of cress germination was observed.
Inhibition of the Hill reaction is a typical ﬁnding for photosystem
II (PS II) inhibitors. However, such inhibitors are also usually
strong inhibitors of algae and Lemna growth, a feature not
observed for analogue 4. This might indicate that the compound
is able to inhibit PSII in isolated thylakoids in vitro but is rapidly
detoxiﬁed in a cellular environment.
Scheme 12. Reaction Sequence Leading to the Side-Chain Synthon 69 for the Preparation of Analogues 15−20
Scheme 13. Reaction Sequence Leading to Phomentrioloxin A Analogues 15 and 19
Scheme 14. Reaction Sequence Leading to Phomentrioloxin A Analogues 16 and 20
Scheme 15. Reaction Sequence Leading to Phomentrioloxin A
Analogue 17
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■ CONCLUSIONS
The present study serves to highlight the utility of our previously
reported8 synthesis of phomentrioloxin A in generating a diverse
range of analogues. However, the biological evaluation of these
analogues has revealed that, as a class and despite some earlier
indications to the contrary,7a,9 the phomentrioloxins are unlikely
to be useful leads for the development of new herbicidal agents.
■ EXPERIMENTAL SECTION
General Protocols. Unless otherwise speciﬁed, proton (1H) and
carbon (13C) NMR spectra were recorded at room temperature in base-
ﬁltered CDCl3 on a spectrometer operating at 400 MHz for proton and
100MHz for carbon nuclei. The signal due to residual CHCl3 appearing
at δH 7.26 and the central resonance of the CDCl3 “triplet” appearing at
δC 77.0 were used to reference
1H and 13C NMR spectra, respectively.
1H NMR data are recorded as follows: chemical shift (δ) [multiplicity,
coupling constant(s) J (Hz), relative integral] where multiplicity is
deﬁned as s = singlet; d = doublet; t = triplet; q = quartet; and m =
multiplet or combinations of the above. Infrared spectra (νmax) were
recorded on a FTIR spectrometer. Samples were analyzed as thin ﬁlms
on KBr plates. Low-resolution ESI mass spectra were recorded on a
single-quadrupole liquid chromatograph−mass spectrometer, while
high-resolution measurements were conducted on a time-of-ﬂight
instrument. Low- and high-resolution EI mass spectra were recorded on
a magnetic-sector machine. Melting points were measured on an
automated melting point system and are uncorrected. Analytical thin-
layer chromatography (TLC) was performed on aluminum-backed 0.2
mm thick silica gel 60 F254 plates. Eluted plates were visualized using a
254 nm UV lamp and/or by treatment with a suitable dip followed by
heating. These dips included phosphomolybdic acid:ceric sulfate:sulfu-
ric acid (conc.):water (37.5 g:7.5 g:37.5 g:720 mL), potassium
permanganate:potassium carbonate:5% sodium hydroxide aqueous
solution:water (3 g:20 g:5 mL:300 mL)), p-anisaldehyde or
vanillin:sulfuric acid (conc.):ethanol (15 g:2.5 mL:250 mL). Flash
chromatographic separations were carried out following protocols
deﬁned by Still et al.21 with silica gel 60 (40−63 μm) as the stationary
phase and using the AR- or HPLC-grade solvents indicated. Starting
materials, reagents, drying agents, and other inorganic salts were
generally commercially available and were used as supplied.
Tetrahydrofuran (THF), methanol, and dichloromethane were dried
using a solvent puriﬁcation system that is based upon a technology
originally described by Grubbs et al.22 Where necessary, reactions were
performed under an nitrogen atmosphere.
The Synthesis of Analogues 8 and 9 as Representative Chemical
Transformations: (3aS,4R,5R,7aS)-7-Iodo-4,5-dimethoxy-2,2-di-
methyl-3a,4,5,7a-tetrahydrobenzo[d]-[1,3]dioxole (35). Sodium hy-
dride (115 mg of a 60% dispersion in mineral oil, 2.88 mmol) was added
to a magnetically stirred solution of compound 3412 (150 mg, 0.48
mmol) and iodomethane (300 μL, 4.80 mmol) in dry THF (25 mL)
maintained at 0 °C under a nitrogen atmosphere. Stirring was continued
for 2 h at 0−18 °C, then the reaction mixture was treated with ice/water
(60 mL; Caution: potential for evolution of hydrogen gas). The separated
aqueous phase was extracted with ethyl acetate (1 × 25 mL), and the
combined organic phases were then dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
Scheme 16. Reaction Sequence Leading to Phomentrioloxin A Analogue 18
Scheme 17. Reaction Sequence Leading to Phomentrioloxin A
Analogue 21
Scheme 18. Reaction Sequence Leading to Phomentrioloxin A Analogue 22
Scheme 19. Reaction Sequence Leading to the Side-Chain
Synthon 76 for the Preparation of Analogues 27−31
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subjected to ﬂash chromatography (silica, 1:1 v/v ethyl acetate/hexane
gradient elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 1:4 v/v ethyl acetate/hexane), compound 35 (77 mg, 47%)
as a white, crystalline solid, mp =46−49 °C; [α]D20 = −33.8 (c = 3.0,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.50 (d, J = 3.2 Hz, 1H), 4.60
(d, J = 5.7 Hz, 1H), 4.38 (m, 1H), 3.88 (t, J = 3.4 Hz, 1H), 3.76 (m, 1H),
3.48 (s, 3H), 3.40 (s, 3H), 1.39 (s, 3H), 1.35 (s, 3H); 13C NMR (CDCl3,
100 MHz) δ 137.5, 109.4, 100.2, 78.8, 77.7, 76.1, 74.5, 59.2, 57.3, 27.4,
25.9; IR νmax 2984, 2929, 2826, 1630, 1459, 1381, 1371, 1233, 1101,
1079, 1039, 1005, 868 cm−1; MS (EI, 70 eV) m/z 340 (M+•, 11%), 325
[(M-CH3•)+, 8%], 115 (100); HRMS M+• calcd for C11H17127IO4
340.0172, found 340.0173.
(3aR,4R,5R,7aR)-4,5-Dimethoxy-2,2-dimethyl-7-(7-methyl-3-
methyleneoct-6-en-1-yn-1-yl)-3a,4,5,7a-tetrahydrobenzo[d][1,3]-
dioxole (9).Cuprous iodide (11 mg, 0.05 mmol) and PdCl2(PPh3)2 (25
mg, 0.04 mmol) were added to a magnetically stirred solution of
compounds 35 (120 mg, 0.35 mmol) and 3614 (95 mg, 0.71 mmol) in
anhydrous diethylamine (3 mL) maintained at 18 °C under a nitrogen
Scheme 20. Reaction Sequence Leading to Phomentrioloxin A Analogues 23, 25, and 27
Scheme 21. Reaction Sequence Leading to Phomentrioloxin A Analogues 24, 26, and 28
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atmosphere. After 3 h, the reaction mixture was concentrated under
reduced pressure, and the residue thus obtained was subjected to ﬂash
chromatography (silica, 1:4 v/v ethyl acetate/hexane gradient elution).
Concentration of the appropriate fractions (Rf = 0.3 in 1:4 v/v ethyl
acetate/hexane) aﬀorded compound 9 (59 mg, 48%) as a clear, light-
yellow oil, [α]D
20 =−17.7 (c = 0.7, CHCl3). 1HNMR (CDCl3, 400MHz)
δ 6.25 (d, J = 4.0 Hz, 1H), 5.37 (d, J = 2.0 Hz, 1H), 5.26 (d, J = 2.0 Hz,
1H), 5.10 (m, 1H), 4.64 (d, J = 6.2 Hz, 1H), 4.46 (t, J = 6.2 Hz, 1H), 4.04
(t, J = 3.8 Hz, 1H), 3.66 (m, 1H), 3.53 (s, 3H), 3.45 (s, 3H), 2.20
(broadened s, 4H), 1.69 (s, 3H), 1.62 (s, 3H), 1.45 (s, 3H), 1.39 (s, 3H);
13C NMR (CDCl3, 100 MHz) δ 133.6, 132.2, 131.2, 123.4, 123.2, 121.7,
109.5, 90.8, 87.4, 79.0, 74.2, 74.0, 73.8, 58.8, 57.4, 37.3, 27.6, 26.8, 25.7,
25.5, 17.7; IR νmax 2983, 2930, 2825, 1631, 1605, 1454, 1379, 1370,
1234, 1113, 1082, 1038, 961, 896, 874 cm−1; MS (EI, 70 eV) m/z 331
[(M-CH3•)+ 6%], 257 (14), 115 (100); HRMS (M-CH3•)+ calcd for
C20H27O4 331.1909, found 331.1907.
(1R,2R,5R,6S)-5,6-Dimethoxy-3-(7-methyl-3-methyleneoct-6-en-
1-yn-1-yl)cyclohex-3-ene-1,2-diol (8). Compound 9 (33 mg, 0.09
mmol) was treated with acetic acid/water (3 mL of a 4:1 v/v mixture),
and the solution thus obtained was heated at 70 °C for 5 h, then cooled,
and concentrated under reduced pressure. Subjection of the ensuing
light-yellow residue to ﬂash chromatography (silica, 3:2 v/v ethyl
acetate/hexane gradient elution) delivered, after concentration of the
appropriate fractions (Rf = 0.4 in 4:2 v/v ethyl acetate/hexane),
compound 8 (24 mg, 81%) as a clear, light-yellow syrup, [α]D
20 = −14 (c
= 0.5, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.27 (d, J = 4.5 Hz, 1H),
5.38 (d, J = 1.9 Hz, 1H), 5.28 (d, J = 1.9 Hz, 1H), 5.11 (m, 1H), 4.36 (d, J
= 4.2 Hz, 1H), 4.17 (m, 1H), 4.10 (t, J = 4.2 Hz, 1H), 3.70 (dd, J = 8.8
and 3.9 Hz, 1H), 3.51 (s, 3H), 3.48 (s, 3H), 2.79 (d, J = 2.0Hz, 1H), 2.69
(d, J = 2.0 Hz, 1H), 2.20 (s, 4H), 1.69 (s, 3H), 1.62 (s, 3H); 13C NMR
(CDCl3, 100MHz) δ 132.4, 132.3, 130.9, 124.6, 123.2, 122.2, 91.4, 87.1,
77.4, 72.6, 68.6, 67.5, 58.1, 57.6, 37.2, 26.8, 25.7, 17.8; IR νmax 3400,
3301, 2953, 2922, 2852, 1633, 1603, 1462, 1377, 1261, 1099, 995, 897
cm−1; MS (EI, 70 eV)m/z 306 (M+•, <1%), 275 (7), 259 (22), 217 (76),
189 (100), 185 (78), 69 (79); HRMS (M+Na)+ calcd for C18H26NaO4
329.1729, found 329.1729.
(3aS,4R,7aS)-7-Iodo-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d]-
[1,3]dioxol-4-ol (39). A magnetically stirred solution of epoxide 3815
(2.91 g, 9.88 mmol) in anhydrous diethyl ether (60 mL) was cooled to
−40 °C and then treated with DIBAL-H (11.9 mL of a 1 M solution in
hexanes, 11.9 mmol) over 0.08 h. The ensuing mixture was maintained
at this temperature for 3 h, then treated with tartaric acid (50 mL of a
saturated aqueous solution), and stirred for a further 0.5 h while being
allowed to warm to 20 °C. The organic phase was separated, and the
aqueous layer was extracted with diethyl ether (2 × 50 mL). The
combined organic layers were then washed with water (1 × 100 mL)
before being dried (MgSO4), ﬁltered, and concentrated under reduced
pressure. The residue thus obtained was subjected to ﬂash
chromatography (silica, 1:1 v/v ethyl acetate/hexane gradient elution)
to furnish, after concentration of the appropriate fractions (Rf = 0.4 in
1:1 v/v ethyl acetate/hexane), the title compound 39 (2.10 g, 72%) as a
white, crystalline solid, mp = 101−103 °C, [α]D20 = −9.3 (c = 1.5,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.43 (m, 1H), 4.65 (d, J = 5.9
Hz, 1H), 4.09 (dd, J = 7.1 and 5.9 Hz, 1H), 3.96 (m, 1H), 2.48 (dt, J =
17.4 and 4.9 Hz, 1H), 2.12 (m, 1H), 1.96 (broad s, 1H), 1.49 (s, 3H),
1.42 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 137.7, 109.4, 94.6, 79.4,
78.6, 67.4, 33.5, 28.1, 26.2; IR νmax 3435, 2985, 2932, 1701, 1633, 1380,
1222, 1161, 1071, 1050, 867 cm−1; MS (EI, 70 eV)m/z 296 (M+•, 12%),
281 (100); HRMS M+• calcd for C9H13
127IO3, 295.9909, found
295.9913.
Scheme 22. Reaction Sequence Leading to Phomentrioloxin A Analogues 29 and 31
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(3aS,4R,7aS)-7-Iodo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxole (40). Silver(I) oxide (1.81 g, 7.81
mmol) and methyl iodide (970 μL, 15.6 mmol) were added to a
magnetically stirred solution of compound 39 (2.10 g, 7.10 mmol) in
acetonitrile (40 mL) maintained under a nitrogen atmosphere. The
ensuing mixture was heated at 82 °C for 16 h, then cooled to 20 °C, and
ﬁltered through a pad of diatomaceous earth that was washed with ethyl
acetate (2 × 20 mL). The combined ﬁltrates were concentrated under
reduced pressure, and the material so obtained subjected to ﬂash
chromatography (silica, 1:1 v/v ethyl acetate/hexane gradient elution).
Concentration of the appropriate fractions (Rf = 0.5 in 1.5:1 v/v ethyl
acetate/hexane) gave the title compound 40 (1.04 g, 47%) as a light-
yellow oil, [α]D
20 =−14 (c = 1.0, CHCl3). 1HNMR (CDCl3, 400MHz) δ
6.37 (t, J = 4.3 Hz, 1H), 4.59 (d, J = 5.6 Hz, 1H), 4.21 (t, J = 5.6 Hz, 1H),
3.61 (m, 1H), 3.43 (s, 3H), 2.43 (dm, J = 17.6 Hz, 1H), 2.15 (m, 1H),
1.47 (s, 3H), 1.40 (s, 3H); 13C NMR (CDCl3, 100MHz) δ 136.6, 109.2,
96.7, 78.8, 76.3, 75.7, 57.7, 29.9, 27.9, 26.3; IR νmax 2985, 2932, 2896,
2824, 1749, 1728, 1636, 1455, 1379, 1370, 1339, 1213, 1163, 1104,
1071, 1032, 968 cm−1; MS (EI, 70 eV)m/z 310 (M+•, 11%), 295 (100);
HRMS M+• calcd for C10H15
127IO3, 310.0066, found 310.0064.
(1R,2S,6R)-3-Iodo-6-methoxycyclohex-3-ene-1,2-diol (41). A sol-
ution of compound 40 (1.04 g, 3.36 mmol) in methanol/THF (20 mL
of a 1:1 v/v mixture) was treated with acidiﬁed AG-50W-X8 acidic resin
(2.09 g, 200 wt %). The resulting mixture was stirred vigorously at 20 °C
for 24 h and then ﬁltered through a pad of diatomaceous earth that was
washed with ethyl acetate (2 × 10 mL). The combined ﬁltrates were
concentrated under reduced pressure, and subjection of the residue to
ﬂash chromatography (silica, 1:1 v/v ethyl acetate/hexane gradient
elution) gave, after concentration of the appropriate fractions (Rf = 0.2
in 1:1.5 v/v ethyl acetate/hexane), the title compound 41 (797 mg,
88%) as a light-cream colored solid, mp = 87 °C, [α]D20 = −140 (c = 0.2,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.37 (m, 1H), 4.40 (d, J = 4.2
Hz, 1H), 3.84 (m, 1H), 3.59 (m, 1H), 3.42 (s, 3H), 2.79 (broad s, 2H),
2.63 (dt, J = 17.5 and 5.3 Hz, 1H), 2.01 (m, 1H); 13C NMR (CDCl3, 100
MHz) δ 137.7, 96.3, 74.7, 74.6, 72.2, 57.2, 33.1; IR νmax 3391, 2971,
2926, 2821, 1633, 1432, 1395, 1196, 1097, 988, 961, 823, 684 cm−1; MS
(EI, 70 eV) m/z 270 (M+•, 8%), 252 (13), 74 (100); HRMS M+• calcd
for C7H11
127IO3 269.9753, found 269.9757.
(1R,2R,6R)-6-Methoxy-3-(7-methyl-3-methyleneoct-6-en-1-yn-1-
yl)cyclohex-3-ene-1,2-diol (4). Alkyne 36 (594 mg, 4.43 mmol) was
added to a magnetically stirred solution of compound 41 (519 mg, 2.95
mmol) in anhydrous diethylamine (25 mL), and the ensuing solution
was sparged with nitrogen for 0.5 h. PdCl2(PPh3)2 (207 mg, 0.30 mmol)
and cuprous iodide (84 mg, 0.44 mmol) were then added, and the
resulting mixture was stirred at 20 °C for 20 h before being concentrated
under reduced pressure. The residue thus obtained was subjected to
ﬂash chromatography (silica, 1:4 → 1:1 e v/v ethyl acetate/hexane
gradient elution) to give, after concentration of the appropriate fractions
(Rf = 0.3 in 1:1 v/v ethyl acetate/hexane), the title compound 4 (519
mg, 64%) as a clear, light-yellow oil, [α]D
20 = + 86 (c = 1.7, CHCl3).
1H
NMR (CDCl3, 100 MHz) δ 6.10 (m, 1H), 5.33 (d, J = 2.0 Hz, 1H), 5.24
(d, J = 2.0 Hz, 1H), 5.10 (m, 1H), 4.34 (d, J = 4.0 Hz, 1H), 3.74 (dd, J =
9.2 and 4.0Hz, 1H), 3.61 (m, 1H), 3.43 (s, 3H), 2.72 (dt, J = 18.8 and 5.3
Hz, 2H), 2.19 (m, 4H), 2.08 (m, 2H), 1.68 (s, 3H), 1.61 (s, 3H); 13C
NMR (CDCl3, 100 MHz) δ 134.0, 132.2, 131.2, 123.3, 121.6, 121.4,
89.4, 87.9, 75.2, 71.5, 69.1, 57.1, 37.4, 30.1, 26.8, 25.7, 17.8; IR νmax 3401,
2918, 2191, 1671, 1605, 1443, 1376, 1196, 1101, 988, 903 cm−1; MS
(ESI, + ve) m/z 299 [(M + Na)+, 100%]; HRMS (M + Na)+ calcd for
C17H24NaO3 299.1623, found 299.1623.
(3aR,4R,5S,7aS)-4-Bromo-7-iodo-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxol-5-ol (43). A solution of compound
3210 (3 g, 12.6 mmol) in THF/water (38 mL of a 4:1 v/v mixture) was
treated with N-bromosuccinimide (3.37 g, 18.9 mmol), and the ensuing
mixture was protected from light and stirred magnetically at 20 °C for 18
h, then quenched with Na2S2O3 (70 mL of a saturated aqueous
solution), and extracted with diethyl ether (2 × 70 mL). The combined
organic phases were washed with brine (1 × 70 mL), then dried
(MgSO4), ﬁltered, and concentrated under reduced pressure to aﬀord an
orange solid 42.18 This material was dissolved in anhydrous 2,2-
dimethoxypropane (30 mL), and the resulting solution maintained
under a nitrogen atmosphere and, while being protected from light, was
treated with p-TsOH·H2O (434 mg, 2.28 mmol). The resulting mixture
was stirred at 20 °C for 18 h, then treated with NaHCO3 (30 mL of a
saturated aqueous solution), and extracted with ethyl acetate (2 × 40
mL). The combined organic layers were then dried (MgSO4), ﬁltered,
and concentrated under reduced pressure. The resulting light-yellow oil
was subjected to ﬂash chromatography (silica, hexane →1:4 v/v ethyl
acetate/hexane gradient elution) and gave, after concentration of the
appropriate fractions (Rf = 0.2 in 1:4 v/v ethyl acetate/hexane), the title
compound 43 (3.38 g, 71%) as a voluminous, white solid, mp = 80−82
°C, [α]D20 = +14 (c = 2.0, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 6.65
(dd, J = 4.4 and 0.7 Hz, 1H), 4.67 (d, J = 5.1 Hz, 1H), 4.57 (t, J = 5.1 Hz,
1H), 4.30 (t, J = 5.0 Hz, 1H), 4.25 (m, 1H), 2.92 (dd, J = 9.3 and 0.7 Hz,
1H), 1.53 (s, 3H), 1.42 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 138.7,
111.8, 100.5, 78.3, 77.6, 71.1, 48.1, 27.9, 26.4; IR νmax 3422, 3339, 2990,
2940, 2873, 1630, 1374, 1260, 1211, 1068, 1047, 1011, 857, 727 cm−1;
MS (EI, 70 eV)m/z 376 and 374 (M+•, both 6%) 361 and 359 (100 and
98), 174 and 172 (33 and 34); HRMS M+• calcd for C9H12
79Br127IO3,
373.9015, found 373.9018.
(3aS,5aS,6aS,6bS)-4-Iodo-2,2-dimethyl-3a,5a,6a,6b-tetrahy-
drooxireno-[2′,3′:3,4]ben -zo[1,2-d][1,3]dioxole (44). NaOH (4.5 mL
of a 2.0 M aqueous solution, 9.00 mmol) was added, dropwise, to a
magnetically stirred solution of compound 43 (3.38 g, 9.00 mmol) in
1,2-dimethoxyethane (50 mL). The resulting mixture was protected
from light, stirred at 20 °C for 48 h, and then concentrated under
reduced pressure. The residue thus obtained was partitioned between
dichloromethane (50mL) andwater (50mL), and the separated organic
layer was washed with brine (1 × 50 mL), then dried (MgSO4), ﬁltered,
and concentrated under reduced pressure. Subjection of the material so
obtained to ﬂash chromatography (silica, 1:7 v/v ethyl acetate/hexane
gradient elution) provided, after concentration of the appropriate
fractions (Rf = 0.1 in 1:9 v/v ethyl acetate/hexane), the title compound
44 (1.18 g, 44%) as a white, crystalline solid, mp = 46−47 °C, [α]D20 =
−82 (c = 1.3, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 7.00 (d, J = 4.2
Hz, 1H), 4.78 (dd, J = 6.7 and 1.8 Hz, 1H), 4.46 (dd, J = 6.7 and 2.7 Hz,
1H), 3.66 (m, 1H), 3.32 (t, J = 4.2 Hz, 1H), 1.55 (s, 3H), 1.41 (s, 3H);
13C NMR (CDCl3, 100 MHz) δ 138.2, 108.1, 100.0, 79.5, 73.7, 54.5,
50.9, 27.2, 25.3; IR νmax 2987, 2937, 2881, 1626, 1371, 1208, 1159, 1056,
Table 1. Evaluation of Phomentrioloxin Derivatives as
Nonspeciﬁc Herbicides Against A. retrof lexus and S. viridis
entry compda averaged resultb entry compda averaged resultb
1 1c + 16 18 ++
2 4c + 17 19 +
3 5c + 18 20 ++
4 6c 0 19 21 +
5 7c + 20 22 ++
6 8 0 21 23 0
7 9 + 22 24 0
8 10 0 23 25d 0
9 11c + 24 26d +
10 12 0 25 27 +
11 13 + 26 28 0
12 14 0 27 29d +
13 15 + 28 30 +
14 16 ++ 29 31 +
15 17 + − − −
aCompounds applied at 2 kg a.i./ha unless otherwise speciﬁed.
bQualitative result over the two plant species used. cCompounds 1, 4−
7, and 11 were applied at 1 kg a.i./ha. dCompounds 25, 26, and 29
were applied at 1.145, 1. 333 and 1.625 kg a.i./ha, respectively.
Evaluation was carried out using a scale from 0−100, where 100 means
complete destruction of at least the aerial moieties, and 0 means no
damage, or normal course of growth; 0−25: 0 (no or very low
activity); >25−50: + (moderate activity); >50−75: ++ (good activity);
>75: +++ (very good activity).
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864 cm−1; MS (EI, 70 eV) m/z 294 (M+•, 18%), 279 (100), 237 (26),
207 (22), 110 (55), 109 (42); HRMS M+• calcd for C9H11
127IO3
293.9753, found 293.9750.
(3aS,4S,7aS)-7-Iodo-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d]-
[1,3]dioxol-4-ol (45). A magnetically stirred solution of epoxide 44
(2.36 g, 8.06 mmol) in anhydrous diethyl ether (40 mL) was cooled to
−40 °C and then treated with a DIBAL-H (9.67 mL of a 1.0 M solution
in hexanes, 9.67 mmol) over 0.08 h. The resulting solution was allowed
to warm to 20 °C over 20 h before being treated with tartaric acid (50
mL of a saturated aqueous solution). After a further 1 h, the aqueous
layer was separated and then extracted with diethyl ether (2 × 50 mL),
and the combined organic layers were then dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:1 v/v ethyl acetate/hexane
gradient elution), and concentration of the appropriate fractions (Rf =
0.4 in 1:1 v/v ethyl acetate/hexane) aﬀorded the title compound 45
(1.57 g, 66%) as a colorless, microcrystalline solid, mp =101 °C, [α]D20 =
+ 41 (c = 1.2, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.35 (dd, J = 6.0
and 2.8 Hz, 1H), 4.62 (m, 1H), 4.39 (m, 1H), 3.99 (m, 1H), 2.39 (m,
1H), 2.30 (m, 1H), 1.45 (s, 3H), 1.43 (s, 3H), (signal due to hydroxyl
group proton not observed); 13C NMR (CDCl3, 100 MHz) δ 136.4,
110.2, 98.9, 80.6, 77.3, 66.6, 32.4, 27.3, 26.6; IR νmax 3413, 2985, 2932,
2870, 1629, 1379, 1371, 1230, 1083, 1046, 864 cm−1; MS (EI, 70 eV)m/
z 296 (M+•, 6%), 281 (100), 94 (75); HRMSM+• calcd for C9H13
127IO3
295.9909, found 295.9909.
(3aS,4S,7aS)-7-Iodo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxole (46). Silver(I) oxide (1.35 g, 5.84
mmol) and iodomethane (730 μL, 11.7 mmol) were added to a
magnetically stirred solution of alcohol 45 (1.57 g, 5.31 mmol) in
anhydrous acetonitrile (40 mL). The ensuing mixture was stirred at 82
°C for 19 h, then cooled to 20 °C, and ﬁltered through a pad of
diatomaceous earth that was washed with ethyl acetate (2× 50mL). The
combined ﬁltrates were concentrated under reduced pressure, and the
residue thus obtained was subjected to ﬂash chromatography (silica, 1:1
v/v ethyl acetate/hexane gradient elution). Concentration of the
appropriate fractions (Rf = 0.6 in 1.5:1 v/v ethyl acetate/hexane)
provided the title compound 46 (1.17 g, 71%) as a light-yellow oil, [α]D
20
= −32 (c = 1.2, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 6.35 (m, 1H),
4.59 (m, 1H), 4.49 (m, 1H), 3.59 (m, 1H), 3.44 (s, 3H), 2.41−2.35
(complex m, 2H), 1.44 (s, 3H), 1.43 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 136.1, 110.6, 99.8, 80.8, 75.1, 75.0, 56.7, 28.8, 27.4, 26.8; IR νmax
2984, 2932, 2822, 1626, 1454, 1380, 1370, 1233, 1168, 1111, 1066,
1035, 865 cm−1; MS (EI, 70 eV) m/z 310 (M+•, 3%), 295 (100), 115
(37), 108 (79); HRMS M+• calcd for C10H15
127IO3 310.0066, found
310.0069.
(1R,2S,6S)-3-Iodo-6-methoxycyclohex-3-ene-1,2-diol (47). A sol-
ution of acetonide 46 (1.17 g, 3.78 mmol) in methanol/THF (30 mL of
a 1:1 v/v mixture) was treated with acidiﬁed AG-50W-X8 acidic resin
(2.35 g, 200 wt %), and the ensuing mixture was stirred vigorously at 20
°C for 24 h. The reaction mixture was then ﬁltered through a pad of
diatomaceous earth that was washed with ethyl acetate (2× 10mL). The
combined ﬁltrates were concentrated under reduced pressure, and the
residue thus obtained was subjected to ﬂash chromatography (silica, 1:1
v/v ethyl acetate/hexane elution) to give, after concentration of the
appropriate fractions (Rf = 0.2 in 1:2 v/v ethyl acetate/hexane), the title
compound 47 (650 mg, 64%) as a light-yellow oil, [α]D
20 = + 1.5 (c = 0.8,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.33 (t, J = 4.0 Hz, 1H), 4.09
(m, 1H), 3.94 (m, 1H), 3.71 (broad s, 1H), 3.37 (s, 3H), 2.92 (broad s,
2H), 2.50 (dt, J = 18.1 and 4.4 Hz, 1H), 2.19 (d, J = 18.1 Hz, 1H); 13C
NMR (CDCl3, 100 MHz) δ 135.4, 100.0, 78.1, 75.0, 69.4, 57.5, 31.1; IR
νmax 3400, 2928, 2830, 1627, 1395, 1151, 1101, 1078, 980, 844 cm
−1; MS
(EI, 70 eV) m/z 270 (M+•, 9%), 252 (3), 196 (14), 74 (100); HRMS
M+• calcd for C7H11
127IO3 269.9753, found 269.9750.
(1R,2R,6S)-6-Methoxy-3-(7-methyl-3-methyleneoct-6-en-1-yn-1-
yl)cyclohex-3-ene-1,2-diol (5). Alkyne 36 (485 mg, 3.62 mmol) was
added to a magnetically stirred solution of compound 47 (650 mg, 2.41
mmol) in anhydrous diethylamine (20 mL). The resulting solution was
sparged with nitrogen for 0.5 h, and then PdCl2(PPh3)2 (169 mg, 0.24
mmol) and cuprous iodide (68.8 mg, 0.36 mmol) were added. The
ensuing mixture was stirred at 20 °C for 21 h and then concentrated
under reduced pressure, and the residue thus obtained was subjected to
ﬂash chromatography (silica, 1:4 →1:1 v/v ethyl acetate/hexane
gradient elution). Concentration of the appropriate fractions (Rf = 0.3
in 1:1 v/v ethyl acetate/hexane) gave the title compound 5 (400 mg,
60%) as a clear, light-yellow oil, [α]D
20 = +11 (c = 1.1, CHCl3).
1H NMR
(CDCl3, 400 MHz) δ 6.05 (t, J = 4.1 Hz, 1H), 5.35 (d, J = 1.6 Hz, 1H),
5.25 (d, J = 1.6 Hz, 1H), 5.11 (m, 1H), 4.09 (m, 1H), 3.88 (m, 1H), 3.66
(m, 1H), 3.38 (s, 3H), 2.95 (broad s, 1H), 2.89 (d, J = 10.0 Hz, 1H), 2.59
(dm, J = 19.2 Hz, 1H), 2.31 (complex m, 1H), 2.25−2.17 (complex m,
4H), 1.68 (s, 3H), 1.61 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 132.2,
132.0, 131.2, 123.3, 121.4, 89.6, 87.8, 78.4, 69.6, 68.7, 57.3, 37.4, 28.5,
26.8, 25.7, 17.8; IR νmax 3427, 2931, 2190, 1717, 1667, 1446, 1376, 1217,
1084, 755 cm−1; MS (ESI, + ve) m/z 575 [(2 M + Na)+, 15%], 299 [(M
+Na)+, 100]; HRMS (M+Na)+ calcd for C17H24NaO3 299.1623, found
299.1622.
(3aS,4R,5S,7aS)-7-Iodo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3] diox-ol-4-ol (48). A magnetically stirred
solution of epoxide 3815 (326 mg, 1.11 mmol) in methanol/CHCl3
(7.5 mL of a 1:1 v/v mixture) maintained at 20 °Cwas treated with (1S)-
(+)-10-camphorsulfonic acid (52 mg, 0.22 mmol), and the ensuing
mixture maintained in the dark for 0.5 h. After this time, the reaction
mixture was concentrated under reduced pressure, and the residue was
subjected to ﬂash chromatography (silica, 1:1 v/v ethyl acetate/hexane
gradient elution). Concentration of the appropriate fractions (Rf = 0.4 in
1.5:1 v/v ethyl acetate/hexane) then gave the title compound 48 (166
mg, 45%) as a clear, colorless oil, [α]D
20 = +34 (c = 4.4, CHCl3).
1HNMR
(CDCl3, 400 MHz) δ 6.53 (s, 1H), 4.68 (d, J = 6.5 Hz, 1H), 4.13 (m,
1H), 3.64 (s, 1H), 3.63 (m, 1H), 3.47 (s, 3H), 2.67 (broad s, 1H), 1.54
(s, 3H), 1.41 (s, 3H); 13CNMR (CDCl3, 100MHz) δ 140.3, 110.3, 93.1,
81.3, 79.5, 77.1, 72.4, 57.5, 28.0, 25.8; IR νmax 3442, 2986, 2933, 2828,
1632, 1455, 1376, 1249, 1217, 1163, 1072, 972, 948, 912, 868, 790, 744
cm−1; MS (EI, 70 eV) m/z 326 (1%), 311 [(M − CH3•)+, 100], 251
(10), 239 (28), 226 (32), 124 (50), 101 (75); HRMS (M − CH3•)+
calcd for C9H12
127IO4 310.9780, found 310.9781.
(1S,2S,3S,6S)-4-Iodo-6-methoxycyclohex-4-ene-1,2,3-triol (49). A
magnetically stirred solution of acetonide 48 (489 mg, 1.50 mmol) in a
mixture of methanol/THF (10 mL of a 1:1 v/v mixture) was treated
with acidiﬁed AG-50W-X8 acidic resin (979 mg, 200 wt %), and the
ensuing mixture was stirred vigorously at 20 °C for 48 h while being
protected from light. The ensuing mixture was ﬁltered through a pad of
diatomaceous earth that was washed with ethyl acetate (2× 20mL). The
combined ﬁltrates were concentrated under reduced pressure, and the
residue so obtained was subjected to ﬂash chromatography (silica, ethyl
acetate gradient elution) to give, after concentration of the appropriate
fractions (Rf = 0.3 in ethyl acetate), the title compound 49 (323 mg,
75%) as a white, crystalline solid, mp =123−124 °C, [α]D20 = − 2.4 (c =
0.5, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.50 (d, J = 2.3 Hz, 1H),
4.41 (t, J = 4.3 Hz, 1H), 3.81 (m, 1H), 3.70−3.64 (complex m, 2H), 3.48
(s, 3H), 3.03 (d, J = 6.4 Hz, 1H), 2.87 (m, 2H); 13C NMR (CDCl3, 100
MHz) δ 139.2, 98.4, 82.7, 75.3, 70.7, 70.2, 57.3; IR νmax 3306, 2989,
2927, 2909, 2848, 1620, 1455, 1362, 1270, 1224, 1186, 1147, 1074, 993,
950, 877 cm−1; MS (ESI, + ve)m/z 309 [(M +Na)+, 100%]. HRMS (M
+ Na)+ calcd for C7H11
127INaO4 308.9600, found 308.9600.
(1S,2R,3R,6S)-6-Methoxy-4-(7-methyl-3-methyleneoct-6-en-1-yn-
1-yl)cyclohex-4-ene-1,2,3-triol (6). Alkyne 36 (1.11 g, 8.28 mmol) was
added to a magnetically stirred solution of iodide 49 (1.18 g, 4.14 mmol)
in anhydrous diethylamine (40 mL). The resulting solution was sparged
with nitrogen for 0.5 h, and then PdCl2(PPh3)2 (291 mg, 0.41 mmol)
and cuprous iodide (118 mg, 0.62 mmol) were added. The ensuing
mixture was stirred at 20 °C for 22 h and then concentrated under
reduced pressure, and the dark brown residue so obtained was subjected
to ﬂash chromatography (silica, hexane →1:7:2 v/v/v methanol/ethyl
acetate/hexane gradient elution). Concentration of the appropriate
fractions (Rf = 0.5 in 1:7:2 v/v/v methanol/ethyl acetate/hexane) gave
the product 6 (484 mg, 40%) as a clear, light-yellow oil, [α]D
20 = +34 (c =
2.0, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.11 (d, J = 2.4 Hz, 1H),
5.36 (s, 1H), 5.26 (d, J = 1.1 Hz, 1H), 5.10 (m, 1H), 4.28 (d, J = 4.1 Hz,
1H), 4.05 (broad s, 2H), 3.89 (m, 1H), 3.80 (m, 1H), 3.63 (m, 1H), 3.56
(m, 1H), 3.48 (s, 3H), 2.19 (m, 4H), 1.68 (s, 3H), 1.61 (s, 3H); 13C
NMR (CDCl3, 100 MHz) δ 134.2, 132.3, 131.0, 123.2, 123.1, 122.0,
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.6b02372
J. Org. Chem. 2017, 82, 211−233
225
93
90.6, 87.5, 81.1, 71.1, 70.2, 69.8, 57.1, 37.2, 26.7, 25.7, 17.8; IR νmax 3400,
2925, 1631, 1605, 1438, 1376, 1083, 943, 894 cm−1; MS (ESI, + ve)m/z
315 [(M + Na)+, 100%]; HRMS (M + Na)+ calcd for C17H24NaO4
315.1572, found 315.1571.
(3aS,4S,5R,7aS)-7-Iodo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-diox-ol-4-ol (50). A magnetically stirred
solution of epoxide 44 (1.18 g, 3.99 mmol) in methanol/CHCl3 (45
mL of a 2:1 v/v mixture) was treated with (1S)-(+)-10-camphorsulfonic
acid (186 mg, 0.80 mmol), and the resulting mixture was stirred in the
dark for 0.5 h. The solvent was then removed under reduced pressure,
and the residue thus obtained was subjected to ﬂash chromatography
(silica, 1:1 v/v ethyl acetate/hexane gradient elution). Concentration of
the appropriate fractions (Rf = 0.2 in 1:3 v/v ethyl acetate/hexane) gave
the title compound 50 (1.21 g, 93%) as a clear, colorless solid, mp = 72−
78 °C, [α]D20 = −29 (c = 7.5, CHCl3). 1H NMR (CDCl3, 400 MHz) δ
6.47 (d, J = 1.8 Hz, 1H), 4.63 (m, 1H), 4.47 (m, 1H), 3.94 (d, J = 8.3 Hz,
1H), 3.81 (dd, J = 8.3 and 2.6 Hz, 1H), 3.50 (s, 3H), 2.61 (broad s, 1H),
1.43 (s, 3H), 1.41 (s, 3H); 13C NMR (CDCl3, 100MHz) δ 137.1, 110.6,
100.6, 80.6, 79.7, 76.3, 71.2, 57.6, 27.4, 26.4; IR νmax 3390, 2984, 2918,
2843, 1697, 1618, 1381, 1217, 1073 cm−1; MS (EI, 70 eV)m/z 311 [(M
− CH3•)+, 14%], 239 (23), 226 (100); HRMS (M − CH3•)+ calcd for
C9H12
127IO4 310.9780, found 310.9773.
(1R,2S,3S,6R)-4-Iodo-6-methoxycyclohex-4-ene-1,2,3-triol (51). A
magnetically stirred solution of acetonide 50 (1.21 g, 3.70 mmol) in
methanol/THF (20 mL of a 1:1 v/v mixture) was treated with acidiﬁed
AG-50W-X8 ion-exchange resin (2.40 g, 200 wt %), and the ensuing
mixture was stirred vigorously at 20 °C for 48 h while being protected
from light. The solvent was then removed under reduced pressure, and
the residue thus obtained was subjected to ﬂash chromatography (silica,
ethyl acetate gradient elution). Concentration of the appropriate
fractions (Rf = 0.2 in 0.5:9.5 v/v ethyl acetate/hexane) gave the title
compound 51 (379 mg, 36%) as a white, crystalline solid, mp = 73−77
°C, [α]D20 = −61 (c = 0.8, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 6.56
(s, 1H), 4.20 (s, 2H), 3.90 (m, 2H), 3.46 (s, 3H), 3.26 (broad s, 3H); 13C
NMR (CDCl3, 100 MHz) δ 136.5, 104.7, 80.1, 73.6, 72.1, 70.1, 57.4; IR
νmax 3217, 2918, 2861, 2821, 1660, 1620, 1415, 1336, 1099, 1081, 1045,
1028, 847 cm−1; MS (EI, 70 eV) m/z 309 [(M + Na)+, 100%]; HRMS
(M + Na)+ calcd for C7H11
127INaO4, 308.9600, found, 308.9600.
(1R,2R,3R,6R)-6-Methoxy-4-(7-methyl-3-methyleneoct-6-en-1-yn-
1-yl)cyclohex-4-ene-1,2,3-triol (7). Alkyne 36 (684 mg, 5.10 mmol)
was added to a magnetically stirred solution of triol 51 (951 mg, 3.33
mmol) in diethylamine (30 mL) maintained at 20 °C. The ensuing
mixture was sparged with nitrogen for 0.5 h, and then PdCl2(PPh3)2
(234 mg, 0.33 mmol) and cuprous iodide (95.1 mg, 0.55 mmol) were
added. After 21 h, the reaction mixture was concentrated under reduced
pressure, and the brown residue thus obtained was subjected to ﬂash
chromatography (silica, hexane →9:1 ethyl acetate/hexane gradient
elution). Concentration of the appropriate fractions (Rf = 0.4 in 1:7:2 v/
v/v methanol/ethyl acetate/hexane) gave the title compound 7 (331
mg, 34%) as a clear, light-yellow oil, [α]D
20 = − 15 (c = 0.8, CHCl3). 1H
NMR (CDCl3, 400 MHz) δ 6.17 (m, 1H), 5.38 (s, 1H), 5.29 (s, 1H),
5.10 (m, 1H), 4.21 (m, 2H), 4.05 (m, 1H), 3.81 (d, J = 6.8 Hz, 1H), 3.47
(s, 3H), 2.98 (broad s, 1H), 2.87 (broad s, 1H), 2.83 (broad s, 1H), 2.21
(m, 4H), 1.69 (s, 3H), 1.62 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ
132.3, 131.7, 131.0, 124.4, 123.2, 122.0, 91.3, 86.8, 78.6, 72.0, 70.5, 69.2,
57.1, 37.2, 26.7, 25.2, 17.7; IR νmax 3390, 2958, 2923, 2857, 2193, 1634,
1438, 1377, 1261, 1084 cm−1; MS (ESI, + ve) m/z 315 [(M + Na)+,
100%]; HRMS (M + Na)+ calcd for C17H24NaO4 315.1572, found
315.1570.
6-Methylheptan-2-one (53). A magnetically stirred mixture of the
commercially available ketone 52 (2.00 g, 15.85 mmol) and Pd on
carbon (100 mg of 10% material) in MeOH (5 mL) was placed under a
balloon of hydrogen at 20 °C. After 5 h, the reaction mixture was ﬁltered
through a short pad of diatomaceous earth, and the ﬁltrate was
concentrated under reduced pressure to give compound 5319 (1.64 g,
81%) as a clear, pale-yellow oil. 1H NMR (500MHz, CDCl3) δ 2.36 (t, J
= 7.5 Hz, 2H), 2.1 (s, 3H), 1.57−1.45 (complex m, 3H), 1.11 (m, 2H),
0.83 (d, J = 6.4 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 209.2, 43.9,
38.3, 29.7, 27.7, 22.4, 21.6; IR (KBr) νmax 2955, 2872, 1717, 1468, 1365,
1168, 1107, 861 cm−1.
6-Methylhept-1-en-2-yl triﬂuoromethanesulfonate (54). A mag-
netically stirred solution of diisopropylamine (2.9 mL, 20.69 mmol) in
THF (30 mL) maintained between −15 and −20 °C under a nitrogen
atmosphere was treated, dropwise, with n-BuLi (12 mL of a 1.6 M
solution in hexanes, 19.2 mmol). After 0.25 h, the cooling bath was
removed, and stirring was continued for 0.5 h. The reaction mixture thus
obtained was cooled to −78 °C and then treated with compound 53
(1.66 g, 12.97 mmol). After stirring at −78 °C for 1 h, PhNTf2 (5.6 g,
15.68 mmol) was added, and the ensuing mixture was stirred for a
further 18 h while being allowed to warm to 20 °C and then poured into
NH4Cl (80 mL of a saturated aqueous solution). The separated aqueous
phase was extracted with diethyl ether (1 × 60 mL), and the combined
organic phases were washed with brine (1 × 80 mL), then dried
(MgSO4), ﬁltered, and concentrated under reduced pressure. Subjection
of residue thus obtained to ﬂash chromatography (silica, 1:50 v/v diethyl
ether/pentane gradient elution) delivered, after concentration of the
appropriate fractions (Rf = 0.5 in 1:80 v/v ethyl acetate/hexane),
compound 54 (2.31 g, 68%) as a clear, pale-yellow oil. 1H NMR (500
MHz, CDCl3) δ 5.09 (d, J = 3.5 Hz, 1H), 4.93 (m, 1H), 2.31 (t, J = 7.6
Hz, 2H), 1.59−1.51 (complex m, 3H), 1.30−1.21 (complex m, 2H),
0.88 (d, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 157.1, 118.6
(q, JC−F = 320 Hz), 103.9, 37.8, 34.0, 27.7, 23.8, 22.3; IRνmax 2959, 2874,
1670, 1419, 1246, 1211, 1141, 937, 897, 612 cm−1; MS (EI 70 eV) m/z
111 [(M-TfO•)+, 36%], 109 (32), 95 (67), 69 (100); HRMS (M-
TfO•)+ calcd for C8H15 111.1174, found 111.1173.
Trimethyl(7-methyl-3-methyleneoct-1-yn-1-yl)silane (55). Trime-
thylsilylacetylene (1.9 mL, 13.45 mmol) was added to a magnetically
stirred mixture of compound 54 (2.33 g, 8.94 mmol), cuprous iodide
(255 mg, 1.34 mmol), and PdCl2(CH3CN)2 (232 mg, 0.90 mmol) in
piperidine/THF (30 mL of a 2:1 v/v mixture) maintained under a
nitrogen atmosphere. After stirring at 20 °C for 1 h, the reaction mixture
was treated with diethyl ether (40 mL) and then NH4Cl (100 mL of a
saturated aqueous solution). The separated aqueous phase was extracted
with diethyl ether (40 mL), and the combined organic phases were
washed with NH4Cl (1 × 100 mL of a saturated aqueous solution)
before being dried (MgSO4), ﬁltered, then concentrated under reduced
pressure. Subjection of the residue thus obtained to ﬂash chromatog-
raphy (silica, pentane elution) delivered, after concentration of the
appropriate fractions (Rf = 0.6 in hexane), compound 55 (1.58 g, 85%)
as a clear, pale-yellow oil. 1H NMR (500MHz, CDCl3) δ 5.35 (d, J = 2.0
Hz, 1H), 5.22 (m, 1H), 2.12 (m, 2H), 1.58−1.49 (complex m, 3H),
1.21−1.16 (complex m, 2H), 0.88 (d, J = 6.3 Hz, 6H), 0.19 (s, 9H); 13C
NMR (125 MHz, CDCl3) δ 132.0, 121.7, 105.8, 93.7, 38.1, 37.2, 27.8,
25.7, 22,6, − 0.0(3); IR νmax 2957, 2870, 2147, 1605, 1468, 1250, 879,
842, 759 cm−1; MS (EI 70 eV)m/z 208 (M+•, 33%), 193 (45), 123 (82),
73 (100); HRMS M+• calcd for C13H24Si 208.1647, found 208.1642.
7-Methyl-3-methyleneoct-1-yne (56). Compound 55 (1.25 g, 5.99
mmol) in methanol (5 mL) was treated with K2CO3 (2.48 g, 17.95
mmol). After stirring at 18 °C for 2 h, the reaction mixture was ﬁltered
through a short pad of diatomaceous earth, and the ﬁltrate then was
concentrated under reduced pressure. Subjection of the residue thus
obtained to ﬂash chromatography (silica, pentane elution) delivered,
after concentration of the appropriate fractions (Rf = 0.7 in hexane),
compound 56 (594 mg, 73%) as a clear, pale-yellow oil. 1H NMR (500
MHz, CDCl3) δ 5.41 (d, J = 1.9 Hz, 1H), 5.29 (m, 1H), 2.88 (s, 1H),
2.14 (m, 2H), 1.54−1.49 (complex m, 3H), 1.21−1.15 (complex m,
2H), 0.88 (d, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 131.0,
122.6, 84.2, 76.7, 38.1, 37.2, 27.8, 25.7, 22.6; IR νmax 3310, 2955, 2870,
1611, 1468, 1384, 1367, 1249, 902, 637, 612 cm−1; MS (EI, 70 eV) m/z
136 (M+•, 13%), 135 (47), 121 (25), 73 (100); HRMS M+• calcd for
C10H16 136.1252, found 136.1249.
(((3aR,4R,5R,7aS)-7-Iodo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d]-[1,3]dioxol-4-yl)oxy)triisopropylsilane (58) and
(((3aS,4S,5R,7aS)-7-Iodo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxol-5-yl)oxy)triisopropylsilane (59). So-
dium hydride (300 mg of a 60% dispersion in mineral oil, 7.50 mmol)
was added to a magnetically stirred solution of compound 578 (1.16 g,
2.48 mmol) and iodomethane (460 μL, 7.39 mmol) in dry THF (25
mL) maintained at 0 °C under a nitrogen atmosphere. Stirring was
continued at 0 to 18 °C for 2 h, then the reaction mixture was treated
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with ice/water (60 mL). The separated aqueous phase was extracted
with ethyl acetate (1 × 25 mL), and the combined organic phases were
then dried (MgSO4), ﬁltered, and concentrated under reduced pressure.
The ensuing light-yellow oil was subjected to ﬂash chromatography
(silica, 1:50 v/v ethyl acetate/hexane gradient elution) to give two
fractions, A and B.
Concentration of fraction A (Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl
acetate/dichloromethane/hexane) gave compound 58 (100 mg, 8%) as
a white, crystalline solid, mp = 66−67 °C, [α]D20 = −27.5 (c = 0.2,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.44 (d, J = 1.9 Hz, 1H), 4.62
(dd, J = 5.3 and 1.6 Hz, 1H), 4.50 (m, 1H), 4.29 (t, J = 5.0 Hz, 1H), 3.84
(m, 1H), 3.41 (s, 3H), 1.41 (s, 3H), 1.39 (s, 3H), 1.07 (m, 21H); 13C
NMR (CDCl3, 100 MHz) δ 137.7, 109.8, 98.9, 79.5, 77.9, 77.2, 69.7,
57.3, 27.5, 26.3, 18.0(4), 17.9(7), 12.6; IR νmax 2940, 2888, 2865, 1636,
1462, 1383, 1335, 1241, 1221, 1198, 1139, 1122, 1081, 1040, 996, 881,
858, 681 cm−1; MS (EI, 70 eV) m/z 467 [(M-CH3•)+, 6%], 439 (35),
381 (42), 349 (37), 257 (40), 254 (100), 222 (55), 145 (88); HRMS
(M-CH3•)+ calcd for C18H32127IO4Si 467.1115, found 467.1112.
Concentration of fraction B (Rf = 0.3 in 0.5:2.5:5.5 v/v/v ethyl
acetate/dichloromethane/hexane) gave compound 598 (1.07 g, 90%) as
a white, crystalline solid. The physical and spectroscopic data recorded
on this material were essentially identical with those reported8
previously.
(1S,2R,3R,4R)-6-Iodo-3-methoxycyclohex-5-ene-1,2,4-triol (60).
Compound 59 (200 mg, 0.42 mmol) was treated with acetic/water
(10 mL of a 7:1 v/v mixture), and the resulting solution was heated at 70
°C for 18 h, then cooled, and concentrated under reduced pressure.
Subjection of the residue thus obtained to ﬂash chromatography (silica,
1:6:3 v/v/v methanol/ethyl acetate/hexane gradient elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 1:7:2 v/v/v
methanol/ethyl acetate/hexane), compound 608 (81 mg, 68%) as a
white, crystalline solid. The physical and spectroscopic data recorded on
this material were essentially identical with those reported8 previously.
(1R,2R,3R,4R)-3-Methoxy-6-(7-methyl-3-methyleneoct-1-yn-1-yl)-
cyclohex-5-ene-1,2,4-triol (10).Cuprous iodide (5mg, 0.03 mmol) and
PdCl2(PPh3)2 (14 mg, 0.03 mmol) were added to a magnetically stirred
solution of compounds 60 (120 mg, 0.42 mmol) and 56 (57 mg, 0.42
mmol) in anhydrous diethylamine (10 mL)maintained at 20 °C under a
nitrogen atmosphere. After 3 h, the reaction mixture was concentrated
under reduced pressure, and the residue thus obtained was subjected to
ﬂash chromatography (silica, 1:6:3 v/v/v methanol/ethyl acetate/
hexane gradient elution). Concentration of the appropriate fractions (Rf
= 0.5 in 1:7:2 v/v/vmethanol/ethyl acetate/hexane) gave compound 10
(99 mg, 80%) as a clear, light-yellow oil, [α]D
20 =−49.1 (c = 2.6, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.15 (d, J = 4.2 Hz, 1H), 5.36 (s, 1H),
5.28 (s, 1H), 4.49 (s, 1H), 4.33 (m, 1H), 4.19 (m, 1H), 3.68 (m, 1H),
3.53 (s, 3H), 2.73 (broad s, 2H), 2.15 (t, J = 7.5 Hz, 2H), 2.09 (s, 1H)
1.56−1.46 (complex m, 3H), 1.25−1.14 (complex m, 2H), 0.88 (s, 3H),
0.86 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 134.6, 131.3, 123.9, 122.0,
91.6, 86.6, 78.6, 68.4, 67.4, 64.0, 58.5, 38.1, 37.2, 27.8, 25.9, 22.6; IR νmax
3400, 2953, 2869, 1630, 1604, 1466, 1384, 1239, 1105, 1094, 1040, 989
cm−1; MS (EI, 70 eV) m/z 294 (M+•, 5%), 276 (15), 247 (37), 220
(100), 150 (53); HRMS M+• calcd for C17H26O4 294.1831, found
294.1832.
(3aR,4R,5R,7aR)-4,5-Dimethoxy-2,2-dimethyl-7-(7-methyl-3-
methyleneoct-1-yn-1-yl)- 3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxole
(61). Cuprous iodide (26 mg, 0.14 mmol) and PdCl2(PPh3)2 (63 mg,
0.09 mmol) were added to a magnetically stirred solution of compounds
35 (306 mg, 0.90 mmol) and 56 (184 mg, 1.35 mmol) in diethylamine
(10 mL) maintained under under a nitrogen atmosphere. After stirring
at 20 °C for 3 h, the reaction mixture was concentrated under reduced
pressure, and the residue thus obtained was subjected to ﬂash
chromatography (silica, 1:5 v/v ethyl acetate/hexane gradient elution).
Concentration of the appropriate fractions (Rf = 0.5 in 2:2.5:5.5 v/v/v
ethyl acetate/dichloromethane/hexane) then gave compound 61 (179
mg, 96%) as a pale-yellow oil, [α]D
20 = −54 (c = 0.5, CHCl3). 1H NMR
(500 MHz, CDCl3) δ 6.23 (d, J = 3.9 Hz, 1H), 5.34 (d, J = 2.0 Hz, 1H),
5.24 (m, 1H), 4.63 (d, J = 6.1 Hz, 1H), 4.44 (t, J = 6.1 Hz, 1H), 4.02 (m,
1H), 3.65 (m, 1H), 3.51 (s, 3H), 3.43 (s, 3H), 2.14 (m, 2H), 1.56−1.49
(complex m, 3H), 1.44 (s, 3H), 1.38 (s, 3H), 1.19−1.15 (complex m,
2H), 0.87 (d, J = 6.6 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 133.5,
131.6, 123.2, 121.5, 109.4, 90.9, 87.2, 79.0, 74.2, 74.0, 73.8, 58.8, 57.4,
38.1, 37.3, 27.8, 27.5, 25.8, 25.5, 22.6; IR νmax 2984, 2953, 2934, 1605,
1463, 1381, 1369, 1234, 1200, 1115, 1081, 874 cm−1; MS (EI, 70 eV)m/
z 348 (M+•, 3%), 333 (6), 234 (17), 115 (100), 75 (15); HRMS M+•
calcd for C21H32O4 348.2316, found 348.2301.
(1R,2R,5R,6S)-5,6-Dimethoxy-3-(7-methyl-3-methyleneoct-1-yn-
1-yl)cyclohex-3-ene-1,2-diol (11).Compound 61 (121mg, 0.35mmol)
was treated with acetic/water (10 mL of a 7:3 v/v mixture). The ensuing
mixture was heated at 70 °C for 14 h, then cooled, and concentrated
under reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 1:6:3 v/v/v methanol/ethyl acetate/hexane
elution) delivered, after concentration of the appropriate fractions (Rf =
0.5 in 1:4:5 v/v/v methanol/ethyl acetate/hexane), compound 11 (64
mg, 60%) as a light-yellow semisolid, [α]D
20 =−135 (c = 0.5, CHCl3). 1H
NMR (500 MHz, CDCl3) δ 6.24 (dd, J = 4.5 and 0.6 Hz, 1H), 5.35 (d, J
= 2.3Hz, 1H), 5.26 (dd, J = 2.3 and 1.0 Hz, 1H), 4.34 (d, J = 4.1Hz, 1H),
4.16 (m, 1H), 4.10 (m, 1H), 3.69 (m, 1H), 3.50 (s, 3H), 3.46 (s, 3H),
2.94 (broad s, 2H), 2.14 (m, 2H), 1.57−1.49 (complex m, 3H), 1.19−
1.15 (complex m, 2H), 0.87 (d, J = 6.6 Hz, 6H); 13C NMR (125 MHz,
CDCl3) δ 132.3, 131.4, 124.7, 121.9, 91.4, 87.0, 77.4, 72.6, 68.7, 67.5,
58.0, 57.6, 38.1, 37.2, 27.7, 25.8, 22.6; IR νmax 3307, 2952, 2899, 2871,
1603, 1465, 1316, 1124, 1103, 885 cm−1; MS (ESI, + ve) m/z 331 [(M
+Na)+, 100%]; HRMS (M+Na)+ calcd for C18H28NaO4, 331.1885,
found 331.1888.
(3aS,4S,5S,7aS)-7-Iodo-2,2-dimethyl-5-((triisopropylsilyl)oxy)-
3a,4,5,7a-tetrahydro-benzo[d][1,3]dioxol-4-ol (63). Triisopropylsilyl
triﬂuoromethanesulfonate (1.02 mL, 3.78 mmol) was added, dropwise,
to a magnetically stirred solution of compound 6215 (982 mg, 3.15
mmol) and 2,6-lutidine (1.5 mL, 12.90 mmol) in dichloromethane (25
mL) maintained at −78 °C under a nitrogen atmosphere. The ensuing
mixture was allowed to warm to 20 °C over 3 h and then treated with
NH4Cl (60 mL of a saturated aqueous solution). The separated aqueous
phase was extracted with dichloromethane (1 × 40 mL), and the
combined organic phases were dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The resulting light-yellow oil
was subjected to ﬂash chromatography (silica, 3:100 v/v ethyl acetate/
hexane gradient elution) to give, after concentration of the appropriate
fractions (Rf = 0.3 in 0.5:2.5:5.5 v/v/v ethyl acetate/dichloromethane/
hexane), compound 63 (722 mg, 49%) as a clear, colorless oil, [α]D
20 =
+12.6 (c = 0.3, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.42 (d, J = 1.2
Hz, 1H), 4.67 (d, J = 6.6 Hz, 1H), 4.17 (d, J = 8.2 Hz, 1H), 4.11 (m, 1H),
3.56 (m, 1H), 2.41 (broad s, 1H), 1.55 (s, 3H), 1.41 (s, 3H), 1.10 (m,
21H); 13C NMR (CDCl3, 100 MHz) δ 136.4, 117.7, 110.9, 77.4, 77.0,
74.6, 72.6, 28.0, 25.8, 18.0(0), 17.9(8), 12.4; IR νmax 3416, 2943, 2892,
2867, 1644, 1463, 1383, 1248, 1218, 1070, 1015, 997, 882, 829, 682
cm−1; MS (EI, 70 eV)m/z 453 [(M-CH3•)+, 5%], 367 (41), 240 (100);
HRMS (M-CH3•)+ calcd for C17H30127IO4Si 453.0958, found 453.0957.
(((3aS,4S,5S,7aS)-7-Iodo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d]- [1,3]-dioxol-5-yl)oxy)triisopropylsilane (64).
Sodium hydride (300 mg of a 60% dispersion in mineral oil, 7.50
mmol) was added to a magnetically stirred solution of compound 63
(1.16 g, 2.48 mmol) and iodomethane (460 μL, 7.39 mmol) in dry THF
(25 mL) maintained at 0 °C under a nitrogen atmosphere. Stirring was
continued at 0 to 18 °C for 3 h, and then the reactionmixture was treated
with ice/water (60 mL) (Caution: possibility of hydrogen generation). The
separated aqueous phase was extracted with ethyl acetate (1 × 25 mL),
and the combined organic phases were then dried (MgSO4), ﬁltered,
and concentrated under reduced pressure. The ensuing light-yellow oil
was subjected to ﬂash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/dichloromethane/hexane),
compound 64 (780 mg, 65%) as a clear, light-yellow oil, [α]D
20 = +33.1 (c
= 1.0, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.55 (d, J = 3.2 Hz, 1H),
4.60 (d, J = 6.0 Hz, 1H), 4.18 (t, J = 6.0 Hz, 1H), 4.04 (t, J = 6.0 Hz, 1H),
3.58−3.48 (complex m, 1H), 3.40 (s, 3H), 1.48 (s, 3H), 1.38 (s, 3H),
1.11 (m, 21H); 13C NMR (CDCl3, 100 MHz) δ 137.9, 110.1, 99.5, 81.2,
78.4, 77.9, 71.1, 57.5, 27.6, 26.1, 18.1, 18.0, 12.5; IR νmax 2941, 2866,
1635, 1463, 1381, 1251, 1214, 1166, 1125, 1075, 975, 882, 768m 679
cm−1; MS (EI, 70 eV)m/z 467 [(M-CH3•)+, 12%], 439 (46), 381 (82),
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349 (46), 254 (100), 222 (64), 145 (73); HRMS (M-CH3•)+ calcd for
C18H32
127IO4Si 467.1115, found 467.1110.
(3aS,4R,5S,7aS)-7-Iodo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-diox-l-5-ol (65). A magnetically stirred
solution of compound 64 (972 mg, 2.02 mmol) in THF (10 mL)
maintained at 18 °C under a nitrogen atmosphere was treated with tetra-
n-butylammonium ﬂuoride (3 mL of 1.0 M solution in THF, 3.00
mmol). After 2 h, the reaction mixture was concentrated under pressure,
and the residue so-formed subjected to ﬂash chromatography (silica, 1:2
v/v ethyl acetate/hexane gradient elution). Concentration of the
appropriate fractions (Rf = 0.4 in 4:2.5:5.5 v/v/v ethyl acetate/
dichloromethane/hexane) then gave compound 65 (592 mg, 90%) as a
clear, light-yellow oil, [α]D
20 = +42.5 (c = 0.4, CHCl3).
1H NMR (CDCl3,
400 MHz) δ 6.51 (s, 1H), 4.67 (d, J = 6.7 Hz, 1H), 4.12 (t, J = 6.7 Hz,
1H), 3.61 (m, 2H), 3.46 (s, 3H), 2.85 (broad s, 1H), 1.52 (s, 3H), 1.39
(s, 3H); 13C NMR (CDCl3, 100 MHz) δ 140.3, 110.3, 93.2, 81.3, 79.5,
77.2, 72.4, 57.5, 28.0, 25.8; IR νmax 3399, 2987, 2932, 2830, 1642, 1457,
1380, 1252, 1218, 1074, 945, 869 cm−1; MS (EI, 70 eV) m/z 326 (8%),
311 [(M-CH3•)+, 73], 225 (32), 124 (58), 101 (100), 55 (51); HRMS
(M-CH3•)+ calcd for C9H12127IO4 310.9780, found 310.9778.
(3aR,4R,5S,7aR)-4-Methoxy-2,2-dimethyl-7-(7-methyl-3-methyle-
neoct-1-yn-1-yl)-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-ol (14).
Cuprous iodide (25 mg, 0.13 mmol) and PdCl2(PPh3)2 (59 mg, 0.09
mmol) were added to a magnetically stirred solution of compounds 65
(275 mg, 0.85 mmol) and 56 (230 mg, 1.69 mmol) in anhydrous
diethylamine (3 mL) maintained at 18 °C under a nitrogen atmosphere.
After 3 h, the reaction mixture was concentrated under reduced
pressure, and the residue obtained was subjected to ﬂash chromatog-
raphy (silica, 2:5 v/v ethyl acetate/hexane gradient elution).
Concentration of the appropriate fractions (Rf = 0.5 in 4:2.5:5.5 v/v/v
ethyl acetate/dichloromethane/hexane) then gave compound 14 (192
mg, 68%) as a clear, light-yellow oil, [α]D
20 = +11.5 (c = 0.2, CHCl3).
1H
NMR (CDCl3, 400 MHz) δ 6.19 (d, J = 1.8 Hz, 1H), 5.36 (s, 1H), 5.27
(s, 1H), 4.58 (d, J = 6.4 Hz, 1H), 4.10 (dd, J = 9.0 and 6.4 Hz, 1H), 3.73
(d, J = 8.9 Hz, 1H), 3.64 (t, J = 8.9 Hz, 1H), 3.47 (s, 3H), 2.75 (s, 1H),
2.16 (t, J = 7.6 Hz, 2H), 1.55 (m, 3H), 1.53 (s, 3H), 1.40 (s, 3H), 1.21−
1.15 (complex m, 2H), 0.88 (s, 3H), 0.87 (s, 3H); 13C NMR (CDCl3,
100MHz) δ 135.6, 131.4, 121.9, 119.5, 110.8, 91.0, 86.4, 79.7, 77.3, 74.5,
72.5, 57.3, 38.1, 37.2, 28.2, 27.8, 25.9, 25.8, 22.6; IR νmax 3345, 2922,
2883, 2861, 1649, 1465, 1382, 1259, 1207, 1123, 1060, 1022, 872 cm−1;
MS (EI, 70 eV) m/z 334 (M+•, 5%), 319 (23), 259 (42), 247 (63), 115
(18), 101 (100); HRMS M+• calcd for C20H30O4 334.2144, found
334.2140.
(1R,2R,3R,4S)-3-Methoxy-6-(7-methyl-3-methyleneoct-1-yn-1-yl)-
cyclohex-5-ene-1,2,4-triol (12). Compound 14 (360 mg, 1.08 mmol)
was treated with acetic/water (10 mL of a 4:1 v/v mixture), and the
solution thus obtained was heated at 70 °C for 5 h, then cooled, and
concentrated under reduced pressure. Subjection of the ensuing light-
yellow residue to ﬂash chromatography (silica, 1:6:3 v/v/v methanol/
ethyl acetate/hexane gradient elution) delivered, after concentration of
the appropriate fractions (Rf = 0.5 in 1:7:2 v/v/v methanol/ethyl
acetate/hexane), compound 12 (228 mg, 72%) as a clear, light-yellow
oil, [α]D
20 =−31.7 (c = 0.7, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 6.15
(d, J = 2.2 Hz, 1H), 5.37 (s, 1H), 5.28 (s, 1H), 4.32 (d, J = 4.1 Hz, 1H),
3.89−3.78 (complex m, 2H), 3.60 (m, 1H), 3.49 (s, 3H), 3.03 (broad s,
1H), 2.92 (broad s, 1H), 2.67 (broad s, 1H), 2.16 (t, J = 7.7 Hz, 2H),
1.57−1.50 (complex m, 3H), 1.25−1.16 (complex m, 2H), 0.86 (d, J =
7.0 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 134.1, 131.4, 123.2, 121.8,
90.6, 87.4, 81.2, 71.1, 70.0, 69.9, 57.1, 38.1, 37.2, 27.7, 25.8, 22.6; IR νmax
3399, 2954, 2928, 1672, 1462, 1384, 1367, 1234, 1185, 1096, 1081, 952
cm−1; MS (EI, 70 eV) m/z 294 (M+•, 2%), 247 (47), 234 (92), 164
(100); HRMS M+• calcd for C17H26O4 294.1831 found 294.1833.
(3aS,4R,5R,7aS)-7-Iodo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-5-ol (66). A magnetically stirred
solution of compound 59 (972 mg, 2.02 mmol) in THF (10 mL)
maintained at 18 °C under a nitrogen atmosphere was treated with tetra-
n-butylammonium ﬂuoride (3 mL of 1.0 M solution in THF, 3.00
mmol). After 2 h, the reaction mixture was concentrated under pressure,
and the residue so-formed was subjected to ﬂash chromatography (silica,
1:2 v/v ethyl acetate/hexane gradient elution). Concentration of the
appropriate fractions (Rf = 0.4 in 4:2.5:5.5 v/v/v ethyl acetate/
dichloromethane/hexane) then gave compound 668 (578 mg, 88%) as a
white, crystalline solid. The physical and spectroscopic data recorded on
this material were essentially identical with those reported8 previously.
(3aR,4R,5R,7aR)-4-Methoxy-2,2-dimethyl-7-(7-methyl-3-methyle-
neoct-1-yn-1-yl)-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-ol (13).
Cuprous iodide (50 mg, 0.25 mmol) and PdCl2(PPh3)2 (118 mg, 0.17
mmol) were added to a magnetically stirred solution of compounds 66
(550 mg, 1.68 mmol) and 56 (460 mg, 3.38 mmol) in anhydrous
diethylamine (3 mL) maintained at 20 °C under a nitrogen atmosphere.
After 3 h, the reaction mixture was concentrated under reduced
pressure, and the residue thus obtained was subjected to ﬂash
chromatography (silica, 2:5 v/v ethyl acetate/hexane gradient elution).
Concentration of the appropriate fractions (Rf = 0.5 in 4:2.5:5.5 v/v/v
ethyl acetate/dichloromethane/hexane) then gave compound 13 (397
mg, 70%) as a clear, light-yellow oil, [α]D
20 = −9.0 (c = 1.4, CHCl3). 1H
NMR (CDCl3, 400 MHz) δ 6.11 (d, J = 3.5 Hz, 1H), 5.35 (d, J = 2.0 Hz,
1H), 5.25 (d, J = 2.0Hz, 1H), 4.57 (d, J = 5.7 Hz, 1H), 4.48 (t, J = 5.7 Hz,
1H), 4.39 (m, 1H), 3.67 (m, 1H), 3.53 (s, 3H), 2.54 (d, J = 8.3 Hz, 1H),
2.15 (t, J = 7.5 Hz, 2H), 1.61−1.47 (complex m, 3H), 1.43 (s, 3H), 1.39
(s, 3H), 1.21−1.13 (complex m, 2H), 0.87 (d, J = 7.0 Hz, 6H); 13CNMR
(CDCl3, 100 MHz) δ 135.5, 131.6, 122.5, 121.5, 109.7, 90.7, 87.2, 79.6,
73.7, 73.1, 64.7, 58.9, 38.2, 37.3, 27.8, 27.6, 26.0, 25.8, 22.6; IR νmax 3454,
2980, 2949, 2935, 2896, 2865, 1631, 1604, 1461, 1379, 1369, 1231,
1109, 1076, 1037, 985 cm−1; MS (EI, 70 eV) m/z 334 (M+•, 3%), 319
(7), 259 (5), 247 (12), 115 (100); HRMS M+• calcd for C20H30O4
334.2144, found 334.2142.
((3,5-Dimethylphenyl)ethynyl)trimethylsilane (68). Commercially
available 1-iodo-3,5-dimethylbenzene 67 (300 mg, 1.29 mmol),
PdCl2(PPh3)2 (45 mg, 0.07 mmol), and cuprous iodide (12 mg, 0.07
mmol) were placed in an oven-dried ﬂask under a nitrogen atmosphere.
Dry diethylamine was added, and the resulting suspension was stirred
magnetically while being cooled at 0 °C. Trimethylsilylacetylene (0.28
mL, 1.94 mmol) was then added dropwise to the reaction mixture that
was then allowed to warm to 20 °C and stirred at this temperature for 3
h. The ensuing reaction mixture was concentrated under reduced
pressure, and diethyl ether (20 mL) then was added to the residue thus
obtained. The ensuing mixture was ﬁltered through a short pad of
diatomaceous earth, and the ﬁltrate was washed with brine (1 × 20 mL)
before being dried (Na2SO4), ﬁltered, and then concentrated under
reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, pentane elution) delivered, after concentration
of the appropriate fractions (Rf = 0.5 in hexane), compound 68
18 (177
mg, 68%) as a clear, light-yellow syrup. 1H NMR (CDCl3, 400 MHz) δ
7.11 (s, 2H), 6.95 (s, 1H), 2.28 (s, 6H), 0.24 (s, 9H); 13C NMR (CDCl3,
100 MHz) δ 137.7, 130.4, 129.6, 122.7, 105.5, 93.2, 21.1, 0.0(1); IR νmax
2962, 2923, 2247, 2150, 2107, 1599, 1251 cm−1; MS (EI, 70 eV) m/z
202 (M+•, 28%) 187 (100); HRMS M+• calcd for C13H18Si 202.1178,
found 202.1184.
1-Ethynyl-3,5-dimethylbenzene (69). A magnetically stirred sol-
ution of compound 68 (850 mg, 4.21 mmol) in MeOH (5 mL)
maintained at 20 °C was treated with K2CO3 (1.63 g, 8.41 mmol), and
after 1 h, the reaction mixture was ﬁltered through a pad of
diatomaceous earth, and the ﬁltrate was concentrated under reduced
pressure. Subjection of the residue thus obtained to ﬂash chromatog-
raphy (silica, pentane elution) delivered, after concentration of the
appropriate fractions (Rf = 0.5 in hexane), compound 69
18 (396 mg,
72%) as a clear, light-yellow syrup. 1H NMR (CDCl3, 400 MHz) δ 7.13
(s, 2H), 6.99 (s, 1H), 3.01 (s, 1H), 2.29 (s, 6H); 13C NMR (CDCl3, 100
MHz) δ 137.9, 130.7, 129.8, 121.7, 84.0, 76.3, 21.1; IR νmax 3307, 3039,
2952, 2922, 2249, 2108, 1601, 1475 cm−1; MS (EI, 70 eV) m/z 130
(M+•, 6%), 102 (100); HRMS M+• calcd for C10H10 130.0783, found
130.0782.
(3aR,4R,5R,7aR)-7-((3,5-Dimethylphenyl)ethynyl)-4-methoxy-2,2-
dimethyl-3a,4,5,7a -tetrahydrobenzo[d][1,3]dioxol-5-ol (19). Com-
pound 66 (250mg, 0.77mmol), PdCl2(PPh3)2 (27mg, 0.04mmol), and
cuprous iodide (7 mg, 0.04 mmol) were placed in an oven-dried ﬂask
under a nitrogen atmosphere. Dry diethylamine (10 mL) was then
added, and the resulting suspension cooled and stirred magnetically at 0
°C. After the dropwise addition of 1-ethynyl-3,5-dimethylbenzene (69)
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(166 μL, 1.15 mmol) was complete, the reaction mixture was stirred at
20 °C for 3 h and then concentrated under reduced pressure, and diethyl
ether (20 mL) was added to the residue thus obtained. The ensuing
mixture was ﬁltered through a pad of diatomaceous earth, and the ﬁltrate
was washed with brine (1 × 30 mL) before being dried (Na2SO4),
ﬁltered, and then concentrated under reduced pressure. Subjection of
the ensuing residue to ﬂash chromatography (silica, 1:4 v/v ethyl
acetate/hexane elution) delivered, after concentration of the appro-
priate fractions (Rf = 0.4 in 1:6 v/v ethyl acetate/hexane), compound 19
(191 mg, 76%) as a clear, yellow syrup, [α]D
20 = +54.5 (c = 0.2, CHCl3).
1HNMR (CDCl3, 400MHz) δ 7.11 (s, 2H), 6.94 (s, 1H), 6.19 (d, J = 3.5
Hz, 1H), 4.65 (d, J = 5.7 Hz, 1H), 4.52 (t, J = 5.7 Hz, 1H), 4.44 (complex
m, 1H), 3.71 (t, J = 4.7 Hz, 1H), 3.55 (s, 3H), 2.58 (d, J = 8.6 Hz, 1H),
2.28 (s, 6H), 1.45 (s, 3H), 1.42 (s, 3H); 13C NMR (CDCl3, 100MHz) δ
137.7, 135.6, 130.3, 129.5, 122.5(0), 122.4(8), 109.8, 90.4, 86.8, 79.6,
73.7, 73.1, 64.8, 59.0, 27.7, 26.0, 21.1; IR νmax 3455, 2986, 2934, 2831,
2204, 1597, 1456, 1371, 1233, 1164, 1076, 955, 872, 850, 689 cm−1; MS
(EI, 70 eV) m/z 328 (M+•, 15%), 115 (100); HRMS M+• calcd for
C20H24O4 328.1675, found 328.1675.
(1R,2R,3R,4R)-6-((3,5-Dimethylphenyl)ethynyl)-3-methoxycyclo-
hex-5-ene-1,2,4-triol (15). Compound 19 (50 mg, 0.15 mmol) was
treated with acetic/water (10 mL of a 7:3 v/v mixture), and the resulting
solution was heated at 70 °C for 5 h, then cooled, and concentrated
under reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 1:6:3 v/v/v methanol/ethyl acetate/hexane
gradient elution) gave, after concentration of the appropriate fractions
(Rf = 0.4 in 9:1 v/v ethyl acetate/hexane), compound 15 (trace) as a
white, crystalline solid, mp =157−159 °C, [α]D20 = −33.3 (c = 0.4,
CHCl3).
1H NMR [(CD3)2CO, 400 MHz] δ 6.84 (s, 2H), 6.77 (s, 1H),
5.85 (d, J = 3.8 Hz, 1H), 4.24 (m, 1H), 4.00 (m, 1H), 3.92 (m, 1H), 3.79
(m, 1H), 3.50 (d, J = 7.2 Hz, 1H), 3.39 (m, 1H), 3.26 (s, 3H), 2.68
(broadened s, 6H) (signal due to one hydroxyl group proton not
observed); 13C NMR [(CD3)2CO, 100 MHz] δ 139.5, 137.7, 131.6,
130.7, 125.8, 124.7, 90.8, 89.8, 81.5, 69.9, 69.8, 66.3, 59.6, 21.8; IR νmax
3389, 3303, 2915, 2848, 1958, 1597, 1432, 1381, 1291, 1093, 1060,
1034, 849, 686 cm−1; MS (EI, 70 eV) m/z 288 (M+•, 12%), 214 (100);
HRMS M+• calcd for C17H20O4 288.1362, found 288.1360.
(3aR,4R,5R,7aR)-7-((3,5-Dimethylphenyl)ethynyl)-4,5-dimethoxy-
2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxole (20). Com-
pound 35 (100mg, 0.30mmol), PdCl2(PPh3)2 (11mg, 0.02mmol), and
cuprous iodide (3 mg, 0.02 mmol) were placed in an oven-dried ﬂask
under a nitrogen atmosphere. Dry diethylamine (10mL) was added, and
the resulting suspension was cooled and magnetically stirred at 0 °C.
After the dropwise addition of 1-ethynyl-3,5-dimethylbenzene (69) (65
μL, 0.44 mmol), the reaction mixture was stirred at 20 °C for 3 h and
then concentrated under reduced pressure. The residue thus obtained
was treated with diethyl ether (10 mL), the resulting mixture ﬁltered
through a pad of diatomaceous earth, and the ﬁltrate was washed with
brine (1 × 20 mL) before being dried (Na2SO4), ﬁltered, and then
concentrated under reduced pressure. Subjection of the residue thus
obtained to ﬂash chromatography (silica, 1:4 v/v ethyl acetate/hexane
gradient elution) gave, after concentration of the appropriate fractions
(Rf = 0.5 in 1:5 v/v ethyl acetate/hexane), compound 20 (72 mg, 72%)
as a clear, yellow syrup, [α]D
20 =−7.3 (c = 0.3, CHCl3). 1HNMR (CDCl3,
400MHz) δ 7.11 (s, 2H), 6.94 (s, 1H), 6.32 (d, J = 3.9 Hz, 1H), 4.71 (d,
J = 6.1 Hz, 1H), 4.48 (m, 1H), 4.07 (m, 1H), 3.69 (m, 1H), 3.54 (s, 3H),
3.46 (s, 3H), 2.28 (s, 6H), 1.48 (s, 3H), 1.42 (s, 3H); 13C NMR (CDCl3,
100 MHz) δ 137.7, 133.6, 130.3, 129.5, 123.2, 122.5, 109.5, 90.7, 86.9,
79.1, 74.3, 74.1, 74.0, 58.9, 57.4, 27.6, 25.6, 21.1; IR νmax 2985, 2933,
2827, 2201, 1598, 1457, 1380, 1370, 1212, 1164, 1107, 1081, 1037, 873,
851, 689 cm−1; MS (EI, 70 eV) m/z 342 (M+•, 20%), 327 (13), 228
(37), 115 (100); HRMS M+• calcd for C21H26O4 342.1831, found
342.1830.
(1R,2R,5R,6S)-3-((3,5-Dimethylphenyl)ethynyl)-5,6-dimethoxycy-
clohex-3-ene-1,2-diol (16). Compound 20 (50 mg, 0.15 mmol) was
treated with acetic/water (10 mL of a 7:3 v/v mixture) and the resulting
solution was heated at 70 °C for 5 h then cooled and concentrated under
reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 9:1 v/v ethyl acetate/hexane gradient elution)
gave, after concentration of the appropriate fractions (Rf = 0.4 in 9:1 v/v
ethyl acetate/hexane), compound 16 (trace) as light-yellow oil, [α]D
20 =
−79.4 (c = 0.82, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 7.10 (s, 2H),
6.96 (s, 1H), 6.35 (d, J = 4.5 Hz, 1H), 4.43 (d, J = 4.5 Hz, 1H), 4.21 (m,
1H), 4.13 (t, J = 4.2 Hz, 1H), 3.72 (dd, J = 8.9 and 3.8 Hz, 1H), 3.53 (s,
3H), 3.50 (s, 3H), 2.80 (s, 1H), 2.74 (s, 1H), 2.29 (s, 6H); 13C NMR
(CDCl3, 100MHz) δ 137.8, 132.3, 130.4, 129.3, 124.8, 122.1, 91.1, 86.7,
77.4, 72.7, 68.7, 67.6, 58.0, 57.5, 21.0; IR νmax 3412, 2920, 2825, 1629,
1597, 1464, 1194, 1098, 990, 850, 689 cm−1; MS (EI, 70 eV) m/z 302
(M+•, 4%), 253 (15), 228 (100), 213 (50), 199 (35), 185 (46), 157 (30);
HRMS M+• calcd for C18H22O4 302.1518, found 302.1519.
(3aS,4R,5R,7aS)-7-Iodo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-4-ol (71). A magnetically stirred
solution of compound 58 (100 mg, 0.21 mmol) in THF (10 mL)
maintained at 18 °C under a nitrogen atmosphere was treated with tetra-
n-butylammonium ﬂuoride (0.3 mL of 1.0 M solution in THF, 0.30
mmol). After 2 h the reaction mixture was concentrated under pressure.
The residue so-formed was subjected to ﬂash chromatography (silica,
1:2 v/v ethyl acetate/hexane gradient elution) to provide, after
concentration of the appropriate fractions (Rf = 0.4 in 4:2.5:5.5 v/v/v
ethyl acetate/dichloromethane/hexane), compound 71 (54 mg, 80%)
as a white, crystalline solid, mp = 79.5 °C, [α]D20 = −29.4 (c = 0.4,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.42 (d, J = 2.6 Hz, 1H), 4.64
(m, 1H), 4.45−4.36 (complex m, 1H), 3.87 (m, 1H), 3.46 (s, 3H), 2.42
(d, J = 2.4 Hz, 1H), 1.42 (s, 3H), 1.40 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 136.2, 109.8, 101.2, 78.3, 76.6, 75.8, 66.9, 57.1, 27.6, 26.2; IR
νmax 3520, 2998, 2934, 2872, 2828, 1627, 1458, 1379, 1148, 1082, 1051,
1025, 996, 930, 897, 871, 860 cm−1; MS (EI, 70 eV) m/z 326 (M+•,
14%), 310 (21), 268 (20), 226 (18), 101 (100); HRMS M+• calcd for
C10H15
127IO4 326.0015, found 326.0016.
(1S,2S,3S,6R)-4-Iodo-6-methoxycyclohex-4-ene-1,2,3-triol (72).
Compound 71 (50 mg, 0.10 mmol) was dissolved in acetic/water (10
mL of a 7:1 v/v mixture) and the resulting solution was heated at 70 °C
for 18 h then cooled and concentrated under reduced pressure.
Subjection of the residue thus obtained to ﬂash chromatography (silica,
1:6:3 v/v/v methanol/ethyl acetate/hexane gradient elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 1:7:2 v/v/v
methanol/ethyl acetate/hexane), compound 72 (32 mg, 72%) as a
white, crystalline solid, mp =117 °C, [α]D20 = −111.3 (c = 0.3, CHCl3).
1H NMR [(CD3)2SO, 400 MHz] δ 6.29 (d, J = 1.4 Hz, 1H), 5.17 (m,
1H), 4.99 (s, 1H), 4.82 (m, 1H), 3.99 (broad s, 2H), 3.83−3.77
(complex m, 2H), 3.36 (s, 3H); 13C NMR [(CD3)2SO, 400 MHz] δ
136.4, 106.9, 76.9, 70.5, 70.1, 67.6, 55.8; IR νmax 3354, 2923, 2857, 2821,
1628, 1461, 1384, 1186, 1098, 1069, 967, 917, 878 cm−1; MS (EI, 70 eV)
m/z 286 (M+•, > 1%), 267 (13), 226 (100), 99 (75); HRMS M+• calcd
for C7H11
127IO4 285.9702, found 285.9696.
(1S,2R,3R,6R)-4-((3,5-Dimethylphenyl)ethynyl)-6-methoxycyclo-
hex-4-ene-1,2,3-triol (17). Compound 72 (100 mg, 0.35 mmol),
PdCl2(PPh3)2 (13 mg, 0.02 mmol) and cuprous iodide (4 mg, 0.02
mmol) were placed in an oven-dried ﬂask under a nitrogen atmosphere.
Dry diethylamine (5 mL) was added and the resulting suspension was
cooled andmagnetically stirred at 0 °C. After the dropwise addition of 1-
ethynyl-3,5-dimethylbenzene (69) (101 μL, 0.70 mmol) was complete
the reactionmixture was stirred at 18 °C for 3 h then concentrated under
reduced pressure and diethyl ether (10 mL) was added to the ensuing
residue. The mixture thus obtained was ﬁltered through a pad of
diatomaceous earth and the ﬁltrate was washed with brine (1 × 25 mL)
then dried (Na2SO4), ﬁltered and concentrated under reduced pressure.
Subjection of the residue so-formed to ﬂash chromatography (silica,
1:6:3 v/v/v methanol/ethyl acetate/hexane gradient elution) delivered,
after concentration of the appropriate fractions (Rf = 0.4 in 9:1 v/v ethyl
acetate/hexane), compound 17 (73 mg, 73%) as a clear, light-yellow oil,
[α]D
20 =−101.9 (c = 0.1, CHCl3). 1HNMR (CDCl3, 400MHz) δ 7.10 (s,
2H), 6.96 (s, 1H), 6.29 (m, 1H), 4.44 (s, 1H), 4.12−4.08 (complex m,
2H), 4.00 (m, 1H), 3.49 (s, 3H), 2.85 (s, 1H), 2.76 (s, 1H), 2.56 (m,
1H), 2.29 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 137.9, 131.7, 130.6,
129.4, 125.1, 122.0, 91.6, 86.4, 74.8, 69.4, 68.4, 67.9, 57.4, 21.1; IR νmax
3400, 2917, 2821, 1597, 1318, 1097, 1070, 1035, 941, 912, 849, 688
cm−1; MS (EI, 70 eV) m/z 288 (M+•, 17%), 228 9100), 213 (54), 199
(60), 185 (59); HRMS M+• calcd for C17H20O4 288.1362, found
288.1361.
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(1S,2R,3R,4S)-6-Iodo-3-methoxycyclohex-5-ene-1,2,4-triol (73).
Compound 65 (208 mg, 0.43 mmol) was dissolved in acetic/water
(10 mL of a 7:1 v/v mixture) and the resulting solution heated at 70 °C
for 18 h then cooled and concentrated under reduced pressure.
Subjection of the residue thus obtained to ﬂash chromatography (silica,
1:6:3 v/v/v methanol/ethyl acetate/hexane gradient elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 1:7:2 v/v/v
methanol/ethyl acetate/hexane), compound 73 (142 mg, 78%) as a
clear, light-yellow oil, [α]D
20 = +2.0 (c = 0.3, CHCl3).
1H NMR
[(CD3)2CO, 400MHz] δ 6.14 (d, J = 2.5 Hz, 1H), 4.54 (s, 1H), 4.25 (m,
1H), 4.14 (s, 1H), 4.02 (s, 1H), 3.73 (m, 1H), 3.63 (m, 1H) 3.54 (m,
1H), 3.43 (s, 3H); 13C NMR [(CD3)2CO, 100 MHz] δ 133.0, 125.6,
83.7, 74.8, 73.0, 72.0, 58.4; IR νmax 3355, 2929, 2826, 1643, 1454, 1262,
1105, 1076, 1002, 942, 882, 820, 697 cm−1; MS (ESI, + ve)m/z 309 [(M
+Na)+, 58%], 263 (95), 261 (100), 120 (5); HRMS (M+Na)+ calcd for
C7H11
127INaO4 308.9600, found 308.9600.
(1R,2R,3R,4S)-6-((3,5-Dimethylphenyl)ethynyl)-3-methoxycyclo-
hex-5-ene-1,2,4-triol (18). Compound 73 (50 mg, 0.18 mmol),
PdCl2(PPh3)2 (7 mg, 0.01 mmol) and cuprous iodide (2 mg, 0.01
mmol) were placed in an oven-dried ﬂask under a nitrogen atmosphere.
Dry diethylamine (3 mL) was added and the resulting suspension was
cooled to 0 °C while being stirred magnetically. After the dropwise
addition of 1-ethynyl-3,5-dimethylbenzene (69) (51 μL, 0.35 mmol)
was complete the reaction mixture was stirred at 20 °C for 3 h then
concentrated under reduced pressure and diethyl ether (10 mL) then
added to the residue thus obtained. The resulting mixture was ﬁltered
through a pad of diatomaceous earth and the ﬁltrate washed with brine
(1 × 10 mL) before being dried (Na2SO4) ﬁltered and then
concentrated under reduced pressure. Subjection of the residue thus
obtained to ﬂash chromatography (silica, 1:6:3 v/v/v methanol/ethyl
acetate/hexane gradient elution) aﬀorded, after concentration of the
appropriate fractions (Rf = 0.4 in 9:1 v/v ethyl acetate/hexane),
compound 18 (35mg, 70%) as a clear, light-yellow oil, [α]D
20 = +15.0 (c =
0.1, CHCl3).
1H NMR [(CD3)2CO, 400 MHz] δ 7.07 (s, 2H), 7.01 (s,
1H), 6.11 (d, J = 2.6 Hz, 1H), 4.35 (d, J = 4.7 Hz, 1H), 4.24 (t, J = 4.7 Hz,
1H), 4.06 (m, 1H), 3.86 (d, J = 6.3 Hz, 1H), 3.90−3.70 (complex m,
2H), 3.47 (s, 3H), 2.77 (s, 1H), 2.28 (s, 6H); 13C NMR [(CD3)2CO,
100 MHz] δ 139.6, 136.7, 131.8, 130.7, 125.2, 124.5, 90.7, 89.9, 83.1,
73.0, 72.3, 71.4, 58.4, 21.8; IR νmax 3368, 2916, 2857, 2826, 1597, 1455,
1373, 1263, 1099, 1083, 952, 941, 848, 688 cm−1; MS (EI, 70 eV) m/z
288 (M+•, 17%), 277 (40), 228 (100), 185 (57); HRMS M+• calcd for
C17H20O4 288.1362, found 288.1373.
(1R,2R,3R,4R)-6-((3,5-Dimethoxyphenyl)ethynyl)-3-methoxycy-
clohex-5-ene-1,2,4-triol (21). Compound 60 (200 mg, 0.70 mmol),
PdCl2(PPh3)2 (25 mg, 0.04 mmol) and cuprous iodide (7 mg, 0.04
mmol) were placed in an oven-dried ﬂask under a nitrogen atmosphere.
Dry diethylamine (10 mL) was added and the resulting suspension was
cooled and stirred magnetically at 0 °C. After the dropwise addition of
commercially available 1-ethynyl-3,5-dimethoxybenzene (70) (252 μL,
1.40 mmol) was complete the reaction mixture was stirred at 20 °C for 3
h then concentrated reduced pressure and diethyl ether (25 mL) was
added. The mixture thus obtained was ﬁltered through a pad of
diatomaceous earth and the ﬁltrate washed with brine (1 × 25 mL)
before being dried (Na2SO4) ﬁltered and concentrated under reduced
pressure. Subjection of the residue thus obtained to ﬂash chromatog-
raphy (silica, 1:6:3 v/v/v methanol/ethyl acetate/hexane gradient
elution) delivered, after concentration of the appropriate fractions (Rf =
0.4 in 9:1 v/v ethyl acetate/hexane), compound 21 (139 mg, 62%) as a
clear, light-yellow oil, [α]D
20 =−38.3 (c = 1.1, CHCl3). 1HNMR (CDCl3,
400MHz) δ 6.62 (d, J = 2.4 Hz, 2H), 6.46 (t, J = 2.4 Hz, 1H), 6.26 (d, J =
4.2 Hz, 1H), 4.52 (m, 1H), 4.41 (s, 1H), 4.23 (m, 1H), 3.78 (s, 6H), 3.71
(dd, J = 7.9 and 4.1 Hz, 1H), 3.55 (s, 3H), 2.68 (m, 2H), 2.51 (d, J = 6.0
Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 160.5, 135.3, 123.8, 123.7,
109.5, 102.1, 91.0, 86.5, 78.6, 68.3, 67.4, 64.0, 58.5, 55.4; IR νmax 3400,
2936, 2839, 1589, 1455, 1420, 1205, 1156, 1095, 1063, 989, 837, 681
cm−1; MS (EI, 70 eV) m/z 320 (M+•, 23%), 273 (18), 270 (21), 246
(100), 217 (33), 189 (39); HRMS M+• calcd for C17H20O6 320.1260,
found 320.1260.
(1R,2S,5R,6S)-3-Iodo-5,6-dimethoxycyclohex-3-ene-1,2-diol (74).
Compound 35 (120 mg, 0.35 mmol) was treated with acetic/water (5
mL of a 7:1 v/v mixture) and the resulting solution heated at 70 °C for
14 h then cooled and concentrated under reduced pressure. Subjection
of the residue thus obtained to ﬂash chromatography (silica, 4:1 v/v
ethyl acetate/hexane gradient elution) gave, after concentration of the
appropriate fractions (Rf = 0.4 in 4:1 v/v ethyl acetate/hexane),
compound 74 (75 mg, 70%) as a white, crystalline solid, mp =78.3−83.3
°C, [α]D20 = −162.5 (c = 0.2, CHCl3). 1H NMR (CDCl3, 400 MHz) δ
6.62 (d, J = 4.5 Hz, 1H), 4.40 (s, 1H), 4.22 (m, 1H), 3.95 (t, J = 4.1 Hz,
1H), 3.66 (m, 1H), 3.49 (s, 3H), 3.46 (s, 3H), 3.12 (broad s, 2H); 13C
NMR (CDCl3, 100 MHz) δ 137.5, 103.5, 77.2, 74.9, 74.0, 68.0, 58.2,
57.8; IR νmax 3401, 2980, 2929, 2826, 1629, 1455, 1369, 1344, 1195,
1097, 1051, 997, 928, 916, 865, 805 cm−1; MS (EI, 70 eV) m/z 300
(M+•, 2%), 282 (5), 226 (100), 99 (63); HRMS M+• calcd for
C8H13
127IO4 299.9859, found 299.9859.
(1R,2R,5R,6S)-3-((3,5-Dimethoxyphenyl)ethynyl)-5,6-dimethoxy-
cyclohex-3-ene-1,2-diol (22). Compound 74 (165 mg, 0.55 mmol),
PdCl2(PPh3)2 (20 mg, 0.03 mmol) and cuprous iodide (5 mg, 0.03
mmol) were placed in an oven-dried ﬂask under a nitrogen atmosphere.
Dry diethylamine (10 mL) was added and the resulting suspension was
cooled andmagnetically stirred at 0 °C. After the dropwise addition of 1-
ethynyl-3,5-dimethoxybenzene (70) (198 μL, 1.10 mmol) to the
reaction mixture was complete it was stirred at 20 °C for 3 h then
concentrated under reduced pressure and diethyl ether (25 mL) added
to the residue thus obtained. The resulting mixture was ﬁltered through
a pad of diatomaceous earth and the ﬁltrate washed with brine (1 × 25
mL) then dried (Na2SO4,), ﬁltered and concentrated under reduced
pressure. Subjection of the residue so-formed to ﬂash chromatography
(silica, 4:1 v/v ethyl acetate/hexane gradient elution) delivered, after
concentration of the appropriate fractions (Rf = 0.4 in 5:1 v/v ethyl
acetate/hexane), compound 22 (114 mg, 62%) as a clear, light-yellow
oil, [α]D
20 =−90.2 (c = 0.5, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 6.62
(d, J = 2.3 Hz, 2H), 6.45 (t, J = 2.3 Hz, 1H), 6.37 (d, J = 4.5 Hz, 1H), 4.44
(m, 1H), 4.20 (m, 1H), 4.13 (t, J = 4.2 Hz, 1H), 3.77 (s, 6H), 3.71 (dd, J
= 8.9 and 3.9 Hz, 1H), 3.52 (s, 3H), 3.49 (s, 3H), 2.87 (d, J = 1.9 Hz,
1H), 2.85 (d, J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 160.5,
133.0, 124.6, 123.9, 109.5, 102.2, 90.8, 86.9, 77.5, 72.6, 68.7, 67.6, 58.1,
57.7, 55.4; IR νmax 3429, 2934, 2909, 2837, 1589, 1455, 1420, 1205,
1156, 1096, 1064, 990, 867, 838, 681 cm−1; MS (EI, 70 eV) m/z 334
(M+•, 20%), 285 (20< 261 (30), 260 (100), 245 (65), 231 (45), 217
(48); HRMS M+• calcd for C18H22O6 334.1416, found 334.1415.
(Z)-2-(3,5-Dimethylstyryl)-4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lane (76). A 50 mL Schlenk tube equipped with a magnetic stirring bar
was charged with 1,5-cyclooctadienerhodium(I) chloride dimer
{[RhCl(cod)]2} (6 mg, 0.01 mmol) and the ﬂushed with argon.
Cyclohexanone (3 mL), triisopropylphosphine [P(i-Pr)3] (10 μL, 0.05
mmol), triethylamine (1 mL) and pinacolborane (HBpin) (75) (110 μL,
0.77 mmol) were then added in that order. After the reaction mixture
had been stirred at 20 °C for 2 h 3,5-dimethylphenylacetylene (69) (200
mg, 1.54 mmol) was added in one portion and the mixture thus formed
stirred at 20 °C for 2 h then quenched with methanol (5 mL). The
ensuing mixture was ﬁltered through a pad of diatomaceous earth and
the ﬁltrate concentrated under reduced pressure to give a light-brown
oil. Subjection of this material to ﬂash chromatography (silica, 5:95 v/v
ethyl acetate/hexane gradient elution) delivered, after concentration of
the appropriate fractions (Rf = 0.3 in 1:9 v/v ethyl acetate/hexane),
compound 76 (205mg, 52%) as a clear, light-yellow oil, [α]D
20 = +4.7 (c =
0.9, CHCl3).
1HNMR (CDCl3, 400MHz) δ 7.15 (m, 3H), 6.91 (s, 1H),
5.54 (d, J = 14.9 Hz, 1H), 2.30 (s, 6H), 1.30 (s, 12H); 13CNMR (CDCl3,
100 MHz) δ 148.2, 138.4, 137.3, 129.7, 126.4, 83.4, 24.8, 21.2 (signal
due to one carbon obscured or overlapping); IR νmax 2978, 2918, 1627,
1601, 1458, 1436, 1379, 1349, 1324, 1262, 1144, 995, 970, 849 cm−1;
MS (EI, 70 eV) m/z 258 (M+•, 100%), 158 (90), 157 (77), 142 (76);
HRMS M+• calcd for C16H23BO2 258.1791, found 258.1791.
(1R,2R,3R,4R)-6-((Z)-3,5-Dimethylstyryl)-3-methoxycyclohex-5-
ene-1,2,4-triol (27). A magnetically stirred solution of alcohol 60 (300
mg, 1.05 mmol), (Z)-2-(3,5-dimethylstyryl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (76) (271 mg, 1.05 mmol), PdCl2dppf•CH2Cl2 (60 mg,
0.08 mmol) and triethylamine (2 mL) in THF/water (6 mL of a 9:1 v/v
mixture) was purged with nitrogen for 0.5 h and then stirred at 20 °C for
2 h before being poured into water (10 mL) and extracted with ethyl
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acetate (3 × 10 mL). The combined organic phases were washed with
brine (1× 20mL) then dried (Na2SO4), ﬁltered and concentrated under
reduced pressure. The ensuing light-yellow oil was subjected to ﬂash
chromatography (silica, 1:6:3 v/v/v methanol/ethyl acetate/hexane
gradient elution) and after concentration of the relevant fractions (Rf =
0.3 in 9:1 v/v ethyl acetate/hexane) gave compound 27 (242 mg, 80%)
as a white, crystalline solid, mp =123−127 °C, [α]D20 = −301.6 (c = 0.2,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 7.00 (s, 2H), 6.86 (s, 1H), 6.53
(d, J = 12.2 Hz, 1H), 6.11 (d, J = 12.2 Hz, 1H), 5.85 (dd, J = 4.6 and 1.5
Hz, 1H), 4.41 (t, J = 4.6 Hz, 1H), 4.33 (m, 1H), 4.07 (m, 1H), 3.62 (dd, J
= 8.9 and 4.2Hz, 1H), 3.52 (s, 3H), 2.44 (broad s, 3H), 2.27 (s, 6H); 13C
NMR (CDCl3, 100 MHz) δ 137.7, 137.5, 136.8, 132.4, 129.1, 128.4,
126.5, 78.7, 68.0, 67.9, 63.8, 58.2, 21.2 (signal due to one carbon
obscured or overlapping); IR νmax 3401, 2914, 2830, 1598, 1456, 1398,
1246, 1093, 1052, 988, 918, 852 cm−1; MS (EI, 70 eV) m/z 290 (M+•,
53%), 212 (58), 198 (100), 119 (53); HRMS M+• calcd for C17H22O4
290.1518, found 290.1518.
(1R,2R,3R,4R)-6-((E)-3,5-Dimethylstyryl)-3-methoxycyclohex-5-
ene-1,2,4-triol (23). A magnetically stirred solution of compound 27
(100 mg, 0.35 mmol) in chlorobenzene (5 mL) maintained under
nitrogen was heated under reﬂux for 144 h then cooled and concentrated
under reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, ethyl acetate gradient elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 9:1 v/v ethyl
acetate/hexane), compound 23 (33 mg, 85% brsm) as a white,
crystalline solid, mp =85 °C, [α]D20 = −128.5 (c = 0.2, CHCl3). 1H NMR
(CDCl3, 400 MHz) δ 7.06 (s, 2H), 6.90 (s, 1H), 6.86 (d, J = 16.3 Hz,
1H), 6.73 (d, J = 16.3 Hz, 1H), 6.01 (d, J = 5.5 Hz, 1H), 4.74 (d, J = 4.0
Hz, 1H), 4.57 (t, J = 4.8 Hz, 1H), 4.04 (m, 1H), 3.65 (dd, J = 10.3 and 4.1
Hz, 1H), 3.56 (s, 3H), 2.74 (broad s, 1H), 2.31 (s, 6H) (signals due to
two hydroxyl group protons not observed); 13C NMR (CDCl3, 100
MHz) δ 138.7, 138.0, 136.8, 131.4, 129.8, 127.6(2), 127.5(6), 124.6,
78.3, 67.8, 66.4, 63.3, 57.8, 21.3; IR νmax 3395, 2916, 2827, 1597, 1446,
1384, 1242, 1104, 1094, 1066, 989, 963, 851 cm−1; MS (EI, 70 eV) m/z
290 (<1%), 289 [(M-H•)+, 2], 272 (8), 211 (15), 183 (17), 133 (100);
HRMS (M-H•)+ calcd for C17H21O4 289.1441, found 289.1440.
(1R,2R,3R,4R,6S)-6-(3,5-Dimethylphenethyl)-3-methoxycyclohex-
ane-1,2,4-triol (25). A magnetically stirred solution of compound 27
(30 mg, 0.10 mmol) in methanol (1 mL) was treated with rhodium on
carbon (9 mg of 5% material). The reaction ﬂask was connected to a
balloon of hydrogen and after stirring the reaction mixture for 2 h at 20
°C the catalyst was removed by ﬁltration through a pad of diatomaceous
earth and the ﬁltrate concentrated under reduced pressure. Subjection of
the residue thus obtained to ﬂash chromatography (silica, 1:6:3 v/v/v
methanol/ethyl acetate/hexane gradient elution) gave, after concen-
tration of the appropriate fractions (Rf = 0.4 in 9.5:0.5 v/v ethyl acetate/
hexane), compound 25 (14 mg, 47%) as a light-yellow oil, [α]D
20 = +21.9
(c = 0.6, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.81 (s, 3H), 4.09 (m,
1H), 4.04 (m, 1H), 3.65 (m, 1H), 3.53 (t, J = 4.3 Hz, 1H), 3.48 (s, 3H),
2.68 (m, 1H), 2.49 (m, 1H), 2.28 (s, 6H), 2.00 (broad s, 3H), 1.97−1.88
(complexm, 2H), 1.79 (m, 1H), 1.61−1.47 (complexm, 2H); 13CNMR
(CDCl3, 100 MHz) δ 142.3, 137.8, 127.4, 126.2, 82.1, 72.5, 69.5, 67.0,
58.4, 36.1, 34.2, 33.0, 31.5, 21.3; IR νmax 3396, 2919, 2861, 2830, 1605,
1458, 1403, 1103, 1087, 1050, 972, 844 cm−1; MS (EI, 70 eV) m/z 294
(M+•, 10%), 244 (20), 133 (40), 132 (100), 120 (55), 119 (72); HRMS
M+• calcd for C17H26O4 294.1831, found 294.1828.
(1R,2R,5R,6S)-3-((Z)-3,5-Dimethylstyryl)-5,6-dimethoxycyclohex-
3-ene-1,2-diol (28). A magnetically stirred solution of alcohol 74 (100
mg, 0.33 mmol) , compound 76 (86 mg, 0.33 mmol),
PdCl2dppf•CH2Cl2 (19 mg, 0.03 mmol), and triethylamine (1 mL) in
THF/water (2 mL of a 9:1 v/v mixture) was purged with nitrogen for
0.5 h, stirred at 18 °C for 2 h then poured into water (6 mL) and
extracted with ethyl acetate (3 × 10 mL). The combined organic phases
were washed with brine (1 × 10 mL) then dried (Na2SO4), ﬁltered and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 3:2 v/v ethyl acetate/hexane
gradient elution) and concentration of the relevant fractions (Rf = 0.4 in
2:1 v/v ethyl acetate/hexane) gave compound 28 (79 mg, 78%) as a
clear, light-yellow oil, [α]D
20 = −178.6 (c = 0.7, CHCl3). 1H NMR
(CDCl3, 400 MHz) δ 7.00 (s, 2H), 6.85 (s, 1H), 6.51 (d, J = 12.2 Hz,
1H), 6.16 (d, J = 12.2 Hz, 1H), 5.96 (dd, J = 5.0 and 1.5 Hz, 1H), 4.36
(dd, J = 4.5 and 1.6 Hz, 1H), 4.13 (m, 1H), 3.99 (t, J = 4.5 Hz, 1H), 3.62
(m, 1H), 3.49 (s, 3H), 3.35 (s, 3H), 2.82 (d, J = 1.7 Hz, 1H), 2.63 (d, J =
2.1 Hz, 1H), 2.27 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 138.5, 137.7,
136.7, 132.1, 129.0, 128.6, 126.6, 125.9, 77.5, 71.9, 68.4, 67.8, 57.4, 57.2,
21.2; IR νmax 3411, 2971, 2916 2823, 1598, 1454, 1381, 1196, 1107,
1095, 1044, 989, 852 cm−1; MS (EI, 70 eV) m/z 304 (M+•, 2%), 272
(12), 230 (78), 212 (85), 198 (100), 183 (55); HRMS M+• calcd for
C18H24O4 304.1675, found 304.1673.
(1R,2R,5R,6S)-3-((E)-3,5-Dimethylstyryl)-5,6-dimethoxycyclohex-
3-ene-1,2-diol (24). A magnetically stirred solution of compound 28
(100 mg, 0.33 mmol) in chlorobenzene (5 mL) maintained under
nitrogen was heated under reﬂux for 144 h then cooled and concentrated
under reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 1:1 v/v ethyl acetate/hexane gradient elution)
delivered, after concentration of the appropriate fractions (Rf = 0.4 in 1:3
v/v ethyl acetate/hexane), compound 24 (36 mg, 80% brsm) as clear,
light-yellow oil, [α]D
20 = +14.2 (c = 1.4, CHCl3).
1H NMR (CDCl3, 400
MHz) δ 7.07 (s, 2H), 6.88 (s, 1H), 6.90 (d, J = 16.3 Hz, 1H), 6.73 (d, J =
16.3 Hz, 1H), 6.09 (d, J = 5.4 Hz, 1H), 4.74 (d, J = 4.2 Hz, 1H), 4.15−
4.11 (complex m, 2H), 3.66 (m, 1H), 3.53 (s, 3H), 3.51 (s, 3H), 2.31 (s,
6H) (signals due to hydroxyl group protons not observed); 13C NMR
(CDCl3, 100 MHz) δ 139.2, 138.0, 136.8, 131.6, 129.7, 127.7, 125.9,
124.6, 77.7, 71.8, 67.8, 66.1, 57.8, 57.3, 21.3; IR νmax 3400, 2917, 2831,
1599, 1463, 1383, 1257, 1196, 1114, 1093, 1046, 963, 851 cm−1; MS (EI,
70 eV)m/z 304 (M+•, 100%), 286 (42), 254 (56); HRMSM+• calcd for
C18H24O4 304.1675, found 304.1674.
(1R,2R,3S,4R,6S)-6-(3,5-Dimethylphenethyl)-3,4-dimethoxycyclo-
hexane-1,2-diol (26). A magnetically stirred solution of compound 28
(30 mg, 0.10 mmol) in methanol (1 mL) was treated with rhodium on
carbon (9mg of 5%material). The ﬂask was then connected to a balloon
of hydrogen and after stirring for 2 h at 20 °C the catalyst was removed
by ﬁltration through a pad of diatomaceous earth and the ﬁltrate
concentrated under reduced pressure. Subjection of the residue thus
obtained to ﬂash chromatography (silica, 9:1 v/v ethyl acetate/hexane
gradient elution) gave, after concentration of the appropriate fractions
(Rf = 0.4 in 4:1 v/v ethyl acetate/hexane), compound 26 (12 mg, 40%)
as a clear, light-yellow oil, [α]D
20 = +16.6 (c = 0.8, CHCl3).
1H NMR
(CDCl3, 400MHz) δ 6.82 (s, 1H), 6.81 (s, 2H), 4.07 (t, J = 4.2 Hz, 1H),
3.66 (m, 3H), 3.48 (s, 3H), 3.41 (s, 3H), 2.68 (m, 1H), 2.50 (m, 1H),
2.28 (s, 6H), 1.98−1.86 (complex m, 3H), 1.76 (m, 1H), 1.63−1.55
(complex m, 2H) (signal due to a hydroxyl group proton not observed);
13C NMR (CDCl3, 100 MHz) δ 142.3, 137.8, 127.4, 126.1, 79.4, 76.6,
72.4, 70.2, 58.4, 56.8, 36.4, 34.2, 33.1, 27.4, 21.3; IR νmax 3401, 2924,
2826, 1606, 1455, 1383, 1195, 1108, 1095, 1055, 974, 844 cm−1; MS
(ESI, + ve) m/z 331 [(M+Na)+, 100%]; HRMS (M+Na)+ calcd for
C18H28NaO4 331.1885, found 331.1885.
(3aS,4S,5S,7aS)-7-Bromo-2,2-dimethyl-5-((triisopropylsilyl)oxy)-
3a,4,5,7a-tetrahyd-robenzo[d][1,3]dioxol-4-ol (81). Triisopropylsilyl
triﬂuoromethanesulfonate (1.95 mL, 7.25 mmol) was added, dropwise,
to a magnetically stirred solution of compound 8019 (1.4 g, 5.30 mmol)
and 2,6-lutidine (2.50 mL, 21.5 mmol) in dichloromethane (30 mL)
maintained at −78 °C under a nitrogen atmosphere. The ensuing
mixture was allowed to warm to 20 °C over 3 h then treated with NH4Cl
(60 mL of a saturated aqueous solution). The separated aqueous phase
was extracted with dichloromethane (1 × 50 mL) and the combined
organic phases were dried (MgSO4), ﬁltered then concentrated under
reduced pressure. The resulting light-yellow oil was subjected to ﬂash
chromatography (silica, 3:100 v/v ethyl acetate/hexane gradient
elution) to give, after concentration of the appropriate fractions (Rf =
0.3 in 0.5:2.5:5.5 v/v/v ethyl acetate/dichloromethane/hexane),
compound 81 (1.15 g, 51%) as a light-yellow oil, [α]D
20 = +23.2 (c =
1.0, CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.42 (d, J = 1.6 Hz, 1H),
4.66 (d, J = 6.6 Hz, 1H), 4.17 (m, 1H), 4.11 (m, 1H), 3.55 (t, J = 8.7 Hz,
1H), 2.45 (s, 1H), 1.54 (s, 3H), 1.40 (s, 3H), 1.15−1.04 (complex m,
21H); 13C NMR (CDCl3, 100 MHz) δ 144.5, 110.2, 92.2, 79.3, 77.0,
74.5, 73.6, 28.0, 25.7, 18.0(1), 17.9(9), 12.4; IR νmax 3469, 2943, 2892,
2866, 1635, 1463, 1382, 1248, 1218, 1162, 1142, 1070, 1019, 997, 882,
866, 828 cm−1; MS (ESI, + ve) m/z 445 and 443 [(M+Na)+, 100 and
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97%]; HRMS (M+Na)+ calcd for C18H33
79BrONaO4Si 443.1229, found
443.1232.
(((3aS,4S,5S,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d]- [1,3]dioxol-5-yl)oxy)triisopropylsilane (82). So-
dium hydride (257 mg of a 60% dispersion in mineral oil, 6.43 mmol)
was added to a magnetically stirred solution of compound 81 (900 mg,
2.14 mmol) and iodomethane (294 μL, 4.73 mmol) in dry THF (20
mL) maintained at 0 °C under a nitrogen atmosphere. Stirring was
continued at 0 to 18 °C for 3 h then the reaction mixture was treated
with ice/water (60 mL) (Caution: possible evolution of hydrogen). The
separated aqueous phase was extracted with ethyl acetate (1 × 25 mL)
and the combined organic phases were then dried (MgSO4), ﬁltered and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 1:50 v/v ethyl acetate/hexane
gradient elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/dichloromethane/hexane),
compound 82 (385mg, 41%) as a light-yellow oil, [α]D
20 = +70.8 (c = 0.5,
CHCl3).
1H NMR (CDCl3, 400 MHz) δ 6.54 (d, J = 3.2 Hz, 1H), 4.60
(d, J = 6.0 Hz, 1H), 4.18 (t, J = 6.0 Hz, 1H), 4.03 (t, J = 5.6 Hz, 1H), 3.56
(m, 1H), 3.40 (s, 3H), 1.48 (s, 3H), 1.38 (s, 3H), 1.14−1.04 (complex
m, 21H); 13C NMR (CDCl3, 100 MHz) δ 137.9, 110.1, 99.4, 81.2, 78.4,
77.9, 71.1, 57.5, 27.6, 26.1, 18.1, 18.0, 12.5; IR νmax 2941, 2879, 2865,
1636, 1463, 1380, 1273, 1251, 1214, 1167, 1126, 1076, 952, 882, 865,
768, 679 cm−1; MS (ESI, + ve) m/z 459 and 457 [(M+Na)+, 98 and
96%], 355 (100); HRMS (M+Na)+ calcd for C19H35
79BrNaO4Si
457.1386, found 457.1389.
(((3aR,4S,5S,7aR)-7-((Z)-3,5-Dimethylstyryl)-4-methoxy-2,2-di-
methyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-yl)oxy)-
triisopropylsilane (31). Amagnetically stirred solution of compound 82
(70 mg, 0.16 mmol), compound 76 (41 mg, 0.16 mmol), PdCl2dppf·
CH2Cl2 (9 mg, 0.01 mmol), and triethylamine (0.5 mL) in THF/water
(3 mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h, heated at
70 °C for 3 h, then cooled, poured into water (6 mL), and extracted with
ethyl acetate (3 × 10 mL). The combined organic phases were washed
with brine (1 × 10 mL) before being dried (Na2SO4), ﬁltered, and then
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 3:97 v/v ethyl acetate/hexane
gradient elution), and concentration of the relevant fractions (Rf = 0.3 in
1:9 v/v ethyl acetate/hexane) aﬀorded compound 31 (61 mg, 78%) as a
clear, light-yellow oil, [α]D
20 =−73.0 (c = 0.2, CHCl3). 1HNMR (CDCl3,
400 MHz) δ 7.02 (s, 2H), 6.83 (s, 1H), 6.51 (d, J = 12.3 Hz, 1H), 6.05
(d, J = 12.3Hz, 1H), 5.81 (s, 1H), 4.61 (d, J = 6.5Hz, 1H), 4.07 (t, J = 7.0
Hz, 1H), 3.85 (t, J = 7.3 Hz, 1H), 3.56 (m, 1H), 3.24 (s, 3H), 2.26 (s,
6H), 1.47 (s, 3H), 1.20 (s, 3H), 1.13−1.05 (complex m, 21H); 13C
NMR (CDCl3, 100 MHz) δ 137.4, 137.1, 132.7, 132.0, 128.7, 128.1,
127.8, 126.5, 109.5, 80.2, 78.5, 73.9, 73.3, 56.7, 27.9, 25.5, 21.2, 18.2,
18.1, 12.7; IR νmax 2941, 2865, 1600, 1463, 1379, 1250, 1213, 1137,
1098, 1063, 947, 883, 850, 680 cm−1; MS (EI, 70 eV) m/z 486 (M+•, <
1%), 443 (12), 385 (86), 353 (100), 257 (98), 223 (73); HRMS M+•
calcd for C29H46O4Si 486.3165, found 486.3166.
(1R,2R,3R,4S)-6-((Z)-3,5-Dimethylstyryl)-3-methoxycyclohex-5-
ene-1,2,4-triol (29). Compound 31 (50 mg, 0.10 mmol) was treated
with acetic/water (10 mL of a 7:3 v/v mixture), and the resulting
solution was heated at 70 °C for 18 h, then cooled, and concentrated
under reduced pressure. Subjection of the residue thus obtained from
ﬂash chromatography (silica, 1:6:3 v/v/v methanol/ethyl acetate/
hexane gradient elution) gave, after concentration of the appropriate
fractions (Rf = 0.4 in 9:1 v/v ethyl acetate/hexane), compound 29 (21
mg, 70%) as a clear, light-yellow oil, [α]D
20 = −93.0 (c = 0.3, CHCl3). 1H
NMR (CDCl3, 400 MHz) δ 6.96 (s, 2H), 6.88 (s, 1H), 6.53 (d, J = 12.2
Hz, 1H), 6.10 (d, J = 12.2 Hz, 1H), 5.83 (s, 1H), 4.25 (d, J = 4.3 Hz, 1H),
3.87 (m, 1H), 3.75 (m, 1H), 3.52 (m, 1H), 3.36 (s, 3H), 2.27 (s, 6H),
1.62 (broad s, 3H); 13C NMR (CDCl3, 100 MHz) δ 137.9, 136.9, 136.2,
132.1, 129.1, 128.3, 126.3, 80.8, 71.4, 70.6, 68.3, 56.3, 21.3 (signal due to
one carbon obscured or overlapping); IR νmax 3369, 2917, 2826, 1599,
1452, 1376, 1261, 1079, 945, 853 cm−1; MS (EI, 70 eV) m/z 290 (M+•,
7%), 224 (44), 198 (100), 183 (47), 119 (45); HRMS M+• calcd for
C17H22O4 290.1518, found 290.1523.
(1S,2R,3S,4R)-6-((Z)-3,5-Dimethylstyryl)-3-methoxy-7-oxabicyclo-
[2.2.1]hept-5-en-2-ol (30). A magnetically stirred solution of
compound 27 (50 mg, 0.17 mmol) in chlorobenzene (5 mL) was
heated under reﬂux for 24 h, then cooled, and concentrated under
reduced pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 3:2 v/v ethyl acetate/hexane elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 3:2 v/v ethyl
acetate/hexane), compound 30 (14 mg, 30%) as light-yellow oil, [α]D
20 =
−333.2 (c = 0.9, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 6.98 (s, 3H),
6.54 (d, J = 9.7 Hz, 1H), 6.01 (dd, J = 9.7 and 4.9 Hz, 1H), 5.89 (s, 1H),
5.79 (d, J = 4.8 Hz, 1H), 4.96 (m, 1H), 4.23 (s, 1H), 3.87 (m, 1H), 3.49
(s, 3H), 2.31 (s, 6H), 2.20 (d, J = 1.9 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ 140.5, 138.5, 135.1, 130.3, 127.5, 126.3, 125.2, 123.4, 87.5, 82.5,
77.5, 67.2, 57.6, 21.3; IR νmax 3421, 2920, 1693, 1607, 1462, 1382, 1243,
1156, 1123, 1089, 957, 851 cm−1; MS (ESI, + ve) m/z 295 [(M+Na)+,
100%], 273 (10), 195 (12); HRMS (M+Na)+ calcd for C17H20NaO3
295.1310, found 295.1311.
Crystallographic Studies. Crystallographic Data. Compound
15. C17H20O4,M = 288.34, T = 200 K, monoclinic, space group P21, Z =
2, a = 4.6659(3) Å, b = 11.9898(9) Å, c = 13.673(1) Å; β = 90.470(4)°;V
= 764.89(9) Å3,Dx = 1.252 g cm
−3, 1423 unique data (2θmax = 50°), R =
0.036 [for 1295 reﬂections with I > 2.0σ(I)]; Rw = 0.083 (all data), S =
1.03.
Compound 23.C17H22O4,M = 290.36, T = 150 K, monoclinic, space
group P21, Z = 2, a = 4.7176(2) Å, b = 11.7310(4) Å, c = 13.7171(6) Å; β
= 90.035(4)°; V = 759.13(5) Å3, Dx = 1.270 g cm−3, 1556 unique data
(2θmax = 143°), R = 0.080 [for 1536 reﬂections with I > 2.0σ(I)]; Rw =
0.220 (all data), S = 1.01.
Compound 27. C17H22O4, M = 290.36, T = 150 K, orthorhombic,
space group P212121, Z = 4, a = 4.5847(2) Å, b = 11.7037(5) Å, c =
29.754(3) Å; V = 1596.54(19) Å3, Dx = 1.208 g cm
−3, 1901 unique data
(2θmax = 146.8°), R = 0.065 [for 1563 reﬂections with I > 2.0σ(I)]; Rw =
0.151 (all data), S = 1.00.
Compound 35. C11H17IO4, M = 340.16, T = 200 K, orthorhombic,
space group P212121, Z = 4, a = 7.8130(1) Å, b = 11.5034(2) Å, c =
14.4925(2) Å; V = 1302.53(3) Å3, Dx = 1.735 g cm
−3, 3799 unique data
(2θmax = 60°), R = 0.021 [for 3669 reﬂections with I > 2.0σ(I)]; Rw =
0.051 (all data), S = 1.00.
Compound 51. C7H11IO4·H2O,M = 304.08, T = 150 K, monoclinic,
space group C2, Z = 4, a = 17.5832(15) Å, b = 4.7115(1) Å, c =
13.4131(8) Å; β = 111.360(12)°; V = 1034.86(14) Å3, Dx = 1.952 g
cm−3, 1906 unique data (2θmax = 143.8°), R = 0.022 [for 1871 reﬂections
with I > 2.0σ(I)]; Rw = 0.059 (all data), S = 1.00.
Compound 72. C7H11IO4·H2O,M = 304.08, T = 200 K, monoclinic,
space group C2, Z = 4, a = 16.8154(8) Å, b = 4.5652(2) Å, c =
15.7010(8) Å; β = 120.5922°; V = 1037.53(9) Å3, Dx = 1.947 g cm−3,
3024 unique data (2θmax = 60.2°), R = 0.031 [for 2812 reﬂections with I
> 2.0σ(I)]; Rw = 0.073 (all data), S = 0.99.
Structure Determination. Images for compound 15, 35, and 72
were measured on a diﬀractometer (MoKα, graphite monochromator, λ
= 0.71073 Å) ﬁtted with an area detector, and the data were extracted
using the DENZO/Scalepack package.23 Images for compounds 23, 27,
and 51 were measured on a diﬀractometer (Cu Kα, mirror
monochromator, λ = 1.54184 Å) ﬁtted with an area detector, and the
data were extracted using the CrysAlis package.24 The structure
solutions for all six compounds were solved by direct methods
(SIR92)25 and then reﬁned using the CRYSTALS program package.26
Atomic coordinates, bond lengths, and angles, and displacement
parameters have been deposited at the Cambridge Crystallographic
Data Centre (CCDC nos. 1504203, 1504204, 1504205, 1504206,
1504207, and 1504208). These data can be obtained free-of-charge via
www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@
ccdc.cam.ac.uk or by contacting The Cambridge Crystallographic
Data Centre, 12 Union Road, Cambridge CB2 1EZ, United Kingdom;
fax: +44 1223 336033.
Biological Testing. The test results shown in Table 1 were derived
from green house studies. The culture vessels used were plastic
ﬂowerpots containing loamy sand with approximately 3% of humus as
the substrate. For the postemergence treatment, the test plants were ﬁrst
grown separately as seedlings, and several of these were transplanted
into the culture vessels a few days prior to treatment. After they reached
a height of 3−10 cm, depending on the plant habit, they were treated
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with the active ingredients which had been emulsiﬁed through the
addition of 3.6 mL of a mixture of cyclohexanone/DMSO/Wettol
EM31 (2:2:1 v/v/v mixture) and 2% Dash diluted with deionized water
to the corresponding spray volume and sprayed on the plants via an
ultrasonic spray nozzle. Unless otherwise speciﬁed, the application rate
corresponded to 2 kg/ha with an application volume of 750 L/ha. The
plants were kept and tended at 15−22 °C over a test period of 21 days.
The responses of the plants to the individual treatments were visually
evaluated after 21 days. The outcomes of these evaluations are presented
in Table 1.
The physiological proﬁling (PP) studies were conducted using
previously published protocols.20a,27
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Figure S1: Structure of compound 15 (CCDC 1504203) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S2: Structure of compound 23 (CCDC 1504204) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S3: Structure of compound 27 (CCDC 1504205) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S4: Structure of compound 35 (CCDC 1504206) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
 
106
!!
!
S6!
!
 
 
Figure S5: Structure of compound 51 (CCDC 1504207) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S6: Structure of compound 72 (CCDC 1504208) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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ABSTRACT: Total syntheses of (+)-asperpentyn (1) and compound
ent-2, the enantiomer of the structure, 2, assigned to the natural
product aspergillusol A are reported. Both reaction sequences employ
the enzymatically derived and enantiomerically pure cis-1,2-dihydro-
catechol 4 as starting material and use Sonogashira cross-coupling
chemistry to install the required enyne side-chain. The 1H and 13C
NMR spectroscopic data derived from compound ent-2 match those
reported for aspergillusol A, thus suggesting that the gross structure of
this natural product has been assigned correctly, although its absolute
stereochemistry remains unclear.
Recently Rukachaisirikul and co-workers described1 theisolation and spectroscopic characterization of a series of
metabolites produced by the soil-derived fungus Aspergillus sp.
PSU-RSPG185 collected at Ratchaprapa Dam in Suratthani
Province, Thailand.2 Among these were the epoxyquininoid
(+)-asperpentyn (1, Figure 1) and the related compounds
aspergillusols A and B, to which the cyclic carbonate containing
structures 2 and 3, respectively, were assigned. While rare,
natural products containing cyclic carbonate residues are
known,3 and the structures of the last two compounds were
proposed1 on the basis of various spectroscopic studies, most
particularly one- and two-dimensional NMR analyses. Another
notable feature of Rukachaisirikul’s work is that it represents
the ﬁrst instance in which the (+)-form of asperpentyn has
been isolated from natural sources.4
Given our continuing interest in the synthesis of
epoxyquininoid natural products5 and the seeming absence of
any previous eﬀorts to establish syntheses of related
compounds containing cyclic carbonate residues, we now
report a chemoenzymatic synthesis of compound ent-2 from cis-
1,2-dihydrocatechol 4 (Figure 2). Compound 4 is readily
obtained in multigram quantities and essentially enantiomeri-
cally pure form through the whole-cell biotransformation of
iodobenzene.6 We also detail a ﬁve-step synthesis of
(+)-asperpentyn (1) from diol 4 using related chemistry.7,8
These studies reveal that the gross structure of aspergillusol A
has probably been assigned correctly.
■ RESULTS AND DISCUSSION
The eight-step reaction sequence leading from cis-1,2-
dihydrocatechol 4 to compound ent-2 is shown in Scheme 1.
This started with the conversion of the former compound into
the corresponding and previously reported acetonide,5e which
was immediately subjected to an Upjohn dihydroxylation
protocol in which the nonhalogenated and thus more
nucleophilic double bond of the diene reacted to aﬀord the
diol 5 (62%).5e,9 This was treated with chlorocarbonyl-1-
methylethyl acetate,10 thus generating the chloro-ester 6 (95%)
in a completely selective manner,11 and the structure was
conﬁrmed by single-crystal X-ray analysis.12 Treatment of
compound 6 with sodium methoxide in THF at 0 °C then gave
the epoxide 7 in 76% yield. While this same product (viz. 7)
could be obtained more directly by treating the previously
Received: April 8, 2015
Published: August 13, 2015
Figure 1. Structure of (+)-asperpentyn (1) and the structures assigned
to aspergillusols A and B (2 and 3, respectively).
Figure 2. Structures of compounds ent-2 and 4.
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mentioned acetonide with m-chloroperbenzoic acid, this
produced the desired oxirane in only 10% yield (from 4)
after 8 days.13 Treatment of epoxide 7 with potassium
hydroxide in THF/water at 90 °C for 48 h then gave, via
nucleophilic ring-opening of the substrate at the allylic carbon
of the oxirane unit,14 the trans-diol 8 in 72% yield, the structure
of which was conﬁrmed by single-crystal X-ray analysis.12
Compound 8 readily engaged in a Sonogashira reaction15 with
commercially available 2-methylbut-1-en-3-yne (9), thus
aﬀording the anticipated cross-coupling product 10 in 91%
yield. Treatment of compound 10 with aqueous hydrogen
chloride in methanol aﬀorded a highly insoluble tetra-ol that
was reacted with triphosgene in dichloromethane at −78 °C to
deliver the target compound ent-2 in 43% yield. Final
conﬁrmation of the structure of this compound followed
from a single-crystal X-ray analysis of the readily derived bis-p-
nitrobenzoate 11 (94%). The derived ORTEP is shown in
Figure 3.
Comparisons of the 1H and 13C NMR spectroscopic data
sets derived from compound ent-2 with those reported for
aspergillusol A (and assigned structure 2) are presented in
Table 1 and reveal a good match. However, the speciﬁc rotation
determined for compound ent-2 was +192.5 (c 0.2, MeOH),
while that reported for the natural product was −4.6 (c 0.49,
MeOH). Furthermore, the carbonyl absorption band for
compound ent-2 appears in the infrared spectrum at 1797
cm−1, while in the corresponding spectrum of aspergillusol A it
is observed at 1776 cm−1. The origins of these discrepancies
remain unclear, but given the secure nature of the illustrated
constitution of compound ent-2 and the especially good match
between the above-mentioned NMR data sets, we conclude
that the structure, but not necessarily the absolute conﬁg-
uration, of aspergillusol A has been assigned correctly.
The diﬀerences in the magnitudes of the speciﬁc rotations
could arise from contaminants in the small amounts of material
(1.2 mg) obtained from the natural source or from the material
decomposing prior to the acquisition of the optical rotation and
infrared spectral data. The possibility that the naturally derived
material is racemic cannot be discounted at this point.
The synthetic sequence used to obtain (+)-asperpentyn (1)
is shown in Scheme 2 and involved treatment of starting
material 4 with N-bromosuccinimide in aqueous THF, thus
aﬀording the previously reported5a bromotriol 12 (66%).
Reaction of the last compound with sodium methoxide gave
the epoxide 135a (79%) in a completely regioselective manner,
and the latter was engaged in a Sonogashira reaction with
alkyne 9, thus forming the cross-coupling product 14 (85%).
Compound 14 participated in a two-fold Mitsunobu reaction
using α-chloroacetic acid as nucleophile5a to aﬀord the bis-ester
15 (74%) of (+)-asperpentyn (1). The natural product itself
Scheme 1. Synthesis and Derivatization of Compound ent-2
Figure 3. ORTEP derived from the single-crystal X-ray analysis of
compound 11 (CCDC 1058037) with labeling of selected atoms.
Anisotropic displacement ellipsoids display 30% probability levels.
Hydrogen atoms are drawn as circles with small radii.
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was obtained in 80% yield by treating compound 15 with zinc
acetate in methanol5a,17 at 20 °C for 12 h. All the NMR
spectroscopic data acquired on synthetically derived (+)-asper-
pentyn were in accord with the assigned structure and matched
those reported7 by Lee (Table 2).
The speciﬁc rotation of compound 1 obtained by the route
just described was of the opposite sign and a little higher in
magnitude that those reported for the enantiomer (−)-asper-
pentyn {[α]20D +30.8 (c 1.2, acetone) vs [α]
25
D −20 (c 0.1,
acetone)4a and [α]20D −18.5 (c 0.1, acetone)4c}.
The chemical synthesis studies reported here have
established that the structure, 2, assigned to the natural
product aspergillusol A is most likely correct, although its
absolute stereochemistry remains in doubt. In addition, a
concise (ﬁve-step) synthesis of (+)-asperpentyn (1) has been
established. As such, the present work further exempliﬁes the
remarkable utility of the enzymatically derived and enantiomeri-
cally pure cis-1,2-dihydrocatechols such as 4 in the
unambiguous synthesis of a range of natural products6 or, in
some instances, the structures erroneously assigned to them.18
■ EXPERIMENTAL SECTION
General Experimental Procedures. Unless otherwise speciﬁed,
proton (1H) and carbon (13C) NMR spectra were recorded at room
temperature in base-ﬁltered CDCl3 on a Varian spectrometer
operating at 400 MHz for proton and 100 MHz for carbon nuclei.
The signal due to residual CHCl3 appearing at δH 7.26 and the central
resonance of the CDCl3 triplet appearing at δC 77.0 were used to
reference 1H and 13C NMR spectra, respectively. 1H NMR data are
recorded as follows: chemical shift (δ) [multiplicity, coupling
constant(s) J (Hz), relative integral], where multiplicity is deﬁned as
s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or
combinations of the above. Infrared spectra (νmax) were recorded on a
Perkin−Elmer 1800 Series FTIR spectrometer. Samples were analyzed
as thin ﬁlms on KBr plates. Low-resolution ESI mass spectra were
recorded on a single quadrupole liquid chromatograph−mass
spectrometer, while high-resolution measurements were conducted
on a time-of-ﬂight instrument. Low- and high-resolution EI mass
spectra were recorded on a magnetic-sector machine. Melting points
were measured on an Optimelt automated melting point system and
are uncorrected. Analytical thin-layer chromatography (TLC) was
performed on aluminum-backed 0.2 mm thick silica gel 60 F254 plates
as supplied by Merck. Eluted plates were visualized using a 254 nm UV
lamp and/or by treatment with a suitable dip followed by heating.
These dips included phosphomolybdic acid/ceric sulfate/sulfuric acid
Table 1. Comparison of the 13C and 1H NMR Data
Recorded for Synthetically Derived Compound ent-2 with
Those Reported for Aspergillusol A16
13C NMR (δC)
1H NMR (δH)
aspergillusol Aa
compound
ent-2b aspergillusol Ac compound ent-2d
154.1 154.2 6.28, dd, J = 2.0 and
0.5 Hz, 1H
6.29, d, J = 1.8 Hz,
1H
143.2 143.2 5.36, d, J = 1.5 Hz,
1H
5.37, m, 1H
127.2 127.3 5.34, d, J = 1.5 Hz,
1H
5.35, m, 1H
123.4 123.5 5.26, br d, J = 8.3 Hz,
1H
5.26, d, J = 7.8 Hz,
1H
116.5 116.7 5.13, br s, 1H 5.06, d, J = 4.6 Hz,
1H
92.2 92.3 4.79, dd, J = 8.3 and
8.0 Hz, 1H
4.80, dd, J = 9.0 and
7.8 Hz, 1H
85.6 85.6 4.79, br s, 1H 4.70, d, J = 5.6 Hz,
1H
79.1 79.1 4.19, m, 1H 4.20, m, 1H
75.9 75.9 3.58, br t, J = 8.0 Hz,
1H
3.60, td, J = 8.7 and
4.0 Hz, 1H
73.9 73.8 1.90, t, J = 1.5 Hz,
3H
1.91, t, J = 1.3 Hz,
3H
69.6 69.5
23.2 23.2
aData obtained from ref 1, recorded in (CD3)2CO at 125 MHz.
bData
recorded in (CD3)2CO at 100 MHz.
cData obtained from ref 1,
recorded in (CD3)2CO at 500 MHz.
dData recorded in (CD3)2CO at
400 MHz.
Scheme 2. Synthesis of (+)-Asperpentyn (1)
Table 2. Comparison of the 13C and 1H NMR Data
Recorded for Synthetically Derived (+)-Asperpentyn (1)
with Those Reported by Lee17
13C NMR (δC)
1H NMR (δH)
(+)-asperpentyna,b compound 1c (+)-asperpentynd compound 1e,f
131.5 131.2 6.08, dd, J = 5.2
and 1.3 Hz, 1H
6.06, dd, J = 5.2
and 1.8 Hz, 1H
126.4 126.2 5.36, s, 1H 5.36, s, 1H
123.4 123.2 5.31, s, 1H 5.30, s, 1H
122.7 122.1 4.51, “overlapped”,
2H
4.52−4.48,
complex m, 2H
92.6 92.2 3.42, s, 1H 3.40, br s, 1H
86.9 86.9 3.35, s, 1H 3.32, br s, 1H
65.9 65.5 3.21, br s, 1H 4.09, br s, 1H
63.1 62.6 3.04, br s, 1H 4.05, br s, 1H
52.4 52.2 1.92, s, 3H 1.91, s, 3H
51.7 51.4
23.5 23.2
aData obtained from ref 7, recorded in CDCl3 at 75 MHz.
bSignals
reported in ref 7 at δC 111.7(5) and 111.7(0) are not listed here since
they appear to be due to minor impurities. cData recorded in CDCl3 at
100 MHz. dData obtained from ref 7, recorded in CDCl3 at 300 MHz.
eData recorded in CDCl3 at 400 MHz.
fData listed so as to align with
signals reported in ref 7.
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(conc)/water (37.5 g/7.5 g/37.5 g/720 mL) or potassium
permanganate/potassium carbonate/5% sodium hydroxide aqueous
solution/water (3 g/20 g/5 mL/300 mL). Flash chromatographic
separations were carried out following protocols deﬁned by Still et al.19
with silica gel 60 (40−63 μm) as the stationary phase and using the
AR- or HPLC-grade solvents indicated. Starting materials and reagents
were generally available from Sigma−Aldrich, Merck, TCI, Strem, or
Lancaster Chemical Company and were used as supplied. Drying
agents and other inorganic salts were purchased from AJAX, BDH, or
Unilab. Tetrahydrofuran (THF), methanol, and dichloromethane were
dried using a Glass Contour solvent puriﬁcation system that is based
upon a technology originally described by Grubbs et al.20 Where
necessary, reactions were performed under an nitrogen atmosphere.
Synthesis of Compound 6. A magnetically stirred solution of cis-
diol 55e,9 (1.50 g, 4.80 mmol) in dry acetonitrile maintained at 0 °C
was treated, in one portion, with chlorocarbonyl-1-methylethyl
acetate10 (1.00 mL, 7.20 mmol). The ensuing mixture was stirred at
18 °C for 1 h, then concentrated under reduced pressure. The residue
thus obtained was diluted with water (20 mL), then extracted with
ethyl acetate (2 × 50 mL), and the combined extracts were washed
with NaHCO3 (2 × 50 mL of a 3% w/v aqueous solution) before
being dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The residue thus obtained was recrystallized (ethyl acetate)
to give compound 6 (1.7 g, 95%).
Compound 6: white, crystalline solid; mp 121−124 °C; [α]D +26.1
(c 0.6, CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.54 (d, J = 2.7 Hz,
1H), 5.33 (t, J = 7.6 Hz, 1H), 4.68 (d, J = 5.7 Hz, 1H), 4.35−4.32
(complex m, 1H), 4.21 (dd, J = 7.6 and 5.7 Hz, 1H), 2.14 (s, 3H), 1.55
(s, 3H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.6, 139.1,
111.1, 96.6, 79.1, 75.2, 72.2, 55.6, 27.6, 26.3, 20.9; IR νmax 2995, 2971,
2883, 1740, 1625, 1376, 1246, 1218, 1063, 1051, 893, 864, 791, 714
cm−1; MS (EI, 70 eV) m/z 357 [(M − CH3•)+, 75%], 255 (100), 254
(80), 128 (93), 110 (33); HRMS (M − CH3•)+ calcd for
C10H11
35Cl137IO4 356.9391, found 356.9390.
Synthesis of Compound 7. A magnetically stirred solution of
chloroacetate 6 (1.50 g, 15.0 mmol) in dry THF (100 mL) maintained
at 0 °C was treated with sodium methoxide (3.00 g, 55.6 mmol), and
the ensuing mixture allowed to warm to 18 °C, then stirred at this
temperature for 4 h before being ﬁltered through a pad of
diatomaceous earth. The ﬁltrate was concentrated under reduced
pressure, and the ensuing residue subjected to ﬂash chromatography
(silica, 1:9 v/v ethyl acetate−hexane elution) to aﬀord, after
concentration of the relevant fractions (Rf = 0.3), compound 7 (900
mg, 76%).
Compound 7: white, crystalline solid; mp 72−76 °C; [α]D +146.4
(c 0.7, CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.80 (dd, J = 4.4 and
1.5 Hz, 1H), 4.77−4.69 (complex m, 1H), 4.37 (dd, J = 6.6 and 1.5
Hz, 1H), 3.61 (dd, J = 3.7 and 2.1 Hz, 1H), 3.15 (m, 1H), 1.47 (s,
3H), 1.43 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 134.2, 111.2,
108.5, 75.8, 72.1, 49.2, 48.6, 27.6, 26.2; IR νmax 2987, 2940, 2879, 1618,
1379, 1369, 1239, 1229, 1072, 1042, 1004, 888, 864, 826 cm−1; MS
(EI, 70 eV) m/z 294 (M+•, 20%), 279 [(M − CH3•)+, 100], 207 (85),
110 (80), 109 (77); HRMS calcd for C9H11
127IO3 293.9753, found
293.9753.
Synthesis of Compound 8. A magnetically stirred solution of
epoxide 7 (3.00 g, 10.2 mmol) in dry THF (100 mL) was treated with
KOH (50 mL of a 10% w/v aqueous solution). The ensuing mixture
was heated at reﬂux for 48 h before being cooled and extracted with
ethyl acetate (2 × 100 mL). The combined organic phases were then
dried (Na2SO4), ﬁltered, and concentrated under reduced pressure.
The residue thus obtained was subjected to ﬂash chromatography
(silica, 1:1 v/v ethyl acetate−hexane elution) to aﬀord, after
concentration of the relevant fractions (Rf = 0.1), compound 8
(2.30 g, 72%).
Compound 8: white, crystalline solid; mp 108−110 °C; [α]D +2.8
(c 0.5, CHCl3);
1H NMR [400 MHz, (CD3)2SO] δ 6.34 (d, J = 2.2 Hz,
1H), 5.28 (d, J = 6.2 Hz, 1H), 5.24 (d, J = 5.0 Hz, 1H), 4.61 (dm, J =
6.5 Hz, 1H), 4.00 (dd, J = 8.6 and 6.5 Hz, 1H), 3.78 (ddt, J = 8.0, 6.2,
and 1.7 Hz, 1H), 3.22 (td, J = 8.3 and 5.0 Hz, 1H), 1.39 (s, 3H), 1.30
(s, 3H); 13C NMR [100 MHz, (CD3)2SO] δ 145.2, 108.6, 93.0, 79.1,
77.5, 72.8, 71.8, 28.0, 25.9; IR νmax 3498, 3306, 2980, 2916, 2882,
1634, 1456, 1383, 1368, 1355, 1259, 1082, 1068, 1013, 988, 903, 868,
842, 798 cm−1; MS (EI, 70 eV) m/z 312 (M+•, 5%), 296 [(M −
CH3
•)+, 100], 185 (31), 110 (59), 101 (45); HRMS calcd for
C9H13
127IO4 311.9859, found 311.9859.
Synthesis of Compound 10. A magnetically stirred mixture of
iodide 8 (850 mg, 2.72 mmol) in degassed triethylamine (10 mL)
maintained at 18 °C was treated with CuI (78 mg, 0.41 mmol),
PdCl2(Ph3P)2 (190 mg, 0.27 mmol), and 2-methyl-1-buten-3-yne
(1.29 mL, 13.6 mmol). After stirring for 16 h at 18 °C, the reaction
mixture was poured into NH4Cl (40 mL of a saturated aqueous
solution) and extracted with ethyl acetate (1 × 50 mL). The separated
aqueous phase was extracted with ethyl acetate (1 × 50 mL), and the
combined organic phases were washed with brine (1 × 100 mL)
before being dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The residue thus obtained was subjected to chromatography
(silica, 1:1 v/v ethyl acetate−hexane elution) to aﬀord, after
concentration of the relevant fractions (Rf = 0.1), compound 10
(620 mg, 91%).
Compound 10: amorphous, brown powder; [α]20D −13.8 (c 0.6,
CH2Cl2);
1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 5.34 (s, 1H),
5.27 (s, 1H), 4.58 (d, J = 6.3 Hz, 1H), 4.15 (d, J = 8.3 Hz, 1H), 4.09
(dd, J = 8.8 and 6.3 Hz, 1H), 3.72 (br s, 1H), 3.61 (br t, J = ca. 8.8 Hz,
1H), 3.42 (br s, 1H), 1.91 (s, 3H), 1.53 (s, 3H), 1.41 (s, 3H); 13C
NMR (100 MHz, CDCl3) δ 138.6, 126.4, 122.8, 118.9, 110.8, 91.6,
85.6, 77.3, 74.6, 74.1, 70.3, 28.2, 25.9, 23.2; IR νmax 3271, 2983, 2918,
1609, 1450, 1371, 1243, 1217, 1157, 1087, 1061, 1015, 989, 905, 869
cm−1; MS (ESI, +ve) m/z 273 [(M + Na)+, 100%], 523 (35); HRMS
calcd for C14H18
23NaO4 273.1103, found: 273.1107.
Synthesis of Compound ent-2. Step i: A magnetically stirred
mixture of compound 10 (100 mg, 0.40 mmol) in methanol (5 mL)
maintained at 18 °C was treated with HCl (0.5 mL of a 1 M aqueous
solution), and after 24 h the reaction mixture was concentrated under
reduced pressure and then dried under high vacuum. The residue thus
obtained was immediately subjected to step ii.
Step ii: A magnetically stirred suspension of the residue obtained
from step i in dry CH2Cl2 (10 mL) maintained at −78 °C was treated
with pyridine (323 μL, 4.0 mmol) and triphosgene (59.4 mg, 0.20
mmol). The ensuing mixture was stirred at −78 °C for 1 h, then
poured into NH4Cl (10 mL of a saturated aqueous solution) and
extracted with CH2Cl2 (2 × 20 mL). The combined organic phases
were dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure, and the residue thus obtained was subjected to ﬂash
chromatography (silica, 1:1 v/v ethyl acetate−hexane elution).
Concentration of the relevant fractions (Rf = 0.3) then gave compound
ent-2 (40 mg, 43%).
Compound ent-2: clear, colorless oil; [α]20D +192.5 (c 0.2,
MeOH); 1H NMR (400 MHz, CDCl3) δ 6.30 (s, 1H), 5.39 (s,
1H), 5.34 (s, 1H), 5.11 (d, J = 7.7 Hz, 1H), 4.66 (t, J = ca. 8.0 Hz,
1H), 4.24 (d, J = 8.4 Hz, 1H), 3.75 (t, ca. J = 8.4 Hz, 1H), 3.57 (br s,
1H), 3.03 (br s, 1H), 1.92 (s, 3H); 1H NMR [400 MHz, (CD3)2CO] δ
see Table 1; 13C NMR (100 MHz, CDCl3) δ 153.5, 139.7, 125.8,
123.9, 116.2, 93.4, 83.3, 77.9, 75.3, 73.3, 68.5, 23.0; 13C NMR [100
MHz, (CD3)2CO] δ see Table 1; IR νmax 3368, 2917, 2849, 1797,
1354, 1165, 1084, 1057, 1019, 994, 903 cm−1; HRMS calcd for
C12H12
23NaO5 259.0582, found 259.0583.
Synthesis of Compound 11. A magnetically stirred solution of
compound ent-2 (20 mg, 0.08 mmol) in dry CH2Cl2 (10 mL)
maintained at 18 °C was treated with triethylamine (111 μL, 0.80
mmol), p-nitrobenzoyl chloride (59.4 mg, 0.32 mmol), and DMAP
(2.4 mg, 0.02 mmol). The ensuing mixture was stirred at 18 °C for 16
h, then concentrated under reduced pressure. The residue thus
obtained was subjected to ﬂash chromatography (silica, 1:3 v/v ethyl
acetate−hexane elution) to aﬀord, after concentration of the relevant
fractions (Rf = 0.5), compound 11 (40 mg, 89%).
Compound 11: amorphous, white powder; [α]20D +90.9 (c 0.22,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 3.1 Hz, 2H), 8.27
(d, J = 3.1 Hz, 2H), 8.17 (d, J = 2.2 Hz, 2H), 8.15 (d, J = 2.2 Hz, 2H),
6.44 (d, J = 3.2 Hz, 1H), 5.90 (dd, J = 7.4 and 3.2 Hz, 1H), 5.79 (t, J =
7.4 Hz, 1H), 5.44 (s, 1H), 5.41 (s, 1H), 5.31 (d, J = 7.7 Hz, 1H), 5.10
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(t, J = ca. 7.7 Hz, 1H), 1.94 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
163.7, 163.3, 152.2, 151.1, 133.6(5), 133.6(2), 133.5, 131.1, 125.5,
124.9, 123.8(0), 123.7(8), 120.2, 95.7, 82.9, 74.0, 73.9, 70.4, 68.4, 22.9
(two signals obscured or overlapping); IR νmax 2917, 2850, 1812, 1735,
1527, 1349, 1270, 1162, 1097, 1070, 872, 717 cm−1. Mass
spectrometric data could not be acquired on this compound, but a
sample of this material suitable for single-crystal X-ray analysis was
grown from a methanol−ethyl acetate−hexane solution. This material
had a melting range of 196−199 °C.
Synthesis of Compound 14. A magnetically stirred mixture of
compound 135a (630 mg, 2.48 mmol) in degassed triethylamine (15
mL) maintained at 18 °C was treated with CuI (70 mg, 0.37 mmol),
PdCl2(Ph3P)2 (180 mg, 0.25 mmol), and 2-methyl-1-buten-3-yne
(1.18 mL, 12.4 mmol). After stirring for 12 h at 18 °C, the reaction
mixture was poured into NH4Cl (40 mL of a saturated aqueous
solution) and extracted with ethyl acetate (1 × 50 mL). The separated
aqueous phase was extracted with ethyl acetate (1 × 50 mL), and the
combined organic phases were washed with brine (1 × 100 mL)
before being dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The residue thus obtained was subjected to ﬂash
chromatography (silica, 1:1 v/v ethyl acetate−hexane elution) to
aﬀord, after concentration of the relevant fractions (Rf = 0.4),
compound 14 (410 mg, 85%).
Compound 14: amorphous, brown powder; [α]20D +7.5 (c 1,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 5.87 (d, J = 2.3 Hz, 1H), 5.36
(s, 1H), 5.29 (s, 1H), 4.46 (s, 1H), 4.26 (s, 1H), 3.68 (m, 1H), 3.63
(m, 1H), 2.75 (br s, 1H), 2.62 (br s, 1H), 1.92 (s, 3H); 13C NMR (100
MHz, CDCl3) δ 133.0, 126.2, 123.1, 122.0, 92.5, 84.9, 65.3, 65.2, 55.2,
55.1, 23.2; IR νmax 3351, 3012, 2918, 1608, 1435, 1373, 1302, 1252,
1044, 976, 921, 903, 881, 752, 722, 674 cm−1; MS (ESI, + ve) m/z 389
(100%), 215 [(M + Na)+, 82]; HRMS calcd for C11H12
23NaO3
215.0684, found 215.0684.
Synthesis of Compound 15. A magnetically stirred solution of
compound 14 (150 mg, 0.78 mmol) in dry THF (10 mL) was treated
with Ph3P (610 mg, 2.34 mmol), α-chloroacetic acid (220 mg, 2.34
mmol), and diethyl azodicarboxylate (370 μL, 2.34 mmol). The
resulting solution was stirred at 18 °C for 4 h, then concentrated under
reduced pressure. The light yellow residue thus obtained was subjected
to ﬂash chromatography (silica, 1:9 v/v ethyl acetate−hexane elution)
to aﬀord, after concentration of the relevant fractions (Rf = 0.2), bis-α-
chloroacetate 15 (200 mg, 74%).
Compound 15: clear, colorless oil; [α]20D −44.0 (c 1.0, CHCl3); 1H
NMR (400 MHz, CDCl3) δ 6.11 (dd, J = 5.0 and 1.7 Hz, 1H), 5.78
(m, 1H), 5.69 (m, 1H), 5.34 (m, 1H), 5.31 (m, 1H), 4.16 (s, 2H), 4.12
(s, 2H), 3.39 (m, 1H), 3.36 (m, 1H), 1.87 (s, 3H); 13C NMR (100
MHz, CDCl3) δ 166.6, 166.5, 128.0, 125.8, 123.9, 120.8, 93.8, 84.9,
67.0, 65.7, 49.9, 49.2, 40.6, 22.9 (one signal obscured or overlapping);
IR νmax 3012, 2955, 2922, 1763, 1408, 1319, 1296, 1276, 1250, 1151,
993, 929, 810, 792 cm−1; MS (ESI, + ve) m/z 369 and 367 [(M +
Na)+, 65% and 100%], 275 (60); HRMS calcd for C15H14
35Cl2
23NaO5
367.0116, found 367.0118.
Synthesis of Compound 1. A magnetically stirred solution of bis-
α-chloroacetate 15 (100 mg, 0.29 mmol) in methanol (10 mL) was
treated with zinc acetate dihydrate (190 mg, 0.87 mmol), and the
ensuing mixture stirred at 18 °C for 12 h, then concentrated under
reduced pressure. The resulting white solid was subjected to ﬂash
chromatography (silica, 1:1 v/v ethyl acetate−hexane elution) to
aﬀord, after concentration of the relevant fractions (Rf = 0.2),
compound 1 (45 mg, 80%).
Compound 1: clear, colorless oil; [α]20D +30.8 (c 1.2, acetone)
{lit.4a (for enantiomer) [α]25D −20 (c 0.1, acetone)}; 1H NMR (400
MHz, CDCl3) see Table 2;
13C NMR (100 MHz, CDCl3) see Table 2;
IR νmax 3339, 3011, 2916, 1636, 1609, 1435, 1374, 1300, 1024, 903,
838, 792 cm−1; MS (ESI, + ve) m/z 215 [(M + Na)+, 100%]; HRMS
calcd for C11H12
23NaO3 215.0684, found 215.0686.
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Crystallographic Data  
Compound 6. C11H14ClIO4, M = 372.59, T = 150 K, orthorhombic, space group P212121, Z = 4, a = 5.5023(1), 
b = 8.0050(2), c = 31.0282(8) Å; V = 1366.67(6) Å3, Dx = 1.811 g cm–3, 3608 unique data (2θmax = 59.6°), R 
= 0.050 [for 2925 reflections with I > 2.0σ(I)]; Rw = 0.060 (all data), S = 1.11. 
Compound 8. C9H13IO4, M = 312.10, T = 200 K, monoclinic, space group C2, Z = 4, a = 17.7416(4), b = 
5.1188(1), c = 12.1148(3) Å; β = 92.9213(13)°; V = 1098.78(4) Å3, Dx = 1.887 g cm–3, 3091 unique data 
(2θmax = 60°), R = 0.024 [for 2918 reflections with I > 2.0σ(I)]; Rw = 0.058 (all data), S = 1.00. 
Compound 11. C26H18N2O5, M = 534.44, T = 150 K, monoclinic, space group P21, Z = 4, a = 21.6418(13), b 
= 6.1229(2), c = 21.6668(12) Å; β = 116.016(7)°; V = 2580.2(3) Å3, Dx = 1.376 g cm–3, 5556 unique data 
(2θmax = 144.6°), R = 0.092 [for 5122 reflections with I > 2.0σ(I)]; Rw = 0.245 (all data), S = 1.04. 
 
Structure Determination.  
Images were measured on a Nonius Kappa CCD diffractometer (MoKα, graphite monochromator, λ = 
0.71073 Å) or an Agilent SuperNova CCD diffractometer (CuKα, mirror monochromator, λ = 1.54184 Å) 
and data extracted using the DENZO1 or CrysAlis packages,2 respectively. Structure solution was by direct 
methods (SIR92).3 The structures were refined using the CRYSTALS program package.4 Atomic 
coordinates, bond lengths and angles, and displacement parameters have been deposited at the Cambridge 
Crystallographic Data Centre (CCDC no. 1058035, 1058036 and 1058037 for compounds 6, 8 and 11, 
respectively). These data can be obtained free-of-charge via www.ccdc.cam.ac.uk/data_request/cif, by 
emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 
Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033. 
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Figure S1: Structure of compound 6 (CCDC 1058035) with labeling of selected atoms. Anisotropic 
displacement ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
 
 
 
Figure S2: Structure of compound 8 (CCDC 1058036) with labeling of selected atoms. Anisotropic 
displacement ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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ABSTRACT: Syntheses of certain di- and mono-oxygenated derivatives (e.g., 2 and 3, respectively) and analogues (e.g., 4, a D-
ring monoseco-analogue of 2) of both the (−)- and (+)-enantiomeric forms of the alkaloid galanthamine [(−)-1] are reported.
All have been assessed for their capacities to inhibit acetylcholine esterase but, in contrast to the predictions from docking
studies, none bind strongly to this enzyme.
■ INTRODUCTION
The alkaloid (−)-galanthamine [(−)-1] (Figure 1) has been
isolated from a range of plant sources and is currently used in
the clinic for the symptomatic treatment of mild to moderate
forms of Alzheimer’s disease.1 It exerts its beneﬁcial eﬀects by
crossing the blood-brain barrier and then, in part at least,
inhibiting acetylcholine esterase (AChE). It also acts as an
allosteric modulator of the nicotinic acetylcholine receptor.1,2
The non-natural enantiomer of compound 1, namely ent-1 or
(+)-galanthamine, has also been shown to accumulate in brain
tissue but does so through nonspeciﬁc binding.3
Currently, (−)-galanthamine is produced industrially by
extraction from various plants sources, most notably the red
spider lily (Lycoris radia), the wild daﬀodil (Narcissus
pseudonarcissus), the summer snowﬂake (Leucojum aestivum),
and the Caucasian snowdrop (Galanthus woronowii).1 However,
both the increasing demands for the natural product and the
erosion of habitat of at least some of the producing plants has
prompted investigations into other methods for obtaining it or
for identifying analogues with improved eﬃcacy. As part of such
eﬀorts, galanthamine has been the subject of a signiﬁcant
number of total synthesis studies with the ﬁrst of these being
reported by Barton and Kirby4 and involving mimicking of the
proposed biogenesis. Substantial reﬁnements of this process
have been reported in the interim,5 and one of these has
formed the basis of a pilot-plant scale synthesis of the alkaloid5a
although it is not clear if this contributes signiﬁcantly to the
commercial production of the alkaloid. Magnus and co-workers
have described6 a related and highly eﬀective approach.
Intramolecular Heck reactions have provided another means
for assembling the tetracyclic framework of galanthamine,7
including those accomplished in an enantioselective manner,
while various chirons (corresponding to the A-ring) have been
employed for the assembly in either enantiomeric form of the
alkaloid.8,9a New routes to (−)-galanthamine continue to be
reported,1e including approaches from our group.9
The identiﬁcation and biological evaluation of analogues of
galanthamine has been another focus of signiﬁcant activity10
that is now greatly assisted by data derived from high-resolution
X-ray analysis of the alkaloid bound to the active site of
acetylcholine esterase.11 Biomimetic diversity-oriented syn-
Received: May 3, 2017
Published: July 3, 2017
Figure 1. Structure of the alkaloid (−)-galanthamine.
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thesis, sophisticated QSAR analyses, multicomponent-coupling
chemistries, as well as more conventional studies have all
revealed active compounds.12 The screening of natural products
for relevant activities remains an ongoing area of investigation
and has also resulted in the isolation of new inhibitors of the
title enzyme.13
As part of an ongoing program to establish concise routes to
the tetracyclic framework of galanthamine,1e,9 we now report
chemoenzymatic syntheses of two oxygenated derivatives, 2
and 3, as well as analogues 4−9 of the natural or (−)-form of
the alkaloid (Figure 2).14
Syntheses of the enantiomers of the ﬁrst ﬁve of these
derivatives/analogues, namely compounds ent-2 to ent-6, are
also described. As detailed below, and contrary to the
predictions arising from molecular docking studies, none of
these is an eﬀective inhibitor of acetylcholine esterase.
Our motivation for undertaking the studies described herein
was that the introduction of additional functionalities within the
galanthamine framework could increase water solubility and/or
provide the means for conjugating the drug with various groups
including peptide fragments10f or other entities (e.g. mem-
antine)10d and thus allow for the development of a multi-
targeted therapeutic approach.10d In principle, then, the
attachment of such moieties could provide new inhibitors (or
even just prodrug forms10e of galanthamine) that are superior
to existing therapies. As revealed below, the nature of our
synthetic strategy is such that additionally oxygenated forms of
the galanthamine A-ring were likely to be the most readily
accessible. Accordingly, and because this region of alkaloid has
not been “explored” previously, such derivatives became a
major focus of the work detailed below.
■ RESULTS AND DISCUSSION
Chemical Synthesis Studies. The reaction sequence used
to assemble ABC-ring substructures of (−)-galanthamine is
shown in Scheme 1 and employs the readily available L-tartaric
acid (10) as starting material. Thus, as speciﬁed in a recent
publication,15 compound 10 can be converted over 11 steps,
involving reduction, Grignard addition, and ring-closing
metatheses as key transformations, into the 1,2-diacetal
annulated bromocyclohexene 11. Coupling of compound 11
with the readily available16 aryl boronic acid ester 12 proceeded
under conventional conditions to give the anticipated arylated
cyclohexene 13 (68%). Following protocols established during
the course of our syntheses of the ribisins,17 this last compound
was engaged in an intramolecular Mitsunobu reaction using
triphenylphosphine in conjunction with di-iso-propyl azodicar-
boxylate (DIAD) wherein the phenolic hydroxyl group served
as the internal nucleophile and so aﬀording the acid-sensitive
isobenzofuran 14 (33%). As demonstrated through work in the
enantiomeric series (see below), if appropriate account is taken
of this acid-sensitivity, then the Mitsunobu reaction can be a
high yielding one. Despite concerns about the potential for
competing isomerization of compound 14 to its more
conjugated (fully aromatic) counterpart, upon subjecting it to
conditions previously employed for eﬀecting the Eschenmos-
er−Claisen rearrangement of allylic alcohols,18 amide 15 was
produced in 84% yield. The structure of this compound
followed not only from the derived NMR, IR, and mass spectral
Figure 2. Galanthamine derivatives/analogues 2−9 targeted for synthesis.
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data but also from a single-crystal X-ray analysis of its
enantiomer (see below). Compound 15 embodies both the
targeted ABC-ring substructure of (−)-galanthamine and the
associated quaternary carbon. In anticipation of installing the
ﬁnal D-ring of the title alkaloid, the amide residue within
compound 15 was reduced using LiBHEt3 and 1° alcohol 16
thereby obtained in 92% yield. Oxidation of compound 16
under conditions deﬁned by Bobbitt and Bailey19 then gave
acid 17 (76%), which represents the key precursor to the
targeted galanthamine derivatives/analogues 2−6.
The straightforward manipulations of acid 17 leading to the
targeted (−)-galanthamine derivatives/analogues 2, 3, 5, and 6
are shown in Scheme 2. Thus, coupling of compound 17 and
methylamine, using 1,1′-carbonyldiimidazole (CDI) for activa-
tion of the acid, aﬀorded amide 5 (79%), and on exposure of
the latter to modiﬁed Pictet−Spengler conditions7c,20 involving
paraformaldehyde in the presence of triﬂuoroacetic acid (TFA),
tetracyclic lactam 2 (47%) was formed as a result of
concomitant cleavage of the Ley acetal moiety. Upon treatment
with sodium bis(2-methoxyethoxy)aluminum dihydride, com-
pound 2 was reduced to azepine 3 (44%), and hydrolysis of the
1,2-diacetal residue within compound 5 using aqueous
triﬂuoroacetic acid (TFA) aﬀorded diol 6 (66%). Compound
6 can be considered as a hybrid of the title alkaloid and the
neurologically active natural product ribisin D.17,21
The synthesis of compound 4, a monoseco derivative of 5R-
hydroxy-(−)-galanthamine (3), simply involved (Scheme 3)
acid-catalyzed hydrolysis of precursor 15 under conventional
conditions. This reaction proceeded in 88% yield.
All of the spectral data obtained on targeted compounds 2−6
were in complete accordance with the assigned structures but
ﬁnal conﬁrmation of that of the ﬁrst (i.e., 2) followed from a
single-crystal X-ray analysis of its enantiomer (see below).
In an eﬀort to establish a more meaningful SAR proﬁle for
the above-mentioned analogues, the enantiomerically related
derivatives/analogues ent-2 to ent-6 (Figure 3) were sought.
Scheme 1. Synthesis of Key Acid 17 Embodying the ABC-Ring Substructure and Associated Quaternary Carbon of
(−)-Galanthamine
The Journal of Organic Chemistry Article
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Although the routes deﬁned above could simply be adapted for
this purpose by starting with D- rather than L-taratric acid, we
were able to establish a shorter pathway by starting with an
enzymatically derived chiron that is readily available in the
required enantiomeric form (but less so in the opposite one
required to prepare the derivatives/analogues just described).
The synthesis of the enantiomeric series of compounds
started, as shown in Scheme 4, with the enzymatically derived
and enantiomerically pure cis-1,2-dihydrocatechol 1822 that was
converted into the corresponding and well-known23 acetonide
19 under standard conditions. Immediate treatment of the last
compound with m-chloroperbenzoic acid (m-CPBA) then
aﬀorded, in a completely regio- and stereo-selective fashion,
epoxide 2023 (93% from 18). Reaction of compound 20 with a
large excess of p-methoxybenzylalcohol (p-MBnOH) in the
presence of boron triﬂuoride etherate (BF3·Et2O) resulted in
selective nucleophilic opening of the epoxide ring at the allylic
Scheme 2. Conversion of Acid 17 into the (−)-Galanthamine Derivatives/Analogues 2, 3, 5, and 6
Scheme 3. Hydrolysis of Biacetal 15 Leading to Compound 4
Figure 3. Enantiomeric series of derivatives/analogues.
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carbon,24 but the protected bromoconduritol thus formed was
not isolated. Rather, it was simply allowed to react with
methanol in the presence of pyridinium tosylate (PPTS) and
thereby aﬀording triol 21 (71%). Treatment of a methanolic
solution of this last compound with 2,2,3,3-tetramethoxybutane
(2,2,3,3-TMB) in the presence of p-toluenesulfonic acid
monohydrate (p-TsOH·H2O) then resulted in the selective
formation of the “Ley”-acetal25 ent-11 (85%) and so establish-
ing an “enantiomeric overlap” with the synthetic sequence
leading to the original sets of analogues.
During the conversion, 21 → ent-11 acetal formation is
presumed to take place prior to cleavage of the PMB-ether unit
because the reverse order of events would lead to an
intermediate conduritol embodying two adjacent trans-diol
moieties and the formation of two isomeric Ley-type acetals
would therefore be expected. Indeed, when the tetra-ol derived
from hydrolysis of compound 21 was subjected to reaction with
2,2,3,3-TMB in the presence of p-TsOH·H2O then an ∼1:1
mixture of the two possible bis-acetals is formed.
Scheme 4. Synthesis of Bromoconduritol ent-11 from the Enzymatically-Derived and Homochiral cis-1,2-Dihydrocatechol
Scheme 5. Synthesis of Key Acid ent-17 from Bromoconduritol ent-11
The Journal of Organic Chemistry Article
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As shown in Scheme 5, and as was the case in the
enantiomeric series, compound ent-11 could be engaged in a
Suzuki−Miyaura cross-coupling reaction26 with arylboronic
acid ester 12, thus aﬀording the anticipated product ent-13
(71%) that participated in an intramolecular Mitsunobu
reaction to give compound ent-14 (96%). Allylic alcohol ent-
14 underwent an Eschenmoser−Claisen rearrangement reac-
tion on thermolysis with the dimethyl acetal of N,N-
dimethylacetamide in reﬂuxing toluene and thereby aﬀording
N,N-dimethylamide ent-15 (86%). The structure of this last
Scheme 6. Synthesis of Aryl Boronate Ester 27
Scheme 7. Synthesis of Analogue 7
The Journal of Organic Chemistry Article
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compound was conﬁrmed by a single-crystal X-ray analysis,
details of which are provided in the Experimental Section and
the Supporting Information (SI). Reduction of compound ent-
15 with lithium triethylborohydride and oxidation of the
resulting 1° alcohol ent-16 (quant.) using the Bobbitt−Bailey
protocol19 then gave acid ent-17 (80%).
Following precisely the same reaction sequences as detailed
above in Schemes 2 and 3, compound ent-17 was converted
into target derivatives ent-2 to ent-6 (Figure 3) with the
structure of the ﬁrst of these being conﬁrmed by single-crystal
X-ray analysis. The monoseco analogue of compound ent-2,
namely amide ent-4, was readily obtained in 77% yield by
simply treating bis-acetal ent-15 with aqueous triﬂuoroacetic
acid (compare to Scheme 3).
As part of an eﬀort to develop galanthamine derivatives
containing additional functionality in the aromatic C-ring,
especially ones capable of conjugation with motifs that might
bind to the so-called peripheral and anionic binding site of
acetylcholine esterase,27 we sought to exploit the synthetic
chemistry detailed above for this purpose. As such, the relevant
arylboronate acid ester (representing a synthon for the C-ring)
was required and the route used to obtain this is shown in
Scheme 6. Thus, vanillin (22) was converted, under established
conditions, into its bromo-derivative 2328 (90%), and the
aldehydic residue within the latter then protected as the
corresponding ethylene acetal using standard conditions and
thus aﬀording compound 24 in 55% yield. The readily derived
MOM-ether 25 (70%) of the last compound was subjected to a
metalation/borylation protocol, and the intermediate boronic
acid 26 obtained on hydrolytic work up was reacted with
sodium iodide/trimethylsilyl chloride (to cleave the MOM
ether) and then pinacol and thus aﬀording the hitherto
unreported ester 27 (45% from 25). The structure of this last
compound was conﬁrmed by single-crystal X-ray analysis (see
Experimental Section and SI for details).
In the opening stages of attempts to exploit ester 27 in the
production of galanthamine analogues related to those
described above, epoxide 19 (Scheme 7) was subjected to
hydrolytic cleavage, thus aﬀording previously reported29 trans-
diol 28 (68%). The allylic hydroxyl group of diol 28 was
selectively protected through its reaction with tri-iso-propylsilyl
triﬂuoromethanesulfonate (TIPS-OTf) in the presence of 2,6-
lutidine and thus producing allylic ether 29 (88%).30 The
location of the TIPS group within this product was established
using COSY experiments. Upon treating compound 29 with
methyl iodide in the presence of sodium hydride, bis-ether 30
(49%) rather than the anticipated regioisomer was obtained.
Because the illustrated locations of the ether residues within
compound 30 (that thwart the application of the anticipated
Eschenmoser−Claisen rearrangement) were not appreciated
until an X-ray analysis was carried out on a derivative, this was
carried forward by ﬁrst treating it with TBAF and thus aﬀording
homoallylic alcohol 31 (98%). Compound 31 was engaged in a
Suzuki−Miyaura cross-coupling reaction with ester 27 to give
Scheme 8. Synthesis of Analogue 8
The Journal of Organic Chemistry Article
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the arylated and crystalline cyclohexene 32 (45%), the
illustrated structure of which was established by single-crystal
X-ray analysis. Acid-catalyzed hydrolysis of the acetonide
residue within the last compound then gave triol 33 (81%).
Even though the position of the methoxy group within
compound 33 precluded the application of the type of EC
rearrangement used earlier, it was subjected to an intra-
molecular Mitsunobu reaction so as to produce a system,
namely compound 7 (85%), that embodies the ABC-ring
ensemble associated with (−)-galanthamine.
The synthesis of analogue 8 is shown in Scheme 8 and
involved, as the initial step, the regio- and diastereo-selective cis-
dihydroxylation of diene 19. Selective silylation of the allylic
hydroxyl group within the resulting and previously repor-
ted17b,31 diol 34 (62%) was readily achieved using TIPS-OTf in
the presence of 2,6-lutidine, and the product ether 35 (88%)
was subjected to O-methylation using methyl iodide/base.
Treatment of product bis-ether 36 (92%) with TBAF
resulted in cleavage of the O-TIPS bond and formation of
alcohol 37 (88%) that could be cross-coupled with boronate
ester 27 under Suzuki−Miyaura conditions and thus aﬀording
the anticipated product 38 (55%). Contrary to expectations,
however, the allylic alcohol residue within compound 38 failed
to engage in an Eschenmoser−Claisen rearrangement upon
treatment with N,N-dimethylacetamide dimethyl acetal. Rather,
the replacement of the associated allylic hydroxyl group with an
N,N-dimethylacetamide residue took place to give, in a
stereoselective manner and after accompanying O-methylation
of the phenolic hydroxyl group, amide 39 (40%). This was
contaminated by small amounts (7%) of its chromato-
graphically inseparable C5 epimer. “Thwarted E-C rearrange-
ments” of this type have been reported previously32 and in this
instance the process may be driven by electron-rich arene
residues facilitating ionization of the intermediate mixed acetal
with the ensuing and extensively stabilized cation then
undergoing nucleophilic capture by 1-methoxy-N,N-dimethy-
lethen-1-amine that is itself generated through thermal cracking
of the starting dimethyl acetal. The basic structure of product
39 follows from the observation that the diastereotopic
methylene hydrogens of the acetamide side-chain both show
vicinal couplings to the adjacent allylic hydrogen. The
illustrated conﬁguration of the C5 acetamide residue is assigned
on the basis that this would be introduced preferentially during
the course of the nucleophilic capture process mentioned above
from that face of the intermediate cation opposite to the
sterically demanding and nearby acetonide residue. Hydrolysis
of this acetonide residue within compound 33 under standard
conditions then gave analogue 8 in 69% yield.
The synthesis of ﬁnal galanthamine analogue 9 followed a
very similar route to that used in preparing congener 8. The
reaction sequence involved is shown in Scheme 9. Thus,
reaction of epoxide 19 with acetic acid in the presence of a
mineral acid gave the previously reported trans-diol mono-
acetate 409a (81%), the free hydroxyl of which was protected as
Scheme 9. Synthesis of Analogue 9
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the corresponding MOM ether using standard protocols and
thus aﬀording compound 419a in 90% yield.
Cleavage of the acetate unit with the last compound could be
eﬀected under conventional conditions, and the resulting allylic
alcohol 429a (95%) then cross-coupled with boronate ester 27
in the usual manner to give product 43 (49%). As was the case
with congener 32 (Scheme 8), upon subjecting compound 43
to conditions often used to eﬀect the EC rearrangement, this
substrate also engaged in both an allylic substitution reaction
and O-methylation of the phenolic hydroxyl of the precursor.
As a consequence, a chromatographically inseparable and 3:1
mixture of amide 44 and its β-epimer (35% combined yield)
was formed. The salient spectral features of compound 44
resembled those of congener 33. Hydrolysis of the mixture of
acetonide 44 and its C5-epimer under conventional conditions
then gave, after chromatographic puriﬁcation, diol 9 (69%)
that, like the other galanthamine derivatives/analogues, was
subjected to molecular docking studies and evaluation as a
potential inhibitor of acetylcholine esterase. Details are
presented in the following section.
Biological Evaluation and Molecular Docking Studies.
The above-mentioned derivatives/analogues of (−)- and
(+)-galanthamine were each evaluated for their ability to
inhibit AChE using a modiﬁed method involving addition of
DMSO so as to ensure dissolution of these otherwise rather
insoluble compounds.33 The inhibitory eﬀect of DMSO itself
on the AChE was taken into account by subtracting a control
measurement for obtaining the IC50 values of the tested
materials. A summary of the inhibition data thus obtained is
shown in Table 1. These assays reveal that only one of the
compounds, namely derivative 3, showed a measurable IC50
value (of 420 μM) compared to the positive control
(−)-galanthamine [(−)-1] which had an IC50 value of 0.9
μM. Clearly, then, and regardless of the absolute stereo-
chemistries of the systems involved, none of the above-
mentioned derivatives/analogues are strong inhibitors of AChE.
Analysis of these inhibition data was undertaken through
molecular docking simulations and using the structure of
(−)-galanthamine bound to human AChE.34 Crystallographic
studies have revealed that (−)-galanthamine binds into the
active site of AChE with the tetrahydroazepine or D-ring
assuming a boat-like conformation and the associated N-methyl
group in a pseudoequatorial orientation spanning the acyl- and
choline-binding sites.35 Docking simulations, using AUTO-
DOCK, matched the solved structure (see Figure 4A) with the
key interactions between AChE and (−)-galanthamine being
evident, thus suggesting that docking simulations of this type
can provide the correct orientation of binding for the
compounds. Surprisingly, with the exception of compounds 5
and ent-5, 8 and 9, for which no bound structures could be
obtained (in the case of the ﬁrst two of these compounds, this
may be a consequence of their signiﬁcantly greater size), the
derivatives all had signiﬁcant docking binding energies, albeit
weaker than (−)-galanthamine (see right-hand column, Table
1). This highlights some of the known limitations in the
prediction of binding aﬃnity by docking programs.36−38 The
docking studies do, however, reveal the likely structural basis
for the reduced aﬃnity of these analogues. For example, the
conﬁguration of compound 3 matches the orientation of
(−)-galanthamine, except that the additional (C5) hydroxyl
moiety is positioned toward tryptophan 84 and thus produces a
distortion in the shape of the A-ring. This most likely results in
destabilization of the π−π stacking interaction between the
indole ring of Trp84 and this ring (A)39 with this loss of
interaction impairing the compound’s capacity to inhibit AChE.
The (+)-enantiomer, ent-3, of compound 3 also has a
hydroxyl positioned toward Trp84, again disrupting the
stabilizing cyclohexene−indole interactions, although on this
occasion it is the same hydroxyl moiety that is present in
galanthamine, potentially explaining, in part at least, why
(+)-galanthamine derivatives are not potent inhibitors of
AChE.
■ CONCLUSIONS
The synthetic chemistry studies detailed above have established
that the ABC-ring system of galanthamine is readily obtained
through the Suzuki−Miyaura cross-coupling of o-hydroxyar-
ylboronates with conduritols incorporating a brominated
double-bond and then engaging the products of such processes
in an intramolecular Mitsunobu reaction. Furthermore, most of
the polyhydroxylated tetrahydrodibenzofurans arising from
such a reaction sequence engage in a thermally promoted
Eschenmoser−Claisen-type rearrangement reaction upon treat-
ment with N,N-dimethylacetamide dimethyl acetal in reﬂuxing
toluene. The angularly substituted tetrahydrodibenzofurans
thus formed, which embody the quaternary carbon center
associated with the title alkaloid and represent monoseco
analogues of the same, can then be elaborated, using Pictet−
Spengler chemistry, to give oxygenated derivatives of galanth-
amine, certain variants of which have recently been isolated
Table 1. Outcomes of Evaluating Galanthamine Derivatives
and Analogues as Inhibitors of AChE and Their Calculated
Docking Binding Energies (BEs)
entry compd IC50 (μM) docking BE (kcal)
1 2 >500 −8.9
2 ent-2 >500 −9.6
3 3 420 ± 57 −8.4
4 ent-3 >500 −9.5
5 4 >500 −6.0
6 ent-4 >500 −9.1
7 5 >500
8 ent-5 >500
9 6 >500 −6.3
10 ent-6 >500 −9.2
11 7 >500 −7.8
12 8 >500
13 9 >500
14 1 (+ve control) 0.9 ± 0.2 −10.2
Figure 4. Overlap of (−)-galanthamine (1) (blue) and the docked
derivatives 3 (A, purple) and ent-3 (B, peach) in the active site of
AChE.
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from Chinese medicinal plants.40 Interestingly, these new
natural products were also poor inhibitors of AChE.
The biological evaluation of the galanthamine derivatives and
analogues obtained by the pathways described above reveals the
ﬁnely tuned nature of the interactions of the parent alkaloid
with the target enzyme AChE. In particular, structurally
“modest” changes to the galanthamine framework, as embodied
in the oxygenated derivatives 2, ent-2, 3, and ent-3, can
completely disrupt binding such that the compounds are
rendered inactive. These studies have also revealed that the
computational prediction of the likely binding aﬃnity of
galanthamine analogues to AChE is fraught.
■ EXPERIMENTAL SECTION
General Protocols. Unless otherwise speciﬁed, proton (1H) and
carbon (13C) NMR spectra were recorded at room temperature in
base-ﬁltered CDCl3 on a spectrometer operating at 400 MHz for
proton and 100 MHz for carbon nuclei. The signal due to residual
CHCl3 appearing at δH 7.26 and the central resonance of the CDCl3
“triplet” appearing at δC 77.0 were used to reference
1H and 13C NMR
spectra, respectively. 1H NMR data are recorded as follows: chemical
shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral]
where multiplicity is deﬁned as s = singlet; d = doublet; t = triplet; q =
quartet; m = multiplet or combinations of the above. Infrared spectra
(νmax) were recorded on an FTIR spectrometer. Samples were
analyzed as thin ﬁlms or ﬁnely divided solids. Low-resolution ESI mass
spectra were recorded on a single quadrupole mass spectrometer
interfaced with a liquid chromatograph, whereas high-resolution
measurements were conducted on a time-of-ﬂight instrument. Low-
and high-resolution EI mass spectra were recorded on a magnetic-
sector machine. Melting points were measured on an automated
melting point system and are uncorrected. Analytical thin layer
chromatography (TLC) was performed on aluminum-backed 0.2 mm
thick silica gel 60 F254 plates. Eluted plates were visualized using a 254
nm UV lamp and/or by treatment with a suitable dip followed by
heating. These dips included phosphomolybdic acid:ceric sulfate:sul-
furic acid (concd):water (37.5 g: 7.5 g: 37.5 g: 720 mL), potassium
permanganate:potassium carbonate:5% w/v aq. sodium hydroxide
solution:water (3 g: 20 g: 5 mL: 300 mL)), p-anisaldehyde or
vanillin:sulfuric acid (concd):ethanol (15 g: 2.5 mL: 250 mL). Flash
chromatographic separations were carried out following protocols
deﬁned by Still et al.41 with silica gel 60 (40−63 μm) as the stationary
phase and using the AR- or HPLC-grade solvents indicated. The
melting points of solids puriﬁed by such means were recorded directly
(i.e., after they had crystallized from the concentrated chromatographic
fractions). Starting materials, reagents, drying agents, and other
inorganic salts were generally commercially available and used as
supplied. THF, methanol, and CH2Cl2 were dried using a solvent
puriﬁcation system that is based upon a technology originally
described by Grubbs et al.42
Speciﬁc Chemical Transformations (2R,3R,4aS,5S,8R,8aS)-6-(2-
Hydroxy-3-methoxy-phenyl)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-di -ol (13) and
Enantiomer ent-13. A magnetically stirred solution of bis-acetal
1115 (805 mg, 2.37 mmol), ester 12 (720 mg, 2.88 mmol), and
triethylamine (3 mL) in THF/water (20 mL of a 9:1 v/v mixture) was
subjected to sonication under an atmosphere of nitrogen for 0.5 h.
PdCl2dppf·CH2Cl2 (140 mg, 0.191 mmol) was then added, and the
ensuing mixture was heated under reﬂux for 2 h before being cooled
and quenched with phosphate buﬀer (5 mL of a 1 M aqueous solution
at pH 7). The mixture thus obtained was cooled to 0 °C, treated with
methanol/30% aq hydrogen peroxide (10 mL of a 1:1 v/v mixture),
and then allowed to warm to room temperature over 1 h. The
resulting mixture was diluted with water (50 mL) and extracted with
ethyl acetate (5 × 20 mL). The combined organic phases were washed
with brine (2 × 20 mL) before being dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The ensuing thick orange oil
was triturated with diethyl ether (5 × 2 mL), and the resulting yellow
solid was subjected to ﬂash column chromatography (silica, 4:15:1 v/v
ethyl acetate/hexane/methanol →12:7:1 v/v ethyl acetate/hexane/
methanol gradient elution). Concentration of the appropriate fractions
(Rf = 0.3 in 10:9:1 v/v/v ethyl acetate/hexane/methanol) aﬀorded
phenol 13 (618 mg, 68%) as a white powder: mp 202−210 °C; [α]20D
−93.8 (c 0.1, methanol); 1H NMR (400 MHz, CD3OD) δ 6.89 (dd, J
= 7.5 and 1.8 Hz, 1H), 6.83−6.73 (complex m, 2H), 5.76 (d, J = 2.5
Hz, 1H), 4.60 (d, J = 3.7 Hz, 1H), 4.23 (dd, J = 8.0 and 2.5 Hz, 1H),
4.09 (dd, J = 11.0 and 8.0 Hz, 1H), 3.85 (s, 3H), 3.69 (dd, J = 11.0 and
3.7 Hz, 1H), 3.34 (s, 3H), 3.28 (s, 3H), 1.34 (s, 3H), 1.33 (s, 3H)
(signals due to hydroxyl protons not observed); 13C NMR (100 MHz,
CD3OD) δ 149.0, 145.0, 138.9, 132.9, 128.6, 123.6, 120.3, 112.2,
100.7, 100.3, 71.4, 70.7, 69.7, 69.0, 56.6, 48.3, 48.2, 18.1(5), 18.1(0);
IR νmax 3456, 3283, 2941, 1589, 1468, 1218, 1129, 1119, 914, 594
cm−1; MS (ESI, +ve) m/z 788 ([(2 M + Na)+, 80%], 405 [(M + Na)+,
100]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for C19H26NaO8
405.1525, found 405.1526.
Compound ent-13 was prepared in an analogous fashion from ent-
11 (2.04 g, 5.34 mmol) to give 1.60 g (71%) of product; [α]20D +86.4
(c 0.1, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 13.
(2R,3R,4aS,5R,11aR,11bS)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,4a,5,11a,11b-hexahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-5-ol (14) and Enantiomer ent-14. A magnetically stirred
solution of phenol 13 (605 mg, 1.58 mmol) and PPh3 (456 mg, 1.74
mmol) in THF (70 mL) maintained at −5 °C was treated dropwise
over 0.5 h with di-iso-propyl azodicarboxylate (364 μL, 1.74 mmol).
The resulting solution was stirred at −5 °C for 4 h and then allowed to
warm to room temperature over 1 h before being concentrated under
reduced pressure. The orange oil thus obtained was subjected to two
successive ﬂash chromatographic separations (silica, hexane→ 1:1 v/v
ethyl acetate/hexane gradient elution), and concentration of
appropriate fractions (Rf = 0.7, 2:1 v/v ethyl acetate/hexane) aﬀorded
allylic alcohol 14 (193 mg, 33%) as a white foam; [α]20D −157 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.99 (dd, J = 7.5 and 1.2 Hz,
1H), 6.89 (apparent t, J = 7.5 Hz, 1H), 6.82 (dd, J = 8.1 and 1.2 Hz,
1H), 5.81 (m, 1H), 5.14 (dt, J = 9.0 and 3.6 Hz, 1H), 4.67−4.61
(complex m, 1H), 4.04 (dd, J = 10.5 and 9.0 Hz, 1H), 3.93 (dd, J =
10.5 and 7.7 Hz, 1H), 3.88 (s, 3H), 3.34 (s, 6H), 2.34 (d, J = 4.8 Hz,
1H), 1.36(3) (s, 3H), 1.35(9) (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 151.6, 145.4, 139.1, 125.7, 122.1, 116.2, 113.6, 113.5, 99.2, 98.9, 84.0,
74.1, 71.3, 70.1, 56.0, 48.4, 48.0, 17.7, 17.6; IR νmax 3486, 2959, 2897,
1614, 1597, 1494, 1445, 1133, 1114, 1098, 1035, 1015, 786 cm−1; MS
(ESI, +ve) m/z 752 [(2 M + Na)+, 25%], 387 [(M + Na)+, 100%];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C19H24NaO7 387.1420,
found 387.1423.
Compound ent-14 was prepared in an analogous fashion from ent-
13 (345 mg, 0.90 mmol) to give 314 mg (96%) of product; [α]20D
+102 (c 1.0, CHCl3). All the other spectral data acquired on this
material were identical with those reported above for compound 14.
N,N-Dimethyl-2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-trimethoxy-
2,3-dimethyl-2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-6a(4aH)-yl)acetamide (15) and Enantiomer ent-15. A
magnetically stirred solution of allylic alcohol 14 (180 mg, 0.494
mmol) in toluene (20 mL) maintained at 22 °C was treated with N,N-
dimethylacetamide dimethyl acetal (900 μL, 4.9 mmol), and the
resulting solution was heated under reﬂux for 18 h. The cooled
reaction mixture was concentrated under reduced pressure, and the
residue thus obtained was triturated with diethyl ether. The resulting
waxy solid was subjected to ﬂash chromatography (silica, 20:79:1 v/v
ethyl acetate/hexane/methanol → 60:39:1 v/v ethyl acetate/hexane/
methanol gradient elution), and concentration of appropriate fractions
(Rf = 0.2 in 2:1 v/v ethyl acetate/hexane) aﬀorded amide 15 (178 mg
84%) as a white foam; [α]20D −89.9 (c 1.0, CHCl3); 1H NMR (400
MHz, CDCl3) δ 6.83 (m, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.72 (d, J =
7.6 Hz, 1H), 6.02 (dd, J = 10.0 and 2.7 Hz, 1H), 5.74 (dd, J = 10.0 and
2.0 Hz, 1H), 5.04 (d, J = 9.6 Hz, 1H), 4.55 (dt, J = 9.6 and 2.0 Hz,
1H), 3.85 (s, 3H), 3.76 (t, J = 9.6 Hz, 1H), 3.30 (s, 3H), 3.16 (s, 3H),
2.89 (s, 3H), 2.78 (s, 3H), 2.71 (d, J = 15.8 Hz, 1H), 2.61 (d, J = 15.8
Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
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169.0, 145.6(4), 145.5(6), 134.2, 128.9, 126.9, 121.5, 115.3, 112.0,
99.8, 87.1, 70.5, 65.9, 56.1, 51.0, 48.1, 47.4, 42.5, 37.3, 35.3, 17.7(4),
17.7(0) (one signal obscured or overlapping); IR νmax 2954, 2889,
1651, 1491, 1459, 1380, 1276, 1115, 1061, 1000, 954, 739 cm−1; MS
(ESI, +ve) m/z 456 [(M + Na)+, 100%], 201 (35); HRMS (ESI, +ve)
m/z (M + Na)+ calcd for C23H31NNaO7 456.1998, found 456.2000.
Compound ent-15 was prepared in an analogous fashion from ent-
14 (234 mg, 0.64 mmol) to give 238 mg (86%) of product as a white
foam. A small sample was crystallized (diethyl ether/methanol/
hexane) to give a white, crystalline solid; mp 160−165 °C (dec);
[α]20D +87.1 (c 1.0, CHCl3). All of the other spectral data acquired on
this material were identical with those reported above for compound
15.
2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]benzofuran-6a-
(4aH)-yl)ethan-1-ol (16) and Enantiomer ent-16. A magnetically
stirred solution of amide 15 (146 mg, 0.337 mmol) in THF (17 mL)
maintained at 0 °C was treated dropwise with lithium triethylborohy-
dride (1.7 mL of a 1 M solution in THF, 1.7 mmol). The resulting
mixture was warmed to room temperature over 2 h, recooled to 0 °C,
quenched with methanol (2 mL), and then treated with silica (200 mg
of ﬂash chromatographic-grade material) before being subjected to
ﬂash chromatography (silica, 1:4 v/v ethyl acetate/hexane → 1:1 v/v
ethyl acetate/hexane gradient elution). Concentration of relevant
fractions (Rf = 0.6, 2:1 v/v ethyl acetate/hexane) aﬀorded compound
16 (122 mg, 92%) as a white foam; [α]20D −131.9 (c 1.8, CHCl3); 1H
NMR (400 MHz, CDCl3) δ 6.84 (apparent t, J = 7.8 Hz, 1H), 6.74
(m, 1H), 6.69 (dd, J = 7.5 and 1.2 Hz, 1H), 5.91 (broad d, J = 10.0 Hz,
1H), 5.70 (broad d, J = 10.0 Hz, 1H), 4.89 (d, J = 9.6 Hz, 1H), 4.31
(ddd, J = 9.6, 2.7, and 1.5 Hz, 1H), 3.84 (s, 3H), 3.72 (t, J = 9.6 Hz,
1H), 3.67−3.57 (complex m, 2H), 3.28 (s, 3H), 3.17 (s, 3H), 1.96 (dt,
J = 13.7 and 6.7 Hz, 1H), 1.85 (dt, J = 13.7 and 6.4 Hz, 1H), 1.40
(triplet, J = 5.2 Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H); 13C NMR (100
MHz, CDCl3) δ 145.7, 145.4, 133.6, 130.1, 126.4, 121.8, 114.9, 112.0,
99.9, 99.7, 86.9, 70.8, 65.4, 59.3, 56.1, 51.7, 48.0, 47.5, 43.5, 17.7, 17.6;
IR νmax 3508, 2948, 2837, 1619, 1588, 1491, 1459, 1281, 1130, 1116,
1036, 753, 736 cm−1; MS (ESI, +ve) m/z 415 [(M + Na)+, 100%];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C21H28NaO7 415.1733,
found 415.1733.
Compound ent-16 was prepared in an analogous fashion from ent-
15 (177 mg, 0.408 mmol) to give 160 mg (quantitative) of product;
[α]20D +108 (c 0.9, CHCl3). All of the other spectral data acquired on
this material were identical with those reported above for compound
16.
2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]benzofuran-6a-
(4aH)-yl)acetic Acid (17) and Enantiomer ent-17. A magnetically
stirred solution of alcohol 16 (122 mg, 0.310 mmol) in acetonitrile/
water (9:1 v/v, 2.3 mL) maintained at room temperature was treated
in one portion with 4-(acetylamino)-2,2,6,6-tetramethyl-1-oxo-piper-
idinium tetraﬂuoroborate (280 mg, 0.93 mmol). The resulting dark-
brown solution was stirred at 22 °C for 48 h (by which time it was a
pale-yellow color) and then poured into water (3 mL) and extracted
with diethyl ether (5 × 4 mL). The combined organic extracts were
washed with HCl (2 × 1 mL of a 1 M aqueous solution) and brine (2
× 5 mL) before being dried (Na2SO4), ﬁltered, and concentrated
under reduced pressure. The residue thus obtained was subjected to
ﬂash chromatography (silica, CH2Cl2 → 1:19 v/v methanol/CH2Cl2
gradient elution) and concentration of appropriate fractions (Rf = 0.2
in 1:19 v/v methanol/CH2Cl2) aﬀorded acid 17 (96 mg, 76%) as a
clear, colorless gum; [α]20D −88.5 (c 0.6, CHCl3); 1H NMR (400
MHz, CDCl3) δ 6.85 (m, 1H), 6.76 (d, J = 7.4 Hz, 1H), 6.74 (d, J =
7.4 Hz, 1H), 5.96 (dd, J = 10.0 and 2.6 Hz, 1H), 5.77 (d, J = 10.0 Hz,
1H), 5.17 (d, J = 9.7 Hz, 1H), 4.40 (d, J = 9.7 Hz, 1H), 3.85 (s, 3H),
3.75 (t, J = 9.7 Hz, 1H), 3.29 (s, 3H), 3.17 (s, 3H), 2.76 (d, J = 15.6
Hz, 1H), 2.63 (d, J = 15.6 Hz, 1H), 1.36 (s, 3H), 1.28 (s, 3H) (signal
due to carboxylic acid group proton not observed); 13C NMR (100
MHz, CDCl3) δ 174.8, 145.6, 132.9, 128.1, 127.9, 121.9, 115.0, 112.3,
99.9, 99.8, 86.0, 70.5, 65.5, 56.1, 50.9, 48.0, 47.5, 44.0, 17.7 (signals
due to two carbons obscured or overlapping); IR νmax 2950, 1710,
1712, 1619, 1491, 1459, 1284, 1128, 1116, 1034, 960, 732 cm−1; MS
(ESI, +ve) m/z 429 [(M + Na)+, 100%]; HRMS (ESI, +ve) m/z (M +
Na)+ calcd for C21H26NaO8 429.1525, found 429.1524.
Compound ent-17 was prepared in an analogous fashion from ent-
16 (150 mg, 0.382 mmol) to give 115 mg (80%) of product; [α]20D
+95.7 (c 1.2, CHCl3). All of the other spectral data acquired on this
material were identical with those reported above for compound 17.
N-Methyl-2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-trimethoxy-2,3-
dimethyl-2,3,-11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-6a(4aH)-yl)acetamide (5) and Enantiomer ent-5. A
magnetically stirred solution of acid 17 (93 mg, 0.23 mmol) in THF
(12 mL) maintained at room temperature was treated with 1,1′-
carbonyldiimidazole (49 mg, 0.30 mmol). The resulting solution was
heated under reﬂux for 1 h before being cooled to room temperature
and then placed in an ice bath at 0 °C. Methylamine (700 μL of a 2 M
solution in THF, 1.4 mmol) was then added dropwise, and the ensuing
solution was maintained at 0 °C for 3 h before being warmed to 22 °C
and stirred at this temperature for another 8 h. After this time, the
reaction mixture was diluted with ethyl acetate (40 mL) and washed
with NH4Cl (3 × 15 mL of a saturated aqueous solution). The
combined aqueous phases were extracted with ethyl acetate (3 × 10
mL), and the combined organic phases were washed with brine (2 ×
10 mL) before being dried (Na2SO4), ﬁltered, and concentrated under
reduced pressure. The residue thus obtained was subjected to ﬂash
chromatography (silica, 4:15:1 v/v ethyl acetate/hexane/methanol →
8:11:1 v/v ethyl acetate/hexane/methanol gradient elution) and
concentration of appropriate fractions (Rf = 0.3 in 10:9:1 v/v ethyl
acetate/hexane/methanol) gave amide 5 (76 mg, 79%) as a clear,
colorless oil; [α]20D −102.1 (c 1.2, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 6.81 (m, 1H), 6.72 (dd, J = 8.0 and 1.2 Hz, 1H), 6.68 (dd, J
= 7.5 and 1.2 Hz, 1H), 6.09 (dd, J = 10.0 and 2.6 Hz, 1H), 5.72 (dd, J
= 10.0 and 1.5 Hz, 1H), 5.36 (broad q, J = 4.8 Hz, 1H), 4.97 (d, J = 9.7
Hz, 1H), 4.37 (ddd, J = 9.7, 2.6, and 1.5 Hz, 1H), 3.81 (s, 3H), 3.71 (t,
J = 9.7 Hz, 1H), 3.27 (s, 3H), 3.13 (s, 3H), 2.71 (d, J = 4.8 Hz, 3H),
2.51 (d, J = 14.0 Hz, 1H), 2.42 (d, J = 14.0 Hz, 1H), 1.32 (s, 3H), 1.26
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.5, 145.5, 133.4, 128.7,
126.9, 121.6, 115.2, 112.1, 99.8, 99.7, 86.9, 70.3, 65.5, 56.0, 51.2, 48.0,
47.4, 46.8, 26.2, 17.7, 17.6 (signal due to one carbon obscured or
overlapping); IR νmax 3317, 2952, 2921, 1646, 1548, 1491, 1457, 1377,
1197, 1114, 1034, 999, 955, 735 cm−1; MS (ESI, +ve) m/z 442 [(M +
Na)+, 100%]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for
C22H29NNaO7 442.1842, found 442.1842.
Compound ent-5 was prepared in an analogous fashion from ent-17
(115 mg, 0.28 mmol) to give 91 mg (79%) of product; [α]20D +89.1 (c
1.3, CHCl3). All of the other spectral data acquired on this material
were identical with those reported above for compound 5.
2 - ( ( 5aR , 6R , 7 S , 9aS ) - 6 , 7 -D i h yd ro x y - 4 -me thoxy - 6 , 7 -
dihydrodibenzo[b,d]furan-9a(5aH)-yl)-N-methylacetamide (6) and
Enantiomer ent-6. A round-bottomed ﬂask charged with a magnetic
stirrer bar and amide 5 (16.7 mg, 0.04 mmol) was treated sequentially
with water (250 μL) and triﬂuoroacetic acid (250 μL) and the ensuing
mixture stirred at 22 °C for 0.5 h; then, the volatiles were removed
under reduced pressure. The residue thus obtained was subject to ﬂash
chromatography (silica, 5:4:1 v/v ethyl acetate/hexane/methanol) and
concentration of appropriate fractions (Rf = 0.3 in 8:1:1 v/v ethyl
acetate/hexane/methanol) aﬀorded diol 6 (8.1 mg, 66%) as a white
foam; [α]20D −11 (c 0.4, methanol); 1H NMR [400 MHz, (CD3)2CO]
δ 7.04 (broad s, 1H), 6.84−6.74 (complex m, 3H), 6.00 (dd, J = 10.1
and 2.3 Hz, 1H), 5.67 (dd, J = 10.1 and 1.5 Hz, 1H), 5.25 (d, J = 8.7
Hz, 1H), 4.75 (broad s, 1H), 4.22 (partially obscured and broad s,
1H), 4.18 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.40 (t, J = 8.7 Hz, 1H),
2.63 (d, J = 4.6 Hz, 3H), 2.48 (d, J = 13.9 Hz, 1H), 2.41 (d, J = 13.9
Hz, 1H); 13C NMR [100 MHz, (CD3)2CO] δ 170.7, 146.9, 146.2,
135.5, 131.6, 128.5, 122.1, 116.1, 113.3, 90.4, 75.8, 69.9, 56.4, 51.6,
46.8, 25.9; IR νmax 3315, 2943, 1642, 1491, 1272, 1199, 1179, 1132,
1064, 945, 723 cm−1; MS (ESI, +ve) m/z 634 [(2 M + Na)+, 40], 328
[(M + Na)+, 100]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for
C16H19NNaO5 328.1161, found 328.1158.
Compound ent-6 was prepared in an analogous fashion from ent-5
(16.7 mg, 0.04 mmol) to give 11.8 mg (97%) of product; [α]20D +16.7
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(c 1.0, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 6.
(4aR,5R,6S,8aS)-5,6-Dihydroxy-3-methoxy-11-methyl-4a,5,11,12-
tetrahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-10(9H)-one (2)
and Enantiomer ent-2. A magnetically stirred solution of amide 5
(56 mg, 0.133 mmol) in acetonitrile (14 mL) was treated sequentially
with paraformaldehyde (20 mg, 0.67 mmol) and triﬂuoroacetic acid
(63 μL, 0.82 mmol). The resulting solution was stirred at room
temperature for 8 h and then quenched with phosphate buﬀer (15 mL
of a 1 M aqueous solution at pH 7) and extracted with CH2Cl2 (3 ×
10 mL). The combined organic extracts were washed with brine (1 × 5
mL) and dried (Na2SO4) before being ﬁltered and then concentrated
under reduced pressure. The residue thus obtained was subjected to
ﬂash chromatography (silica, 4:15:1 v/v ethyl acetate/hexane/
methanol → 8:1:1 v/v ethyl acetate/hexane/methanol gradient
elution) and concentration of the appropriate fractions (Rf = 0.4 in
8:1:1 v/v ethyl acetate/hexane/methanol) aﬀorded lactam 2 (19.7 mg,
47%) as a white, amorphous solid; [α]20D −139 (c 0.4, methanol). 1H
NMR (400 MHz, CDCl3) δ 6.71 (apparent s, 2H), 5.97 (dd, J = 10.2
and 4.7 Hz, 1H), 5.58 (d, J = 10.2 Hz, 1H), 4.78−4.73 (complex m,
1H), 4.67−4.63 (complex m, 1H), 4.53 (d, J = 16.0 Hz, 1H), 4.32 (d, J
= 16.0 Hz, 1H), 4.12 (m, 1H), 3.85 (s, 3H), 3.18 (d, J = 14.2 Hz, 1H),
3.07 (d, J = 14.2 Hz, 1H), 3.04 (s, 3H) (signals due to hydroxyl group
protons not observed); 13C NMR (100 MHz, CDCl3) δ 171.8, 145.9,
144.8, 131.9, 128.7, 125.7, 125.1, 120.4, 111.9, 88.4, 68.5, 67.0, 56.1,
52.1, 43.2, 42.3, 35.9; IR νmax 3357, 2924, 1623, 1508, 1438, 1280,
1101, 1070, 1031, 971, 880, 793 cm−1; MS (ESI, +ve) m/z 657 [(2 M
+ Na)+, 40%], 340 [(M + Na)+, 100]; HRMS (ESI, +ve) m/z (M +
Na)+ calcd for C17H19NNaO5 340.1161, found 340.1159.
Compound ent-2 was prepared in an analogous fashion from ent-5
(20 mg, 0.048 mmol) to give 9.5 mg (63%) of product as a white,
amorphous solid. A small sample was recrystallized (diethyl ether) to
give a white, crystalline solid; mp 135−140 °C; [α]20D +127 (c 0.4,
methanol). All of the other spectral data acquired on this material were
identical with those reported above for compound 2.
(4aR,5R,6S,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahy-
dro-6H-benzo[2,3]-benzofuro[4,3-cd]azepine-5,6-diol (3) and
Enantiomer ent-3. A magnetically stirred solution of lactam 2 (9.5
mg, 0.03 mmol) in THF (5 mL) maintained at room temperature was
treated with NaAlH2(OCH2CH2OCH3) 2 (60 μL of a 60% w/v
solution in toluene, 0.184 mmol) and the ensuing mixture heated
under reﬂux for 24 h after which time it was cooled to 0 °C (ice-bath),
quenched with potassium sodium tartrate (2 mL of a saturated
aqueous solution), diluted with water (10 mL) and then extracted with
CHCl3 (3 × 5 mL). The combined organic extracts were washed with
brine (1 × 2 mL) before being dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:19 v/v NH3 saturated
methanol/CHCl3→ 1:9 v/v NH3 saturated methanol/CHCl3 gradient
elution) and concentration of appropriate fractions (Rf = 0.2 in 1:9 v/v
NH3 saturated methanol/CHCl3) aﬀorded amine 3 (4.0 mg, 44%) as a
white, amorphous solid; [α]20D −86.6 (c 0.3, CDCl3); 1H NMR (400
MHz, CDCl3) δ 6.66 (d, J = 8.2 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H),
6.23 (d, J = 10.2 Hz, 1H), 5.93 (dd, J = 10.2 and 3.8 Hz, 1H), 4.57 (d,
J = 4.6 Hz, 1H), 4.30 (m, 1H), 4.19−4.09 (complex m, 2H), 3.84 (s,
3H), 3.63 (m, 1H), 3.27 (m, 1H), 2.98 (broad d, J = 14.8 Hz, 1H),
2.34 (s, 3H), 2.18 (m, 1H), 1.81 (dd, J = 13.4 and 2.2 Hz, 1H) (signals
due to hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ 145.4, 144.0, 132.3, 129.1, 128.1, 126.6, 122.4, 111.1, 90.9,
72.4, 67.6, 60.1, 55.9, 54.2, 49.8, 42.0, 36.0; IR νmax 3345, 2921, 1626,
1596, 1507, 1439, 1282, 1041, 948, 793, 726 cm−1; MS (ESI, +ve) m/z
629 [(2 M + Na)+, 30%], 326 [(M + Na)+, 100], 304 [(M + H)+, 7];
HRMS (ESI, +ve) m/z (M + H)+ calcd for C17H22NO4 304.1549,
found 304.1544.
Compound ent-3 was prepared in an analogous fashion from ent-2
(9.5 mg, 0.030 mmol) to give 4.0 mg (44%) of product, [α]20D +60.5
(c 0.4, CDCl3). All of the other spectral data acquired on this material
were identical with those reported above for compound 3.
2 - ( ( 5aR , 6R , 7 S , 9aS ) - 6 , 7 -D i h yd ro x y - 4 -me thoxy - 6 , 7 -
dihydrodibenzo[b,d]furan-9a-(5aH)-yl)-N,N-dimethylacetamide (4)
and Enantiomer ent-4. Amide 15 (15 mg, 0.035 mmol) was treated
triﬂuoroacetic acid/water (200 μL of a 1:1 v/v mixture), and the
resulting mixture was stirred at 22 °C for 0.5 h; then, the volatiles were
removed under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:19 v/v methanol/
CH2Cl2), and concentration of the relevant fractions (Rf = 0.1)
aﬀorded diol 4 (9.8 mg, 88%) as a clear, colorless oil; [α]20D +5.7 (c
0.9, CH3OH);
1H NMR (400 MHz, CDCl3) δ 6.86 (m, 1H), 6.78−
6.73 (complex m, 2H), 5.98 (d, J = 9.9 Hz, 1H), 5.83 (d, J = 9.9 Hz,
1H), 5.01 (d, J = 7.5 Hz, 1H), 4.45 (broad s, 1H), 3.85 (s, 3H), 3.71
(m, 1H), 2.88 (s, 3H), 2.81 (s, 3H), 2.79 (m, 1H), 2.58 (d, J = 15.8
Hz, 1H) (signals due to hydroxyl protons not observed); 13C NMR
(100 MHz, CDCl3) δ 169.7, 145.5, 145.3, 134.1, 129.4, 128.5, 122.0,
115.4, 111.9, 90.5, 74.4, 69.2, 56.1, 50.1, 42.7, 37.5, 35.6; IR νmax 3389,
2927, 1616, 1489, 1457, 1402, 1271, 1093, 1058, 941, 749, 731 cm−1;
MS (ESI, +ve) m/z 661 [(2 M + Na)+, 40%], 342 [(M + Na)+, 100];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C17H21NNaO5 342.1317,
found 342.1311.
Compound ent-4 was prepared in an analogous fashion from ent-15
(23.7 mg, 0.055 mmol) to give 13.4 mg (77%) of product; [α]20D −8.2
(c 1.3, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 4.
(1S,2S,3S,6S)-4-Bromo-6-((4-methoxybenzyl)oxy)cyclohex-4-ene-
1,2,3-triol (21). Step i. BF3·OEt2 (100 μL of a 10% v/v solution in
CH2Cl2) was added dropwise over 0.25 h to a magnetically stirred
solution of epoxide 2023 (2.00 g, 8.09 mmol) and p-methoxybenzyl
alcohol (23.8 g, 175 mmol) in dry CH2Cl2 (80 mL) maintained at −20
°C. The resulting solution was allowed to warm to −10 °C over 2 h
after which time a second aliquot of BF3·OEt2 (150 μL of a 10% v/v
solution in CH2Cl2) was added dropwise over 0.25 h. The reaction
mixture thus formed was warmed to 22 °C over 12 h then quenched
with phosphate buﬀer (3 mL of a 1 M aqueous solution at pH 7), and
the solvent was then removed under reduced pressure. The residue
thus obtained, which was comprised of a mixture of the desired PMB-
ether and p-methoxybenzyl alcohol, was submitted directly to step ii as
detailed immediately below.
Step ii. A magnetically stirred solution of the material obtained from
step i in methanol (160 mL) was treated with pyridinium p-
toluenesulfonate (2.03 g, 8.09 mmol) and the mixture so-formed was
heated at 50 °C for 48 h; then, it was cooled to 22 °C and treated with
NaHCO3 (500 mg), and the solvent was removed under reduced
pressure. The residue thus obtained was treated with ethyl acetate
(200 mL) and then water (100 mL), and the separated aqueous layer
was extracted with ethyl acetate (4 × 50 mL). The combined organic
phases were washed with brine (1 × 30 mL) and then dried (Na2SO4),
ﬁltered, and concentrated under reduced pressure. The resulting
yellow oil was subjected to ﬂash column chromatography (silica,
CH2Cl2 → 1:19 v/v methanol/CH2Cl2 gradient elution), and
concentration of appropriate fractions (Rf = 0.2 in 1:19 v/v
methanol/CH2Cl2) aﬀorded triol 21 (1.98 g, 71% from 20) as a
white foam; [α]20D +132.1 (c 1.1, CHCl3);
1H NMR [400 MHz,
(CD3)2CO] δ 7.32 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.14
(d, J = 2.4 Hz, 1H), 4.67 (s, 2H), 4.58 (d, J = 5.1 Hz, 1H), 4.27−4.20
(complex m, 2H), 4.03 (broad s, 1H), 3.86 (dd, J = 7.4 and 2.0 Hz,
1H), 3.82 (broad d, J = 9.7 Hz, 1H), 3.78 (s, 3H), 3.54 (m, 1H); 13C
NMR [100 MHz, (CD3)2CO] δ 160.2, 132.8, 131.8, 130.2, 124.8,
114.4, 80.8, 74.1, 72.3(2), 72.2(5), 71.8, 55.5; IR (KBr) νmax 3437,
2918, 2848, 1732, 1449, 1368, 1241, 1072, 1026 cm−1; MS (ESI, +ve)
m/z 369 and 367 [(M + Na)+, 100 and 98%]; HRMS (ESI, +ve) m/z
(M + Na)+ calcd for C14H17
79BrNaO5 367.0155, found 367.0157.
(2S,3S,4aR,5S,8S,8aR)-6-Bromo-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-diol (ent-11). A
magnetically stirred solution of triol 21 (2.57 g, 7.44 mmol), 2,2,3,3-
tetramethoxybutane (1.91 g, 10.7 mmol), and trimethyl orthoformate
(3.40 mL, 31.1 mmol) in dry methanol (50 mL) was treated with p-
TsOH·H2O (73 mg, 5 mol %). The resulting mixture was heated
under reﬂux for 24 h, cooled to 22 °C, and treated with NaHCO3
(2.00 g), and the solvent was removed under reduced pressure. The
residue thus obtained was treated with ethyl acetate (100 mL) and
then NaHCO3 (30 mL of a saturated aqueous solution). The separated
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organic phase was washed with NaHCO3 (1 × 30 mL of a saturated
aqueous solution) and water (1 × 30 mL), and then the combined
aqueous layers were extracted with ethyl acetate (3 × 30 mL). The
combined organic phases were washed with brine (2 × 20 mL) and
then dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The resulting thick, orange oil was subjected to ﬂash column
chromatography (silica, 1:20 v/v methanol/CH2Cl2 elution), and
concentration of appropriate fractions (Rf = 0.3) aﬀorded bis-acetal
ent-11 (2.14 g, 85%) as a white foam; [α]20D +72.6 (c 1.1, CHCl3)
{lit.15 (for 11); [α]20D −76.5 (c 1.0, CHCl3)}; 1H NMR (400 MHz,
CD3OD) δ 6.05 (d, J = 2.5 Hz, 1H), 4.22 (d, J = 4.1 Hz, 1H), 4.06
(dd, J = 7.9 and 2.5 Hz, 1H), 3.87 (dd, J = 11.1 and 7.9 Hz, 1H), 3.63
(dd, J = 11.1 and 4.1 Hz, 1H), 3.30 (s, 3H), 3.25 (s, 3H), 1.32 (s, 3H),
1.29 (s, 3H) (signals due to hydroxyl group protons not observed);
13C NMR (100 MHz, CD3OD) δ 135.2, 124.0, 100.8, 100.2, 73.1,
71.8, 69.8, 69.2, 48.3, 48.2, 18.1, 18.0; IR (KBr) νmax 3160, 2940, 1636,
1454, 1375, 1136, 1077, 1031, 980, 915 cm−1; MS (ESI, +ve) m/z 363
and 361 [(M + Na)+, 95 and 100%]; HRMS (ESI, +ve) (M+Na)+
calcd for C12H19
79BrNaO6 361.0263, found 361.0263.
3-Bromo-4-hydroxy-5-methoxybenzaldehyde (23). A magneti-
cally stirred solution of vanillin (22) (4.00 g, 26.3 mmol) in acetic
acid (10 mL) was treated with molecular bromine (1.34 mL, 0.03
mol), and the ensuing mixture was stirred at 22 °C for 3 h during
which time a precipitate appeared. The reaction mixture was quenched
with water (30 mL), and the precipitate was ﬁltered oﬀ, washed with
water (1 × 50 mL) and then methanol (1 × 20 mL) before being dried
under vacuum to aﬀord compound 2328 (5.40 g, 90%) as a white,
crystalline solid; mp 164 °C (lit.28 mp 160−162 °C); 1H NMR
(CDCl3, 400 MHz) δ 9.79 (s, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.36 (d, J
= 1.7 Hz, 1H), 6.52 (s, 1H), 3.99 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 189.6, 148.9, 147.7, 130.1, 130.0, 108.2, 108.0, 56.6; IR νmax
3305, 2980, 1674, 1590, 1463, 1290, 1157, 1047, 680 cm−1; MS (ESI,
+ ev) m/z 255 and 253 [(M+Na)+, 100 and 99%]; HRMS (ESI, +ve)
(M+Na)+ calcd for C8H7
79BrNaO3 252.9476, found 252.9479.
2-Bromo-4-(1,3-dioxolan-2-yl)-6-methoxyphenol (24). Com-
pound 23 (5.00 g, 21.8 mmol), toluene (120 mL), p-TsOH·H2O
(39 mg, 0.21 mmol) and ethylene glycol (3.60 mL, 65.2 mmol) were
placed in a round-bottom ﬂask ﬁtted with a Dean−Stark trap and
condenser. The ensuing mixture was heated under reﬂux for 5 h before
being cooled, quenched with NaHCO3 (100 mL of a saturated
solution), and extracted with ethyl acetate (1 × 100 mL). The organic
phase was dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure, and the light-yellow oil thus obtained was subjected ﬂash
chromatography (silica, 5:1 v/v hexane/ethyl acetate elution).
Concentration of the relevant fractions (Rf = 0.4 in 1:9 v/v ethyl
acetate/hexane) gave compound 24 (3.30 g, 55%) as a light-yellow oil.
1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 1.5 Hz, 1H), 6.94 (d, J =
1.5 Hz, 1H), 5.97 (s, 1H), 5.71 (s, 1H), 4.14−4.11 (complex m, 2H),
4.04−3.98 (complex m, 2H), 3.92 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 147.2, 143.8, 130.7, 123.2, 108.0, 107.9, 102.9, 65.2, 56.4; IR
νmax 3358, 2963, 2887, 1684, 1603, 1589, 1503, 1466, 1426, 1280,
1181, 1090, 1044 cm−1; MS (ESI, +ve) m/z 299 and 297 [(M+Na)+,
92 and 100%] 277 and 275 [(M+H)+, 45 and 40]; HRMS (ESI, +ve)
(M+H)+ calcd for C10H12
79BrO4 274.9919, found 274.9921.
2-(3-Bromo-5-methoxy-4-(methoxymethoxy)phenyl)-1,3-dioxo-
lane (25). A magnetically stirred mixture of phenol 24 (3.23 g, 11.79
mmol) in dry THF (30 mL) maintained at 0 °C was treated with NaH
(564 mg of a 60% suspension in oil, 14.2 mmol). After 0.5 h, the
reaction mixture was treated with chloromethyl methyl ether (980 μL,
12.9 mmol) and then stirred at 22 °C for 18 h before being quenched
with water (100 mL; CAUTION! possibility of hydrogen gas
evolution). The separated aqueous layer was extracted with diethyl
ether (3 × 30 mL), and the combined organic phases were washed
with brine (1 × 30 mL) and then dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to ﬂash chromatography (silica, 1:4 v/v ethyl acetate/hexane
elution) and gave, after concentration of the relevant fractions (Rf =
0.5 in 1:3 v/v ethyl acetate/hexane), bromide 25 (2.65 g, 70%) as a
clear, colorless oil; 1H NMR (CDCl3, 400 MHz) δ 7.28 (d, J = 1.9 Hz,
1H), 6.98 (d, J = 1.9 Hz, 1H), 5.74 (s, 1H), 5.17 (s, 2H), 4.13−4.01
(complex m, 4H), 3.86 (s, 3H), 3.64 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 153.3, 143.9, 135.1, 123.1, 117.6, 109.6, 102.6, 98.6, 65.3,
58.0, 56.1; IR νmax 2941, 2891, 2839, 1696, 1570, 1484, 1463, 1416,
1384, 1274, 1157, 1081, 1043, 942, 854 cm−1; MS (EI, 70 eV) m/z
320 and 318 (M+•, 99 and 100%), 289 and 287 (55 and 53), 239 (85),
166 (25); HRMS (EI, 70 eV) M+• calcd for C12H15
79BrO5 318.0103,
found 318.0104.
4-Hydroxy-3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)benzaldehyde (27). Step i. A magnetically stirred mixture of
bromide 25 (1.30 g, 4.15 mmol) in dry THF (15 mL) maintained at
−78 °C was treated with n-BuLi (3.1 mL of a 1.6 M solution in THF,
5.0 mmol). After 1 h, the reaction mixture was treated with tri-iso-
propyl borate (1.9 mL, 8.3 mmol) and then stirred at 22 °C for 15 h
before being quenched with HCl (10 mL of a 10% w/v aqueous
solution). The separated aqueous layer was extracted with ethyl acetate
(3 × 50 mL), and the combined organic phases were washed with
brine (1 × 50 mL) before being dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The residue thus obtained, and
which is presumed to contain boronic acid 26, was subjected directly
to step ii of the reaction sequence.
Step ii. A magnetically stirred mixture of the product obtained from
step i in dry acetonitrile (40 mL) maintained at 0 °C was treated with
sodium iodide (0.62 g, 14.5 mmol) and chlorotrimethylsilane (530 μL,
14.5 mmol). The resulting solution was warmed to 22 °C over 4 h and
then treated with Na2S2O3 (20 mL of a saturated aqueous solution).
The separated aqueous layer was extracted with ethyl acetate (3 × 20
mL), and the combined organic phases were washed with brine (1 ×
20 mL) before being dried (Na2SO4), ﬁltered, and concentrated under
reduced pressure. The residue thus obtained was immediately
subjected to step iii of the reaction sequence.
Step iii. A magnetically stirred suspension of the product obtained
from step ii in benzene (30 mL) was treated with pinacol (990 mg,
8.40 mmol), and the solution thus obtained was heated under reﬂux
for 2 h in an apparatus ﬁtted with a Dean−Stark trap and a condenser.
The cooled reaction mixture was treated with water (20 mL), and the
separated aqueous layer was extracted with ethyl acetate (3 × 20 mL).
The combined organic phases were then washed with brine (1 × 50
mL) before being dried (Na2SO4), ﬁltered, and concentrated under
reduced pressure. The residue thus obtained was subjected to ﬂash
chromatography (silica, 2:3 v/v diethyl ether/hexane elution) to
aﬀord, after concentration of the relevant fractions (Rf = 0.4), boronic
ester 27 (520 mg, 45% from 25) as a white, crystalline solid; mp 73
°C; 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 8.33 (s, 1H), 7.72 (d,
J = 1.9 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 3.93 (s, 3H), 1.38 (s, 12H);
13C NMR (CDCl3, 100 MHz) δ 190.9, 158.6, 148.3, 133.8, 129.6,
111.7, 85.1, 56.0, 24.8; IR νmax 3407, 2992, 2931, 2830, 2797, 2714,
1683, 1620, 1587, 1467, 1388, 1372, 1298, 1256, 1140, 1056, 980, 846,
674 cm−1; MS (EI, 70 eV) m/z 278 (M+•, 38%), 221 (100), 178 (51),
177 (30); HRMS (EI, 70 eV) M+• calcd for C14H19BO5 278.1326,
found 278.1326.
(3aS,4S,5S,7aS)-7-Bromo-2,2-dimethyl-5-((triiso-propylsilyl)oxy)-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (29). Tri-iso-propylsilyl
triﬂuoromethanesulfonate (1.95 mL, 7.3 mmol) was added dropwise
to a magnetically stirred solution of compound 2829 (1.40 g, 5.3
mmol) and 2,6-lutidine (2.5 mL, 21.5 mmol) in CH2Cl2 (30 mL)
maintained at −78 °C under a nitrogen atmosphere. The ensuing
mixture was allowed to warm to 22 °C over 3 h and then treated with
NH4Cl (60 mL of a saturated aqueous solution). The separated
aqueous phase was extracted with CH2Cl2 (1 × 20 mL), and the
combined organic phases were dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The resulting light yellow oil
was subjected to ﬂash chromatography (silica, 3:100 v/v ethyl acetate/
hexane elution) and gave, after concentration of the appropriate
fractions (Rf = 0.3 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane),
an ∼6:1 mixture of compound 29 and its regioisomeric silyl ether
(1.95 g, 88% combined yield) as a light-yellow oil; 1H NMR (400
MHz, CDCl3) δ 6.42 (s, 1H), 4.66 (d, J = 6.6 Hz, 1H), 4.17 (m, 1H),
4.11 (m, 1H), 3.55 (t, J = 8.7 Hz, 1H), 2.45 (s, 1H), 1.54 (s, 3H), 1.40
(s, 3H), 1.15−1.04 (complex m, 21H); 13C NMR (100 MHz, CDCl3)
δ 144.5, 110.2, 92.2, 79.3, 77.0, 74.5, 73.6, 28.0, 25.7, 18.0(1), 17.9(9),
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12.4; IR νmax 3469, 2943, 2893, 2866, 1635, 1463, 1382, 1248, 1070,
1019, 997, 882, 866, 828 cm−1; MS (ESI, +ve) m/z 445 and 443 [(M
+Na)+, 100 and 97%]; HRMS (ESI, +ve) (M + Na)+ calcd for
C18H33
79BrNaO4Si 443.1229, found 443.1232.
(((3aR,4R,5S,7aS)-7-Bromo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-4-yl)oxy)tri-iso-propylsilane (30).
Sodium hydride (342 mg of a 60% dispersion in mineral oil, 8.6
mmol) was added to a magnetically stirred solution of an ∼6:1 mixture
of compound 29 and its regioisomer (1.20 g, 2.9 mmol) and
iodomethane (391 μL, 6.3 mmol) in dry THF (20 mL) maintained at
0 °C under a nitrogen atmosphere. Stirring was continued for 2 h at 22
°C, and then the reaction mixture was treated with ice-water (70 mL)
(CAUTION! possibility of hydrogen evolution). The separated
aqueous phase was extracted with ethyl acetate (1 × 30 mL), and
the combined organic phases were then dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/ hexane), an ∼5:1
mixture of compound 30 and its regioisomer (612 mg, 49% combined
yield) as a yellowish oil; 1H NMR (400 MHz, CDCl3) δ (major
regioisomer) 6.16 (m, 1H), 4.63 (m, 1H), 4.47 (m, 1H), 4.36 (m, 1H),
3.86 (m, 1H), 3.41 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.12−0.95
(complex m, 21H); 13C NMR (100 MHz, CDCl3) δ (major
regioisomer) 129.4, 122.3, 110.0, 77.3, 77.2(3), 77.2(2), 69.9, 57.3,
27.5, 26.2, 18.0(2), 17.9(5), 12.5; IR νmax 2939, 2892, 2866, 1645,
1463, 1381, 1234, 1163, 1078, 1039, 1011, 941, 882, 815, 680 cm−1;
MS (ESI, +ve) m/z 459 and 457 [(M+Na)+, 98 and 96%], 355 (100),
347 and 345 (67 and 65); HRMS (ESI, +ve) (M+Na)+ calcd for
C19H35
79BrNaO4Si 457.1386, found 457.1389.
(3aS,4R,5S,7aS)-7-Bromo-5-methoxy-2,2-dimethyl-3a,4,5,7a-tet-
rahydrobenzo-[d][1,3]dioxol-4-ol (31). A magnetically stirred sol-
ution of an ∼5:1 mixture of compound 30 and its regioisomer (600
mg, 1.4 mmol) in THF (10 mL) maintained at 22 °C under a nitrogen
atmosphere was treated with tetra-n-butylammonium ﬂuoride (2 mL
of 1.0 M solution in THF, 2.0 mmol). After 2 h, the reaction mixture
was concentrated under reduced pressure, and the residue so-formed
was subjected to ﬂash chromatography (silica, 1:2 v/v ethyl acetate/
hexane elution) to provide, after concentration of the appropriate
fractions (Rf = 0.4 in 4:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane),
compound 31 (377 mg, 98%) as a light-yellow oil; [α]20D −15.7 (c 2.4,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.28 (s, 1H), 4.68 (d, J = 6.5
Hz, 1H), 4.15 (m, 1H), 3.66 (m, 2H), 3.48 (s, 3H), 2.64 (broad s,
1H), 1.55 (s, 3H), 1.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
132.2, 118.8, 111.0, 80.3, 77.5, 77.2, 72.5, 57.5, 28.1, 25.9; IR νmax
3453, 2987, 2934, 2826, 1646, 1457, 1381, 1217, 1164, 1074, 869
cm−1; MS (EI, 70 eV) m/z 280 and 278 (M+•, both 3%), 265 and 263
(both 35%), 101 (100); HRMS (EI, 70 eV) M+• calcd for
C10H15
79BrO4 278.0154, found 278.0148.
4-Hydroxy-3-((3aR,6S,7R,7aS)-7-hydroxy-6-methoxy-2,2-dimeth-
yl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-methoxybenzal-
dehyde (32). A magnetically stirred solution of compound 31 (150
mg, 0.54 mmol), ester 27 (180 mg, 0.65 mmol), PdCl2dppf·CH2Cl2
(31.5 mg, 0.04 mmol), and triethylamine (3 mL) in THF/water (18
mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h and then
heated under reﬂux for 2 h before being cooled, poured into water (50
mL), and extracted with ethyl acetate (3 × 30 mL). The combined
organic phases were washed with brine (1 × 40 mL) and then dried
(Na2SO4), ﬁltered, and concentrated under reduced pressure. The
ensuing light-yellow oil was subjected to ﬂash chromatography (silica,
1:4 v/v ethyl acetate/hexane elution), and concentration of the
relevant fractions (Rf = 0.5 in 1:3 v/v ethyl acetate/hexane) aﬀorded
phenol 32 (85 mg, 45%) as a white, crystalline solid; mp 129 °C,
[α]20D +16.0 (c 0.2, CHCl3);
1H NMR (400 MHz, CDCl3) δ 9.83 (s,
1H), 7.45 (d, J = 1.8 Hz, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.09 (s, 1H),
6.19 (d, J = 1.3 Hz, 1H), 5.17 (d, J = 6.4 Hz, 1H), 4.27 (dd, J = 8.9 and
6.4 Hz, 1H), 3.98 (s, 3H), 3.86 (m, 1H), 3.79 (m, 1H), 3.54 (s, 3H),
2.71 (broad s, 1H), 1.53 (s, 3H), 1.40 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 190.9, 149.2, 147.7, 132.3, 131.7, 129.2, 128.2, 125.1, 110.7,
108.4, 79.9, 77.7, 73.9, 72.9, 57.5, 56.4, 28.2, 26.0; IR νmax 3400, 2986,
2935, 2830, 1681, 1588, 1488, 1455, 1432, 1373, 1301, 1254, 1217,
1148, 1067, 990, 863, 732 cm−1; MS (EI, 70 eV) m/z 350 (M+•, 5%),
292 (53), 260 (55), 232 (100), 231 (72), 218 (53), 203 (39), 189
(33); HRMS (EI, 70 eV) M+• calcd for C18H22O7 350.1366, found
350.1369.
(2′R,3′R,4′S,5′S)-2′ ,3′ ,4′ ,6-Tetrahydroxy-5,5′-dimethoxy-
2′,3′,4′,5′-tetrahydro-[1,1′-biphenyl]-3-carbaldehyde (33). Com-
pound 32 (60 mg, 0.17 mmol) was treated with acetic acid/water
(10 mL of a 2:1 v/v mixture), and the resulting mixture was stirred at
22 °C for 18 h and then cooled and concentrated under reduced
pressure. Subjection of the residue thus obtained to ﬂash
chromatography (silica, 1:8:1 v/v/v methanol/ethyl acetate/hexane
elution) gave, after concentration of the appropriate fractions (Rf =
0.4), compound 33 (43 mg, 81%) as a white powder; mp 191 °C;
[α]20D +7.5 (c 0.1, CHCl3);
1H NMR [400 MHz, (CD3)2CO] δ 9.83
(s, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.39 (d, J = 1.9 Hz, 1H), 6.03 (d, J =
2.5 Hz, 1H), 4.63 (d, J = 3.8 Hz, 1H), 3.97 (m, 1H), 3.92 (s, 3H), 3.84
(dd, J = 7.6 and 2.5 Hz, 1H), 3.62 (dd, J = 10.3 and 3.8 Hz, 1H), 3.49
(s, 3H), 2.83 (broad, s, 3H) (signal due to a hydroxyl group proton
not observed); 13C NMR [100 MHz, (CD3)2CO] δ 191.3, 151.3,
149.5, 137.4, 132.1, 129.9, 128.6, 128.4, 110.1, 82.9, 72.7, 71.8, 70.2,
57.6, 56.6; IR νmax 3346, 2926, 2839, 2821, 1678, 1586, 1454, 1429,
1383, 1298, 1257, 1145, 1106, 1070, 943, 858, 696 cm−1; MS (ESI,
+ve) m/z 643 [(2M + Na)+, 35%], 333 [(M + Na)+, 100]; HRMS
(ESI, +ve) (M+Na)+ calcd for C15H18NaO7 333.0950, found 333.0952.
(5aS,6S,7S,8S)-6,7-Dihydroxy-4,8-dimethoxy-5a,6,7,8-
tetrahydrodibenzo[b,d]-furan-2-carbaldehyde (7). A magnetically
stirred solution of phenol 33 (40 mg, 0.13 mmol) in THF (12 mL)
was treated with Ph3P (40 mg, 0.15 mmol), cooled to 0 °C, and
treated dropwise with a solution of di-iso-propyl azodicarboxylate (25
μL, 0.13 mmol) in THF (1 mL). The reaction mixture thus obtained
was stirred at 0 °C for 2 h and then concentrated under reduced
pressure, and the ensuing light-yellow oil was subjected to ﬂash
chromatography (silica, 3:97 v/v methanol/CH2Cl2 elution). Con-
centration of the relevant fractions (Rf = 0.4 in 0.5:9.5 v/v methanol/
CH2Cl2) aﬀorded benzofuran 7 (32 mg, 85%) as a clear, light-yellow
oil; [α]20D +92.0 (c 0.2, CHCl3);
1H NMR [400 MHz, (CD3)2CO] δ
9.87 (s, 1H), 7.69 (d, J = 1.5 Hz, 1H), 7.44 (d, J = 1.5 Hz, 1H), 6.19 (t,
J = 3.6 Hz, 1H), 5.09 (m, 1H), 4.94 (s, 1H), 4.48 (broad s, 1H), 4.09
(m, 1H), 3.95 (s, 3H), 3.81−3.77 (complex m, 2H), 3.49 (s, 3H); 13C
NMR [100 MHz, (CD3)2CO] δ 191.1, 157.6, 146.9, 138.0, 133.1,
127.7, 118.2, 117.6, 114.0, 89.1, 83.8, 77.3, 75.6, 57.5, 56.6; IR νmax
3339, 2926, 2892, 2853, 2823, 1686, 1604, 1590, 1437, 1337, 1313,
1185, 1119, 1092, 1069, 997, 920, 721, 694 cm−1; MS (ESI, +ve) m/z
607 [(2M + Na)+, 40%], 315 [(M + Na)+, 100], 293 (23), 195 (30);
HRMS (ESI, +ve) (M + Na)+ calcd for C15H16NaO6 315.0845, found
315.0847.
(3aS,4S,5R,7aS)-7-Bromo-2,2-dimethyl-5-((tri-iso-propylsilyl)oxy)-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (35). Tri-iso-propylsilyl
triﬂuoromethanesulfonate (620 μL, 2.3 mmol) was added dropwise to
a magnetically stirred solution of compound 3431 (500 mg, 1.9 mmol)
and 2,6-lutidine (880 μL, 7.6 mmol) in CH2Cl2 (15 mL) maintained at
−78 °C under a nitrogen atmosphere. The ensuing mixture was
allowed to warm to 22 °C over 3 h and then treated with NH4Cl (30
mL of a saturated aqueous solution). The separated aqueous phase was
extracted with CH2Cl2 (1 × 10 mL), and the combined organic phases
were dried (MgSO4), ﬁltered, and concentrated under reduced
pressure. The resulting light-yellow oil was subjected to ﬂash
chromatography (silica, 3:100 v/v ethyl acetate/hexane elution) and
gave, after concentration of the appropriate fractions (Rf = 0.3 in
0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane), an ∼6:1 mixture of
ether 35 and its regioisomer (700 mg, 88% combined yield) as a light-
yellow oil. 1H NMR (400 MHz, CDCl3) δ (major regioisomer) 6.00
(m, 1H), 4.62 (dd, J = 5.2 and 1.5 Hz, 1H), 4.49 (m, 2H), 4.24 (m,
1H), 2.67 (d, J = 1.5 Hz, 1H), 1.40 (s, 3H), 1.39 (s, 3H), 1.12−0.99
(complex m, 21H); 13C NMR (100 MHz, CDCl3) δ (major
regioisomer) 130.8, 123.5, 110.0, 75.9, 75.7, 69.3, 68.3, 27.5, 26.2,
17.9(4), 17.9(3), 12.2; IR νmax 3560, 2943, 2893, 2867, 1645, 1463,
1382, 1370, 1340, 1236, 1080, 1055, 882, 863, 682 cm−1; MS (EI, 70
eV) m/z 423 and 421 [(M+ H)+, 10 and 9%], 407 and 405 [(M −
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CH3•)+, 7 and 6], 321 and 319 (100 and 97); HRMS (EI, 70 eV) (M
− CH3•)+ calcd for C17H3079BrO4Si 405.1097, found 405.1096.
(((3aS,4S,5R,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]diox-ol-5-yl)oxy)tri-iso-propylsilane (36).
Sodium hydride (172 mg of a 60% dispersion in mineral oil, 4.3
mmol) was added to a magnetically stirred solution of an ∼6:1 mixture
of compound 35 and its regioisomer (600 mg, 1.4 mmol) and
iodomethane (267 μL, 4.3 mmol) in dry THF (15 mL) maintained at
0 °C under a nitrogen atmosphere. Stirring was continued for 2 h at 22
°C, and then the reaction mixture was treated with ice-water (30 mL)
(CAUTION! possibility of hydrogen gas evolution). The separated
aqueous phase was extracted with ethyl acetate (1 × 15 mL), and the
combined organic phases were then dried (MgSO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to ﬂash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane), an ∼5:1
mixture of compound 36 and its regioisomer (570 mg, 92% combined
yield) as a clear, colorless oil; 1H NMR (400 MHz, CDCl3) δ (major
regioisomer) 6.15 (d, J = 3.0 Hz, 1H), 4.62 (m, 1H), 4.56 (m, 1H),
4.44 (t, J = 5.4 Hz, 1H), 3.70 (m, 1H), 3.54 (s, 3H), 1.41 (s, 3H), 1.38
(s, 3H), 1.10−0.98 (complex m, 21H); 13C NMR (100 MHz, CDCl3)
δ (major regioisomer) 133.1, 122.2, 109.9, 80.3, 76.9, 75.1, 68.2, 59.7,
27.5, 26.0, 17.9(8), 17.9(6), 12.2; IR νmax 2941, 2887, 2865, 1649,
1460, 1383, 1335, 1241, 1197, 1138, 1121, 1079, 1040, 956, 880, 858,
680 cm−1; MS (ESI, +ve) m/z 459 and 457 [(M + Na)+, 83 and 81%],
437 and 435 (88 and 86), 205 and 203 (97 and 100); HRMS (ESI,
+ve) (M + Na)+ calcd for C19H35
79BrNaO4Si 457.1386, found
457.1375.
(3aS,4R,5R,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-5-ol (37). A magnetically stirred
solution of an ∼5:1 mixture of compound 36 and its regioisomer
(600 mg, 1.4 mmol) in THF (10 mL) maintained at 22 °C under a
nitrogen atmosphere was treated with tetra-n-butylammonium ﬂuoride
(2 mL of 1.0 M solution in THF, 4.1 mmol). After 2 h, the reaction
mixture was concentrated under reduced pressure, and the residue so-
formed was subjected to ﬂash chromatography (silica, 1:2 v/v ethyl
acetate/hexane elution). Concentration of the relevant fractions (Rf =
0.4 in 4:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane) gave compound
37 (338 mg, 88%) as a white powder; mp 61 °C; [α]20D +15.3 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3, 400 MHz) δ 6.15 (d, J = 3.0
Hz, 1H), 4.59 (m, 1H), 4.53 (t, J = 5.1 Hz, 1H), 4.33 (complex m,
1H), 3.76 (t, J = 4.4 Hz, 1H), 3.54 (s, 3H), 2.55 (broad s, 1H), 1.42 (s,
3H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 132.0, 123.2,
110.3, 78.7, 76.2, 73.9, 66.3, 59.2, 27.6, 26.2; IR νmax 3453, 2987, 2935,
2900, 2831, 1646, 1457, 1381, 1372, 1231, 1109, 1077, 1041, 964, 868
cm−1; MS (EI, 70 eV) (EI, 70 eV) 280 and 278 (M+•, both 1%), 265
and 263 (74 and 76), 177 and 175 (13 and 15), 124 (28), 115 (100);
HRMS M+• calcd for C10H15
79BrO4 278.0154, found 278.0153.
4-Hydroxy-3-((3aR,6R,7R,7aR)-6-hydroxy-7-methoxy-2,2-dimeth-
yl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-methoxybenzal-
dehyde (38). A magnetically stirred solution of compound 37 (116
mg, 0.42 mmol), boronate ester 27 (139 mg, 0.50 mmol), PdCl2dppf·
CH2Cl2 (25 mg, 0.03 mmol), and triethylamine (2 mL) in THF/water
(15 mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h and
then heated under reﬂux for 3 h before being cooled, poured into
water (40 mL), and extracted with ethyl acetate (3 × 20 mL). The
combined organic phases were washed with brine (1 × 30 mL) and
then dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The ensuing light-yellow oil was subjected to ﬂash
chromatography (silica, 1:4 v/v ethyl acetate/hexane elution), and
concentration of the relevant fractions (Rf = 0.5 in 1:3 v/v ethyl
acetate/hexane) gave phenol 38 (80 mg, 55%) as a light-yellow oil;
[α]20D +7.0 (c 0.2, CHCl3);
1H NMR (400 MHz, CDCl3) δ 9.82 (s,
1H), 7.39 (d, J = 1.5 Hz, 1H), 7.37 (d, J = 1.5 Hz, 1H), 6.10 (d, J = 3.3
Hz, 1H), 5.15 (d, J = 5.8 Hz, 1H), 4.64 (t, J = 5.5 Hz, 1H), 4.52 (m,
1H), 3.96 (s, 3H), 3.79 (t, J = 4.6 Hz, 1H), 3.59 (s, 3H), 2.65 (broad
d, J = 8.3 Hz, 1H), 1.46 (s, 3H), 1.40 (s, 3H) (signal due to hydroxyl
group proton not observed); 13C NMR (100 MHz, CDCl3) δ 190.8,
149.4, 147.9, 134.8, 132.0, 129.2, 128.3, 125.9, 109.8, 108.4, 79.7, 73.6,
73.3, 65.0, 59.1, 56.3, 27.6, 25.9; IR νmax 3368, 2985, 2936, 1681, 1588,
1456, 1432, 1297, 1149, 1120, 1071, 913, 873 cm−1; MS (EI, 70 eV)
m/z 350 (M+•, 4%), 274 (41), 115 (100); HRMS (EI, 70 eV) M+•
calcd for C18H22O7 350.1366, found 350.1370.
2-((3aS,4R,5R,7aR)-7-(5-Formyl-2,3-dimethoxyphenyl)-4-me-
thoxy-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-yl)-
N,N-dimethylacetamide (39). A magnetically stirred solution of
compound 38 (60 mg, 0.17 mmol) in toluene (10 mL) was treated
with N,N-dimethylacetamide dimethyl acetal (126 μL, 0.87 mmol),
and the ensuing mixture was heated under reﬂux for 18 h. The cooled
reaction mixture was concentrated under reduced pressure, and the
residue thus obtained was subjected to ﬂash chromatography (silica,
4:1 v/v ethyl acetate/hexane elution). Concentration of the
appropriate fractions (Rf = 0.3 in 5:1 v/v ethyl acetate/hexane) then
gave an ∼5:1 mixture of amide 39 and its β-epimer (30 mg, 40%
combined yield) as a clear, colorless oil; 1H NMR (400 MHz, CDCl3)
δ (major epimer) 9.87 (s, 1H), 7.39−7.36 (complex m, 2H), 6.01 (d, J
= 4.6 Hz, 1H), 5.20 (d, J = 6.7 Hz, 1H), 4.41 (t, J = 6.7 Hz, 1H), 3.91
(s, 3H), 3.86 (s, 3H), 3.65−3.59 (complex m, 1H), 3.48 (s, 3H), 3.34
(m, 1H), 3.01 (s, 3H), 2.94 (s, 3H), 2.73 (dd, J = 15.9 and 5.1 Hz,
1H), 2.27 (dd, J = 15.9 and 9.4 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H);
13C NMR (100 MHz, CDCl3) δ (major epimer) 191.2, 171.3, 153.3,
152.1, 134.6, 133.9, 133.1, 132.3, 127.5, 109.6, 109.0, 79.7, 74.4, 73.6,
60.8, 58.1, 56.0, 37.3, 35.5, 33.7, 33.4, 27.9, 25.7; IR νmax 2982, 2932,
2857, 2831, 1691, 1646, 1578, 1458, 1421, 1384, 1240, 1142, 1034,
1002, 913, 863, 733 cm−1; MS (ESI, +ve) m/z 456 [(M + Na)+, 78%],
434 (100), 376 (21); HRMS (ESI, +ve) (M + Na)+ calcd for
C23H31NNaO7 456.1998, found 456.1996.
2-((3R,4R,5R,6R)-5′-Formyl-5,6-dihydroxy-2′,3′,4-trimethoxy-
3,4,5,6-tetrahydro[1,1′-biphenyl]-3-yl)-N,N-dimethylacetamide (8).
An ∼5:1 mixture of compound 39 and its β-epimer (16 mg, 0.04
mmol) was treated with acetic acid/water (10 mL of a 2:1 v/v
mixture), and the resulting solution was heated at 50 °C for 22 h and
then cooled to 22 °C and concentrated under reduced pressure.
Subjection of the residue thus obtained to ﬂash chromatography
(silica, 1:8:1 v/v methanol/ethyl acetate/hexane elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 1:9 v/v
methanol/ethyl acetate), an ∼6:1 mixture of compound 8 and its β-
epimer (10 mg, 69% combined yield) as a light-yellow oil; 1H NMR
(400 MHz, CDCl3) δ (major epimer) 9.87 (s, 1H), 7.39 (complex m,
2H), 5.99 (m, 1H), 4.71 (m, 1H), 4.01 (dd, J = 9.2 and 4.0 Hz, 1H),
3.92 (s, 3H), 3.87 (s, 3H), 3.80 (m, 1H), 3.50 (m, 1H), 3.46 (s, 3H),
3.02 (s, 3H), 2.95 (s, 3H), 2.85 (broad s, 1H), 2.74 (dd, J = 15.9 and
5.0 Hz, 1H), 2.20 (dd, J = 15.9 and 9.0 Hz, 1H) (signal due to a
hydroxyl group proton not observed); 13C NMR (CDCl3, 100 MHz) δ
(major epimer) 191.1, 171.4, 153.2, 151.7, 135.1, 134.9, 133.3, 132.4,
127.5, 109.8, 77.7, 69.0, 68.5, 61.0, 57.9, 56.0, 37.3, 35.6, 34.3, 32.4; IR
νmax 3395, 2957, 2935, 2828, 1688, 1627, 1463, 1420, 1387, 1260,
1128, 1105, 1089, 797 cm−1; MS (ESI, +ve) m/z 787 [(2M + H)+,
30%], 416 [(M + Na)+, 100], 394 (92), 376 (20); HRMS (ESI, +ve)
(M + Na)+ calcd for C20H27NNaO7 416.1685, found 416.1685.
4-Hydroxy-3-((3aR,6S,7R,7aR)-6-hydroxy-7-(methoxymethoxy)-
2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-me-
thoxybenzaldehyde (43). A magnetically stirred solution of
compound 429a (100 mg, 0.33 mmol), boronate ester 27 (108 mg,
0.39 mmol), PdCl2dppf·CH2Cl2 (19 mg, 0.02 mmol), and triethyl-
amine (3 mL) in THF/water (18 mL of a 9:1 v/v mixture) was purged
with nitrogen for 0.5 h and then heated under reﬂux for 2 h before
being cooled, poured into water (50 mL), and extracted with ethyl
acetate (3 × 30 mL). The combined organic phases were washed with
brine (1 × 40 mL) and then dried (Na2SO4), ﬁltered, and
concentrated under reduced pressure. The ensuing light-yellow oil
was subjected to ﬂash chromatography (silica, 1:1 v/v ethyl acetate/
hexane elution), and concentration of the relevant fractions (Rf = 0.3
in 1:3 v/v ethyl acetate/hexane) then gave phenol 43 (60 mg, 49%) as
a light-yellow oil; [α]20D +18.4 (c 0.9, CHCl3);
1H NMR (400 MHz,
CDCl3) δ 9.82 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.6 Hz,
1H), 7.07 (s, 1H), 6.16 (d, J = 2.2 Hz, 1H), 5.21 (d, J = 6.2 Hz, 1H),
4.90 (d, J = 6.8 Hz, 1H), 4.86 (d, J = 6.8 Hz, 1H), 4.36 (dd, J = 8.4 and
6.2 Hz, 1H), 4.27 (broad d, J = 8.1 Hz, 1H), 4.08 (d, J = 3.3 Hz, 1H),
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3.97 (s, 3H), 3.67 (m, 1H), 3.50 (s, 3H), 1.51 (s, 3H), 1.40 (s, 3H);
13C NMR (100 MHz, CDCl3) δ 190.8, 149.2, 147.6, 133.6, 131.8,
129.2, 128.5, 125.0, 110.5, 108.1, 98.0, 83.2, 76.5, 74.0, 69.4, 56.4, 55.9,
28.2, 26.0; IR νmax 3370, 2985, 2948, 2936, 1683, 1588, 1488, 1456,
1432, 1372, 1300, 1250, 1217, 1149, 1105, 1058, 1037, 996, 866, 732
cm−1; MS (EI, +ve) m/z 380 (M+•, 2%), 362 (12), 260 (59), 259 (54),
231 (100), 218 (48); HRMS (EI, +ve) M+• calcd for C19H24O8
380.1471, found 380.1478.
2-((3aS,4R,5R,7aR)-7-(5-Formyl-2,3-dimethoxyphenyl)-4-(me-
thoxymethoxy)-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]-
dioxol-5-yl)-N,N-dimethylacetamide (44). A magnetically stirred
solution of compound 43 (33 mg, 0.09 mmol) in toluene (10 mL)
was treated with N,N-dimethylacetamide dimethyl acetal (64 μL, 0.44
mmol), and the ensuing mixture was heated under reﬂux for 18 h. The
cooled reaction mixture was concentrated under reduced pressure, and
subjection of the ensuing residue to ﬂash chromatography (silica,
9.5:0.5 v/v ethyl acetate/hexane elution) gave, after concentration of
the appropriate fractions (Rf = 0.4 in ethyl acetate), an ∼3:1 mixture of
amide 44 and its β-epimer (14 mg, 35% combined yield) as a clear,
colorless oil; 1H NMR (400 MHz, CDCl3) δ (major epimer) 9.87 (s,
1H), 7.38 (m, 2H), 5.98 (d, J = 4.3 Hz, 1H), 5.22 (d, J = 6.0 Hz, 1H),
4.77 (m, 2H), 4.46 (t, J = 6.5 Hz, 1H), 4.04 (dd, J = 6.9 and 4.5 Hz,
1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.43 (s, 3H), 3.30 (m, 1H), 3.01 (s,
3H), 2.94 (s, 3H), 2.75 (dd, J = 15.8 and 5.1 Hz, 1H), 2.33 (dd, J =
15.8 and 9.5 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H); 13C NMR (mixture
of epimers) (100 MHz, CDCl3) δ 191.3, 171.2, 153.3, 152.0, 134.6,
134.0, 133.0, 132.3, 129.3, 127.7, 113.8, 109.6, 109.2, 100.0, 96.5, 76.2,
75.0, 74.1, 73.8, 60.8, 56.0, 55.7, 37.2, 35.5, 34.2, 33.8, 28.0, 27.9, 26.0;
IR νmax 2982, 2933, 2843, 1692, 1647, 1579, 1455, 1384, 1243, 1145,
1070, 1037, 918, 863 cm−1; MS (ESI, +ve) m/z 486 [(M + Na)+,
100%], 464 (3), 60 (10); HRMS (ESI, +ve) (M + Na)+ calcd for
C24H33NNaO8 486.2104, found 486.2105.
2-((3R,4R,5R,6R)-5′-Formyl-5,6-dihydroxy-2′,3′-dimethoxy-4-(me-
thoxymethoxy)-3,4,5,6-tetrahydro[1,1′-biphenyl]-3-yl)-N,N-dime-
thylacetamide (9). Compound 44 (8 mg, 0.02 mmol) was treated
with acetic acid/water (10 mL of a 2:1 v/v mixture), and the resulting
solution was heated at 50 °C for 22 h and then cooled and
concentrated under reduced pressure. Subjection of the residue thus
obtained to ﬂash chromatography (silica, 1:8:1 v/v methanol/ethyl
acetate/hexane elution) gave, after concentration of the appropriate
fractions (Rf = 0.4 in 1:9 v/v methanol/ethyl acetate), an ∼6.5:1
mixture of compound 9 and its β-epimer (5 mg, 69%) as a light-yellow
oil; 1H NMR (400 MHz, CDCl3) δ (major epimer) 9.87 (s, 1H), 7.38
(m, 2H), 5.97 (d, J = 4.4 Hz, 1H), 4.76−4.71 (complex m, 3H), 4.14
(dd, J = 9.1 and 5.7 Hz, 1H), 4.01 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H),
3.45 (s, 3H), 3.34 (broad s, 1H), 3.02 (s, 3H), 2.94 (s, 3H), 2.84 (dd, J
= 15.9 and 5.2 Hz, 1H), 2.25 (dd, J = 15.9 and 8.9 Hz, 1H) (signal due
to hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ (major epimer) 191.2, 171.4, 153.2, 151.7, 135.2, 135.0,
133.3, 132.5, 127.4, 109.8, 97.5, 76.9, 69.2, 68.9, 61.0, 56.0(1), 55.9(6),
37.3, 35.8, 35.6, 33.2; IR νmax 3384, 2919, 2848, 1688, 1630, 1579,
1463, 1419, 1387, 1329, 1292, 1245, 1147, 1130, 1037, 917, 862 cm−1;
MS (ESI, +ve) m/z 446 [(M + Na)+, 68%], 424 (100); HRMS (ESI,
+ve) (M + Na)+ calcd for C21H29NNaO8 446.1791, found 446.1780.
Crystallographic Studies. Crystallographic Data. Compound
ent-2. C17H19NO5, M = 317.34, T = 150 K, orthorhombic, space group
P212121, Z = 4, a = 6.58612(5) Å, b = 9.28140(8) Å, c = 23.3001(2) Å;
V = 1424.30(2) Å3, Dx = 1.480 g cm
−3, 2794 unique data (2θmax =
144.6°), R = 0.027 [for 2725 reﬂections with I > 2.0σ(I)]; Rw = 0.072
(all data), S = 1.01.
Compound ent-15. C23H31NO7, M = 433.50, T = 150 K,
monoclinic, space group P21, Z = 2, a = 10.14845(9) Å, b =
10.61199(7) Å, c = 10.80864(10) Å; β = 106.8796(9)°; V =
1113.89(2) Å3, Dx = 1.292 g cm
−3, 3907 unique data (2θmax = 144.8°),
R = 0.026 [for 3843 reﬂections with I > 2.0σ(I)]; Rw = 0.067 (all
data), S = 1.03.
Compound 27. C14H19BO5, M = 278.11, T = 150 K, orthorhombic,
space group Pbam, Z = 8, a = 23.0535(6) Å, b = 18.2756(6) Å, c =
6.8183(2) Å; V = 2872.66(15) Å3, Dx = 1.286 g cm
−3, 3098 unique
data (2θmax = 145.2°), R = 0.084 [for 2982 reﬂections with I >
2.0σ(I)]; Rw = 0.191 (all data), S = 1.06.
Compound 32. C18H22O7, M = 359.38, T = 150 K, monoclinic,
space group P21, Z = 4, a = 7.3153(1) Å, b = 31.4358(3) Å, c =
7.8245(1) Å; β = 94.8743(8)°; V = 1792.83(4) Å3, Dx = 1.331 g cm−3,
7018 unique data (2θmax = 145°), R = 0.030 [for 6919 reﬂections with
I > 2.0σ(I)]; Rw = 0.080 (all data), S = 0.99.
Structure Determination. Diﬀraction images for compounds ent-2,
ent-15, 27, and 32 were all measured on a diﬀractometer (Mo Kα,
mirror monochromator, λ = 0.71073 Å or, for 32, Cu Kα mirror
monochromator, λ = 1.54184 Å) ﬁtted with an area detector, and the
data were extracted using the DENZO/Scalepack package.43 The
structure solutions for all four compounds were solved by direct
methods (SIR92)44 and then reﬁned using the CRYSTALS program
package.45 Atomic coordinates, bond lengths and angles, and
displacement parameters have been deposited at the Cambridge
Crystallographic Data Centre (CCDC nos. 1517512, 1517513,
1517514 and 1517515). These data can be obtained free-of-charge
via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@
ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic
Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: + 44
1223 336033.
AChE Inhibition Testing. The galanthamine derivatives/ana-
logues described above were tested for inhibition against AChE as
described by Sangnoi et al.46 Thus, the compounds were dissolved in
DMSO and made up to concentrations ranging from 5 mM to 3.05
μM by serial dilution with DMSO. Then, 2.5 μL of a solution of each
compound was added to a solution of 5,5′-dithiobis(2-nitrobenzoic
acid) (125 μL of a 1.5 mM aqueous solution), tris(hydroxymethyl)-
aminomethane buﬀer (72.5 μL of a 15 mM solution at pH 8.0), and
acetylthiocholine iodide (25 μL of a 150 μM aqueous solution) in
water. Enzyme activity was followed after the addition of AChE (25 μL
of 0.03 μM solution of Electrophorus electricus, Type V−S, EC 3.1.1.7)
by measuring the absorption at 412 nm using a microplate
spectrophotometer. Assays were repeated in triplicate, and the
hydrolysis rate was calculated during the data from the absorptions
observed over the ﬁrst 2 min. Standard commercially available graphic
software was used to calculate the tabulated IC50 values.
Molecular Docking Studies. The three-dimensional coordinates
of each compound were generated with the PRODRG server (http://
davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg).47 Galanthamine and the
above-mentioned derivatives/analogues were docked into the structure
of human acetylcholine esterase (4EY6) using Autodock Vina v1.1.2
after removal of galanthamine from the active site gorge.48
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Figure S1: Structure of compound ent-2 (CCDC 1517512) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S2: Structure of compound ent-15 (CCDC 1517513) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S3: Structure of compound 27 (CCDC 1517514) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S4: Structure of compound 32 (CCDC 1517515) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii.!!
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Appendix One: 
Single-crystal X-ray report for compound 15 of Publication 2: 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1504203). 
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Appendix Two: 
Single-crystal X-ray report for compound 23 of Publication 2: 
  
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1504204). 
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Appendix Three: 
Single-crystal X-ray report for compound 27 of Publication 2: 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1504205). 
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Appendix Four: 
Single-crystal X-ray report for compound 35 of Publication 2: 
 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1504206). 
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Appendix Five: 
Single-crystal X-ray report for compound 72 of Publication 2: 
 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1504208). 
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Appendix Six: 
Single-crystal X-ray report for compound 6 of Publication 3: 
 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1058035). 
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Appendix Seven: 
Single-crystal X-ray report for compound 8 of Publication 3: 
 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1058036). 
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Appendix Eight: 
Single-crystal X-ray report for compound 27 of Publication 4: 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1517514). 
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Appendix Nine: 
Single-crystal X-ray report for compound 32 of Publication 4: 
 
  
 
 
Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Center (CCDC no. 
1517515). 
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